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INTRODUCTION 
Tuberculosis: The HIV factor 
Of the 40 million persons living with HIV/AIDS to-date, over 60 percent 
reside in sub-Saharan Africa, making it the most affected region of the 
world, Figure 1 (1;2).  HIV infection rate is still on the increase. In 2006 
alone of the estimated world total of 4.3 million (3.6 – 6.6 million) new 
HIV infections, sub-Saharan Africa was estimated to have 2.8 million (2.4 
– 3.2 million) adults and children infected with HIV. This was more than 
all other regions of the world combined together (2). The 2.1 million AIDS 
deaths in sub-Saharan Africa represented 72% of global AIDS death (2).   
 
Figure 1. Adults and children estimated to be living with HIV/AIDS 
(UNAIDS, 2004) 
 
 
 
 
 
 
 
 
In Tanzania in particular, at the end of 2005, the estimated number of 
adults and children who were living with HIV was 1.4 million (1.3 – 1.6 
million), making Tanzania one of the most affected countries in the world 
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(2). It was projected that in Tanzania new infections and death will 
increase steadily to reach 250,000 and 120,000 cases per year, 
respectively in 2010, Figures 2,3,4 (3).  
 
Figure 2. Estimates and projections of HIV infection among adult 
Tanzanians from 1980 to 2010 
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Figure 3. Estimates and projections of new cases of HIV infection among 
adult Tanzanians from 1980 to 2010 
 
 
Figure 4. Estimates and projections of aids deaths among adult 
Tanzanians from 1980 to 2010 
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Mycobacterium tuberculosis (MTB) is the world’s most deadly bacterial 
pathogen (4). About one-third of the world population is infected with 
MTB. By 2000 there were 8.3 million new cases and up to 2.2 million 
deaths per year due to tuberculosis (TB) (5). HIV infection is a potent risk 
factor for TB. The interaction of TB and HIV is formidable: rates of active 
TB are higher in HIV infected persons than in persons without HIV, 
because HIV increases the risk of reactivation of latent MTB (6) as well as 
the risk of rapid TB progression after infection or reinfection with MTB (7). 
HIV also increases TB transmission rates in the general community (8). 
Patients co-infected with TB/HIV exhibit higher rates of mortality than 
CD4-matched controls with TB but without HIV infection (9).  The TB 
burden in countries with a generalized HIV epidemic has therefore 
increased rapidly over the past couple of decades, especially in the 
severely affected countries of eastern and southern Africa (2;10) Figure 
5. In these countries up to 31% of new TB cases are attributed to HIV 
infection (5). In Tanzania, new TB cases increased five fold from 11,753 
in 1983 to 61,603 in 2001 largely due to HIV/AIDS (11). TB therefore has 
become the most common disease associated with HIV/AIDS and the 
leading cause of morbidity and mortality (12).   
 
Unlike the straightforward diagnosis and typical presentation of 
pulmonary tuberculosis (PTB) in HIV-1 seronegative individuals (13;14), 
PTB in HIV/AIDS frequently has atypical clinical and radiographic 
presentation (15-17). Often PTB is hardly distinguishable from other 
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causes of pulmonary infection on clinical and radiographic basis (18). This 
makes the diagnosis of TB in HIV infection considerably difficult, 
particularly in view of the resource limitations in the highly affected 
countries of sub-Saharan Africa. This amounts to delayed diagnosis and 
treatment, which affect the control strategies. To-date HIV infection is the 
single most potent factor for increase in TB morbidity and mortality in the 
African sub-continent.  
 
Consequently, this deadliest TB/HIV tandem will result into approximately 
one billion new MTB infections in the world, over 150 million people with 
TB disease, and up to 36 million deaths due to TB between now and 2020 
if the current trend is not abated (www.iuatld.org. 2002).  
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This alarming magnitude of the TB disease asks for renewed and 
alternative control strategies directed mainly to the most affected regions 
“the TB/HIV Hot spots”. Researches are needed specifically from these 
“Hot spots” to understand the pathophysiology behind TB disease in HIV 
co-infection. Relevant research questions are for instance; why do some 
individuals develop the disease while other don’t?, what are the 
mechanisms leading to the atypical presentation of the disease?, what are 
the factors associated with high  mortality?, what are the current MTB 
subtypes in the wake of high transmission rate due to HIV infection? We 
Figure 5. Tuberculosis cases per 100,000 people (2001)  
Source: Globalis/UNEP/Global Virtual 
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equally need to take bold operational approaches by re-evaluating PTB 
diagnostic methods in HIV infection given the sputum scarcity associated 
with AIDS (19) and by monitoring the effectiveness of currently used 
antibiotics for TB treatment.  
 
Current information available from sub-Saharan Africa on TB/HIV co-
infection is insufficient: studies from this most affected part of the globe 
are sparse and not optimal. Only in few studies on TB in HIV infection 
from this region samples from the bronchoalveolar compartment (i.e. 
bronchoalveolar lavage fluid) have been used. This is important for better 
understanding the disease as the actual events take place in the 
broncholveolar parts of the lungs, and because of the sputum scarcity in 
AIDS patients (19). Accurate diagnosis of TB is important in 
understanding and characterizing the disease. Combination of 
microbiological and molecular techniques offers a more accurate diagnosis 
of TB and avoids erroneously assigning a patient as either TB positive or 
negative. However data on such an approach for diagnosing TB are 
lacking from this part of the world. Similarly, from this region no studies 
are available which characterize a broad range of cytokines and their 
interaction in TB/HIV co-infection. Such an approach is important given 
the immunological complexity associated with HIV infection.  
 
For this reason we conducted pathophysiological and operational studies 
in an attempt to shed more light on the TB/HIV co-infection in a sub-
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Saharan African country, using bronchoalveolar lavage fluid from 
accurately defined TB patients with HIV co-infection. All subjects studied 
in this work were indigenous Tanzanians, i.e. a true representation of one 
of the most affected countries of sub-Saharan Africa (10)  
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Outline of the thesis 
 
Chapter 1. 
In the introductory chapter the complex relationship between 
pulmonary tuberculosis (TB) and HIV infection is highlighted in the 
context of the HIV epidemic in tropical Africa and Tanzania in 
particular. Also, an outline is given of the research reported in the 
following chapters of this thesis.  
Chapter 2.  
In this study the ten-year trend in leading causes of hospitalisation 
and in-hospital morbidity and mortality attributed to HIV-infection is 
examined in a tertiary health care facility in northern Tanzania. 
Also, the prevalence of HIV infection in in-patients and the 
proportion of patients unaware of HIV infection as the cause of their 
ailing health are examined.    
Chapter 3. 
In this chapter the aetiological agents of pulmonary infection in a 
cohort of adult HIV infected patients are determined and correlated 
with the levels of immunosuppression, clinical presentation, chest 
radiographic findings and prognosis.  
Chapter 4. 
Due to an ongoing breakdown of cellular immunity in TB/HIV dual 
infection, the host is subject to a variety of infections including 
viruses. In this study we determine the prevalence of the most 
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common human herpes viruses in bronchoalveolar lavage (BAL) 
fluid and discuss their possible contribution to the high mortality in 
patients with TB/HIV co-infection.  
Chapter 5. 
Accurate microbiological diagnosis is crucial for TB control in the era 
of TB/HIV co-infection, particularly since clinical and radiographic 
features cannot adequately differentiate TB from other causes of 
pulmonary infection. In this study data are presented on the 
performance of diagnostic laboratory tests for pulmonary TB, 
including microbiological, serological and molecular methods 
(including real time PCR), using sputum, bronchoalveolar lavage 
fluid and serum in a TB and HIV endemic setting.  
Chapter 6. 
This chapter presents the results of a study into the dominant 
genotypes of Mycobacterium tuberculosis (MTB), determined by 
spoligotyping, in HIV infected and non-HIV patients in Tanzania. 
The genotypes are correlated with anti-TB drug sensitivity patterns. 
Also, the results of genotypic and phenotypic anti-TB drug 
susceptibility testing are compared.  
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Chapter 7. 
In patients not infected with HIV, the role of macrophage migration 
inhibitory factor (MIF) in the course of MTB infection showed that 
MIF levels were determined by dose and virulence of the MTB strain 
and that high MIF levels were associated with fatal outcome. We 
report data on MIF in HIV infected patients with pulmonary TB or 
other pulmonary infections compared to TB patients without HIV 
infection and healthy controls. Also, the association of MIF levels 
with mortality is examined.    
Chapter 8. 
Our understanding of atypical presentation of tuberculosis in 
advanced AIDS, such as the lack of upper lobe cavitation, is 
insufficient. In particular it is not clear which events take place at 
the site of infection in the lungs. This study examines the local 
immune response in HIV infected patients with TB compared with 
HIV infected patients with non-TB pulmonary disease from 
Tanzania, using bronchoalveolar lavage (BAL) fluid. It correlates 
chest radiographic features and CD4 T cell level with levels of a 
panel of cytokines/chemokines present in BAL.   
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Chapter 9. 
 Infection with MTB is common to citizens of sub-Saharan Africa, 
however only a proportion of individuals develop active TB while in 
the majority the disease remains latent. Toll-like receptors (TLR) 
are important for host defence against MTB. TLR4 299 functional 
polymorphism is common in sub-Saharan Africa. Therefore, we 
investigated the association between TLR4 Asp 299Gly 
polymorphism and the development of active TB in HIV infected 
patients and examined whether there was an association with level 
of CD4 T cells. 
Chapter 10. 
This chapter discusses the findings from the above studies, puts the 
findings into perspective, and winds up by outlining avenues for 
future research.  
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ABSTRACT 
Background  
Hospitalized persons with HIV infection are among the most likely to benefit 
from expanding availability of antiretroviral therapy in sub-Saharan Africa.   
Methods 
Between 1990 and 2000, 3,667 HIV-infected persons were admitted to 
Kilimanjaro Christian Medical Centre in Moshi.  Annual inpatient mortality rate 
ranged from 15-21%, and the proportion of female patients increased 
significantly during this time from 45 to 52 % (p < 0.001).   Charts were 
abstracted from 1,683 HIV-infected patients admitted between 1996 and 2001.   
Results 
The most prevalent diagnoses in adults were pulmonary tuberculosis (21%), 
malaria (14%), and gastroenteritis/diarrhoea (12%), and those for children were 
non-tuberculosis pulmonary infection (21%), pulmonary tuberculosis (19%), and 
gastroenteritis/diarrhoea (12%).  The relative risk of inpatient death was 
greatest for adults presenting with meningitis (RR 2.3, 95% CI 1.7-3.0), 
septicaemia (RR 2.0, 95% CI 1.2-3.3), and renal disease (RR 1.9, 95% CI 1.2-
2.9), and mortality was higher for men than women (OR, 1.4, p <0.005).  A 
single day point-prevalence survey in September 2001 identified HIV infection in 
21% of those surveyed; 44% were not known to be infected.   
Conclusion 
HIV infection remains a major cause for admission and mortality in this 
population.  A policy of routine testing would increase case finding and 
potentially enhance care and prevention efforts.  
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INTRODUCTION 
Of the 42 million persons living with HIV/AIDS at the end of 2002, over 70 
percent resided in Sub-Saharan Africa, making it easily the most affected region 
of the world (1).  In Tanzania specifically, by the end of 2001, approximately 2.2 
million individuals aged 15 and above were estimated to be living with 
HIV/AIDS, a 3% increase from the previous year.  In the Kilimanjaro Region the 
prevalence of HIV infection among women attending some antenatal clinics has 
nearly tripled since 1992, with estimates between 1997 and 2000 ranging from 
17 to 20% (2).  Between 1992 and 1998, across 51 villages surveyed in Hai 
District of this region, HIV/AIDS accounted for 57% of deaths, reflecting the 
dramatic impact of this disease among younger, sexually active adults (3). 
Unfortunately, in Tanzania as in other countries in sub-Saharan Africa, many 
persons infected with HIV are not aware of their serostatus. This hampers efforts 
to prevent transmission and limits access to treatment and care services.  A 
growing number of HIV voluntary counseling and testing (VCT) sites are 
beginning to address this problem. However, missed opportunities may occur 
when persons presenting to hospitals are not offered HIV testing. 
 
As increased international attention and resources are focused on the AIDS crisis 
in sub-Saharan Africa and plans for more intensive and effective therapeutic 
interventions are developed, it has become increasingly important to describe 
the clinical manifestations of hospitalized patients (who likely have advancing 
disease), as this population could derive immediate benefit from antiretroviral 
medications.  Others have reported hospital-based data from other regions in 
Tanzania (4) and elsewhere in sub-Saharan Africa (5-7), but to date, there have 
been no descriptions of hospital-based patient series of HIV infection in Northern 
Chapter Two: Inpatient HIV-associated morbidity and mortality 
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Zone of Tanzania.  Recently, a policy of offering VCT to all persons admitted to 
hospitals in sub-Saharan Africa has been advocated (8).  However, the number 
of additional HIV infections that might be detected with this method has not 
been estimated. 
 
To describe clinical characteristics of HIV-infected persons and HIV 
seroprevalence among patients admitted to the major referral hospital in 
Northern Tanzania, we reviewed medical records of patients found to be HIV-
positive over an 11-year period and offered widespread VCT testing in the 
context of a cross-sectional seroprevalence survey.  To calculate the proportion 
of HIV infections missed by a testing policy based on clinical and behavioral 
criteria, we compared data from current testing strategy with those from the 
cross-sectional seroprevalence survey. 
 
MATERIALS AND METHODS 
Study site 
Kilimanjaro Christian Medical Centre (KCMC) is located in Moshi municipality in 
the Kilimanjaro Region of Northern Tanzania.  As one of four national referral 
centers, the 450-bed hospital serves >10 million persons living in the Northern 
and Central Zones of Tanzania.  In addition, KCMC hosts a medical school and 
15 other schools of allied health sciences.  In 2001, 17,812 admissions and 
1,121 inpatient deaths were recorded, and bed occupancy was nearly 100%. 
 
Hospital inpatient series 
Between 1990 and 2001, patients suspected by clinicians at KCMC to be at risk 
for HIV infection were routinely offered HIV testing; testing was not offered 
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routinely to all inpatients.  According to World Health Organization guidelines 
(9), patients were tested for HIV antibody with two sequential rapid tests, 
commonly Capillus (Trinity Biotech, Wicklow, Ireland) and an enzyme 
immunoassay (Vironosticka HIV Uni-Form II Ag/Ab Microwell EIA, Biomerieux, 
France system).  Demographic information and the status of the patient at 
discharge were extracted from discharge and HIV testing logs.   An additional set 
of data, based on a chart review, was generated for patients admitted between 
1997 and 2001 using a standardized form.  These data included patient age, 
gender, status at discharge, and admission diagnoses. The recorded admission 
diagnoses reflected the opinions of senior consultant physicians who reviewed 
cases on the day of admission; if further investigation resulted in an alternate 
definitive diagnosis, this was recorded as the admitting diagnosis.  For analysis, 
composite diagnostic categories were formulated by combining etiologically or 
syndromically related diagnoses to shorten the list of the numerous diagnoses 
observed in the data. 
  
Cross-sectional seroprevalence survey 
To assess the seroprevalence in this hospitalized population and, specifically, to 
help establish estimates of unsuspected HIV disease, a point prevalence survey 
was performed on September 18, 2001.  The protocol was approved by the 
Ethical Clearance Committee at KCMC, and patients were enrolled only after 
informed consent was obtained.  All patients on the general medical and 
pediatric wards at KCMC were approached to participate in the study.  On the 
pediatric wards the child’s guardian or parent provided consent.  Patients who 
were younger than 6 months of age or were admitted to the intensive care unit 
or private medical service were excluded from the study. Clinical information, 
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including the patient’s HIV serostatus known at the time, was abstracted from 
patient’s charts and directed historical information and physical examinations 
targeting the World Health Organization surveillance case definition for AIDS 
(10) were performed on study participants.  Blood was obtained by fingerstick 
and four drops of blood were transferred to filter paper, allowed to air dry, and 
sealed in plastic for transfer to Duke University Medical Center.  A waiver for 
anonymized testing for HIV antibody was granted by the Investigational Review 
Board.  Bloodspot samples were then eluted from filter paper and HIV testing 
was performed using the Vironostika HIV-1 Microelisa system (Organon Teknika 
Corp., Durham, NC) according to the manufacturer’s instructions.  Samples 
testing positive were confirmed with repeat testing using the same kit.  
Statistical issues 
Statistical computations were made using JMP 4.04 (SAS Institute, Cary, NC) 
and Epi Info 2002 (CDC, Atlanta, GA).  
  
RESULTS 
Hospital inpatient series 
The number of patients known to be HIV seropositive increased approximately 
2-fold from the first half of the decade to the second (Figure 1), and the male: 
female ratio shifted around 1997 to reflect a preponderance of females.  The 
proportion of female patients known to be HIV seropositive increased 
significantly over these 11 years (P < 0.001, Chi-square test for trend), from 
consistently <50% between 1990-1996 (with a low of 38% in 1994) to 
consistently >50% since 1998.  The annual in-hospital mortality for these 
patients generally increased, ranging between 14.6 to 21.2% during this time. 
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More detailed data available for 1997-2001 describes 1,553 adults known to be 
HIV-infected: 814 (52%) female and 739 (48%) male patients.  The median 
(range) age for the adult population (>13 years) was 35 (13-92) years and the 
median (range) age for those who died was 36 (13-77) years.  Female patients 
were significantly younger (median age 33, range 13-92 years) than male 
patients (median age 38, range 14-80, rank-sum P < 0.001).  In-hospital 
mortality data were available for 1,549 patients.  Of the 386 inpatient deaths, 
28% of men and 178 (22%) of women died as inpatients (OR of death for men 
vs. women, 1.4, 95% CI 1.1 –1.8, p =0.004). 
 
Table 1 lists the diagnostic categories assigned to 1,242 HIV-infected adults 
between 1997 and 2001 and the inpatient mortality rates among patients with 
these diagnoses.  Most prevalent was pulmonary tuberculosis, which was seen in 
21% of patients, followed by malaria (13.6%), gastroenteritis/diarrhea (12.2%), 
and non-tuberculosis pulmonary infection (10.1%).  Taken together, pulmonary 
infections accounted for nearly one-third of all admissions.  Whereas central 
nervous system disease was more frequently recorded in women than men (47 
vs. 26, OR = 1.7, p =0.034), Kaposi’s sarcoma (15 vs. 30, OR = 0.4, p = 0.009) 
and renal disease (9 vs. 18, OR = 0.5, p = 0.04) were seen more frequently in 
men.  No significant gender differences were seen among other diagnoses.  
There was little variation in the median patient age across the diagnostic 
categories with the exception of intraabdominal infections (median age, 42; 
range, 24 to 57 years).  Mortality rates were highest for those presenting with 
meningitis (RR 2.3, 95% CI 1.7– 3.0), septicaemia (RR 2.0, 95% CI 1.2 –3.3), 
renal disease (RR 1.9, 95% CI 1.2 –2.9) and non-tuberculosis pulmonary 
infections (RR 1.6, 95% CI 1.2 – 2.1).   
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Table 3 shows the diagnoses assigned to 130 paediatric patients between the 
ages of 2 and 13 years who tested positive for HIV-1 antibody.  High prevalence 
rates of chest disease, particularly with non-tuberculosis pulmonary infection, 
were noted in this population.  Whereas the median age for most diagnostic 
categories was quite young, that for extrapulmonary tuberculosis was 9 years 
(range 2-10 years). 
Cross-sectional seroprevalence survey 
On September 18, 2001, anonymous HIV testing was offered to all patients 
admitted to the general internal medicine and pediatric wards.  Of the 61 adults 
on the medicine wards and 29 children on the pediatric wards offered testing, 
consent was provided by 58 adult patients (median age, 45; range 20-94 years) 
and by the guardians of 25 children (median age 1.9, range 0.7 to 14 years).  
Twelve adults (21%) and 4 of the 16 children over 18 months of age (25%) 
were found to be HIV-infected by antibody testing.  Four (33%) of the adult 
patients were not known to be HIV seropositive.  One of the four HIV-
seropositive children was previously thought to be HIV-seronegative and two 
had unknown HIV-serostatus.  No significant differences in sex or age were 
found between those testing HIV-antibody positive versus those who tested 
negative.  Fifteen percent of the 26 women and 25% of the 32 men tested were 
HIV-infected (p =0.3686), and the mean age of those infected versus uninfected 
was 44 years versus 52 (p = 0.2415).  For the adult inpatients, the sensitivity of 
the WHO case definition for AIDS surveillance was 0.58 (95% CI, 0.31-0.74).  
For specific symptoms and signs the sensitivity was 0.75 (95% CI, 0.47-0.91) 
for weight loss, 0.33 (95% CI, 0.47-0.91) for chronic diarrhea, 0.50 (95% CI, 
0.25-075) for prolonged fever, 0.58 (95% CI, 0-32-0.81) for cough, and 0.25 
(95% CI, 0.09-0.53) for thrush. 
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DISCUSSION 
We describe the diagnoses and mortality associated with HIV infection in a large 
referral hospital for the Northern Zone of Tanzania based on retrospective but 
systematic review of medical records.  Our findings, consistent with those of 
others in sub-Saharan Africa, highlight the morbidity and mortality of HIV/AIDS 
seen in a relatively young, potentially economically productive population and 
the number of missed cases.  We further describe increasing hospitalization 
rates for women over the decade of the 1990’s, enumerate mortality rates 
associated with the most common hospital presentations among those known to 
be HIV-infected, and estimate the yield of a more aggressive testing strategy. 
 
Significant gender differences in age and mortality were noted. The longitudinal 
data document an increasing proportion of women hospitalized with known HIV 
infection, and the women in our study were approximately 5 years younger than 
the men.  Others have noted similar age differences in hospital-based studies in 
Kenya, Uganda, and Malawi (5-7).  It remains unclear why hospitalized women 
are generally younger than men, but this may be explained by differences in age 
at acquisition of HIV (11), health seeking behaviour, and/or differences in the 
rate of progression.  The hospital mortality rate for women was 22% whereas 
that for men was 28% (p = 0.004).  Others have noticed more striking 
differences in gender-associated mortality in sub-Saharan Africa, speculating 
that cultural reasons may account for such differences; for example, very sick 
women may not be taken to the hospital as frequently as very sick men (5). 
The most prevalent diagnoses recorded in adults were pulmonary tuberculosis 
(21%), malaria (14%), gastroenteritis/diarrhoea (12%), and non-tuberculosis 
pulmonary infection (10%).  Excepting malaria, the prevalence of these findings 
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are similar to findings in those reported from other regions of sub-Saharan Africa 
(5;7;12;13).  Among patients known to be HIV-infected at KCMC, very high 
inpatient mortality was observed among patients with diagnoses of meningitis, 
septicaemia, renal disease, and non-tuberculosis pulmonary infection (inpatient 
death rates of 52, 47, 44, and 36%, respectively).  Although relatively high 
death rates are expected with meningitis, septicaemia, and renal disease even 
among patients not infected with HIV in resource-poor settings, the relatively 
high death rate among patients with non-tuberculosis pneumonia is surprising 
and highlights the need for more intense investigations of chest disease in this 
population.  We suspect that the case fatality rate for several of these diagnoses 
(e.g. cryptococcal meningitis) is higher than the inpatient mortality rate 
reported, as many of these patients were likely discharged home to die. 
 
Our single-day point-prevalence survey documented HIV seroprevalence of 21% 
on the adult ward and 25% on the paediatrics ward.  Within this small sample 
alone, the HIV serostatus was not previously known in 44% of HIV-infected 
patients, reflecting a sizeable proportion of patients who are unaware that they 
are infected.  The greatest limitation to this serosurvey was the small sample 
size.  A prevalence study conducted over a period of a few weeks may give a 
more precise picture of the prevalence of HIV seropositivity and clinical 
symptomatology at KCMC.  Despite these limitations, our data suggest that 
using a testing policy directed by clinical suspicion, a considerable number of 
HIV-infections go undiagnosed.  De Cock et al. have argued for routine testing of 
all those admitted to general medical wards (8).   This ‘opt-out’ policy of offering 
HIV testing to all persons admitted irrespective of perceived risk would detect 
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many more patients living with HIV/AIDS and, therefore, would provide 
additional prevention and treatment opportunities. 
 
The relatively low seroprevalence at KCMC compared with other similar studies 
in sub-Saharan Africa (4-6;12;14) may reflect regional differences in overall 
seroprevalence.  An alternative explanation is the substantial burden of chronic 
HIV/AIDS care taken on by the community, including the regional activities of a 
well-organized home-based care program by KIWAKKUKI which cares for 
between 700 and 1000 patients in the surrounding Kilimanjaro Region (personal 
communication, Lightness Kaale). Notably, at Kenyatta National Hospital in 
Nairobi, despite predictions of overwhelming numbers of AIDS cases, a decrease 
in clinical AIDS presentations was noted between 1992 and 1997 (5). 
 
Although HIV seroprevalence is not as high in the Kilimanjaro Region as in many 
other parts of sub-Saharan Africa, it remains a significant contributor to the 
inpatient census and mortality in this referral hospital.  HIV infection has 
increasingly affected women, and disproportionately affects an otherwise 
economically productive segment of the population.  In our relatively small 
point-prevalence survey, over 40% of patients in this facility who were HIV-
infected were not known to be so.  A more liberal testing strategy would likely 
identify additional individuals, giving them opportunity to access expanding HIV 
care options, including antiretroviral therapy, and to receive targeted prevention 
education to prevent further transmission. 
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ABSTRACT 
Background  
The objectives of this study were to determine the aetiological agents of 
pulmonary infections in HIV-infected Tanzanians and to correlate the causative 
agents with clinical, radiographic features, and one-month mortality.   
Methods 
In a prospective study at KCMC hospital we obtained bronchoalveolar lavage 
fluid (BAL) from 120 HIV infected patients with pulmonary infections. We 
analyzed BAL for causative agents.  
Results 
Causative agents were identified in 71 patients (59.2%) and multiple agents 
were in 16 patients. Common bacteria were identified in 35 patients (29.2%), 
Mycobacterium tuberculosis (MTB) in 28 (23.3%), Human Herpes Virus 8 (HHV8) 
in 12 (10%), Pneumocystis jiroveci in 9 (7.5%) and fungi in 5 (4.2%) patients. 
Median CD4 T cell count of the patients with identified causes was 47 cells/μl 
(IQR 14-91) and in the 49 patients with undetermined aetiology was 100 cells/μl 
(IQR 36-188; p=0.01). Micronodular chest radiographic lesions were associated 
with presence of MTB (p=0.002). The one-month mortality was 20 (16.7%). The 
highest mortality was associated with HHV8 (41.7%) and MTB (32.1%). 
Mortality in patients with undetermined aetiology was 11.3%. No death occurred 
in patients with PCP.  
Conclusion    
In this study of severely immunosuppressed HIV-infected patients with 
pulmonary infection a variety of causative agents was identified. Micronodular 
radiographic lesions were indicative of TB. High mortality was associated with M. 
tuberculosis or HHV8. No death occurred patients with P. jiroveci infection. 
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INTRODUCTION 
Sub-Saharan Africa is the region of the world most affected by HIV/AIDS, more 
than 70% of HIV infected individuals live in this African sub-continent, (1) and 
the HIV pandemic is still increasing. Despite this, data pertaining to the disease 
presentation from this region compared to the developed world are scarce. The 
clinical presentation of HIV/AIDS and the occurrence of opportunistic infections 
depend on different factors such as the presence of endemic diseases, quality of 
health services, availability of and access to anti-retroviral treatment, and levels 
of education of the population. Pulmonary infections are the leading causes of 
morbidity and mortality in HIV-infected individuals (2;3). A microbiological 
diagnosis is of crucial importance in HIV infected patients with pulmonary 
infections because of atypical clinical and radiographic manifestations and high 
mortality (4), Because in these settings resources are limited, treatment is 
largely empirical, but to be effective, it should be tailored to locally prevailing 
causative organisms. Therefore health facilities equipped with advanced 
diagnostic techniques should monitor the trend of diseases and obtain data on 
aetiological pathogens, so that empirical treatment regimens can be improved.  
 
The aim of this study was to find the aetiological pathogens of pulmonary 
infections in HIV infected patients presenting with pulmonary infection. 
Furthermore, we correlated the pathogens identified with clinical and 
radiographic presentations, level of immunity, and outcome after one month.   
 
MATERIALS AND METHODS  
At Kilimanjaro Christian Medical Centre (KCMC) in northern Tanzania we enrolled 
120 HIV infected patients of 18 years and above, who presented with features of 
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chest infection such as cough (dry or productive) and/or chest pain, dyspnoea, 
fever and chest radiographic abnormalities. These patients were referred by 
clinicians for bronchoscopy as part of patient’s management. Pregnant women 
and patients with oxygen saturation less than 90% under 6 l/min of oxygen were 
excluded from the study. 
 
Bronchoscopy and bronchoalveolar lavage (BAL) was performed by standard 
procedure using flexible fiberoptic bronchoscope. Briefly, the bronchoscope was 
wedged in one of the heavily involved segmental bronchi as seen on the chest 
radiograph. In case of diffuse lung involvement, the scope was wedged in one of 
the segmental bronchi of the right middle lobe. Then aliquots of 50 ml or less of 
sterile saline at body temperature, up to a maximum of 150 ml, were instilled 
and at least 40 ml was sucked back into a sterile container. The sediments of 
BAL fluid obtained by centrifugation at 1500 g for 10 minutes were used for 
laboratory tests to identify the aetiological agent of the chest infection.  
 
For identification of M. tuberculosis, BAL samples were decontaminated with 4% 
NaOH, centrifuged and cultured using in-house made Lowenstein-Jensen (LJ) 
solid medium, with a maximum of 8 weeks incubation. Diagnosis of M. 
tuberculosis was based on positive culture results showing acid fast bacilli (AFB) 
in ZN stain.  
Diagnosis of Pneumocystis pneumonia (PCP) was based on identification of 
Pneumocystis (P) jiroveci with at least one of the following techniques: Giemsa 
stain, Gomori methenamine silver (GMS) stain or immunofluorescence test (IFT). 
Also real time PCR was performed for detection of P. jiroveci DNA in the BAL 
fluid, using 40 as the cycle threshold (CT) cut off value (5). 
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Conventional PCR was used for the diagnosis of Human herpes virus 8 (HHV8) as 
described by Chang and collaborators (6).  
Fungi were diagnosed by direct smear and culture for seven days using 
Sabouraud dextrose agar and for 21 days in Sabouraud dextrose liquid medium 
(Oxoid, Basingstoke, Hampshire, England).  Cryptococci were identified 
microscopically in Giemsa stained slides and confirmed by Mucicarmine stain. 
Murex cryptococcal antigen test in serum was done as described by Jaye et al 
(7).     
Significant growth of common bacteria was determined by routine culture 
procedures. Antibacterial susceptibility testing could not be done.  
Peripheral blood samples were taken for total and differential white blood cell 
count (WBC), haemoglobin, HIV test and CD4 T cell count. Blood was tested for 
anti-HIV antibodies by both Capillus ™ HIV-1/HIV-2 rapid test (Trinity Biotech, 
Bray, Ireland), and Vironostika ® HIV uniform II ag/ab microwell enzyme 
immunoassay (bioMerieux, Marcy 1’Etoile, France). CD4 T cell counting was done 
by flow-cytometry technique (Becton Dickinson Facs Count machine with BD 
FacscountTM reagent).  
Chest radiographs were read by an experienced radiologist, who was informed 
that the patient had symptoms and signs of chest infection and were HIV 
infected, but who was not given other clinical information. Reading was done in 
all cases in a systematic way, describing for each chest film presence or absence 
of the following characteristics: nodules (miliary: < 3 mm; micronodules: 3-6 
mm; macronodules: 6 mm – 3 cm); infiltrates (alveolar, interstitial or mixed), 
cavities and their diameter, and other abnormalities (pleural effusion or 
thickening, masses (> 3 cm), hilar and/or mediastinal adenopathy).  
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Data on outcome of the patients were obtained at the time of discharge and for 
outpatients after 4 weeks of follow up. All patients were given appropriate 
treatment based on the diagnosis reached by the attending physicians. The 
study in no way interfered with the management of patients. Results obtained 
from this study during the course of patient’s management were used in the 
management as needed.    
 
Data analysis was done by SPSS version 12-software for Windows. Normally 
distributed values were presented as mean with standard deviation (SD). In 
other cases data were expressed as median with interquartile range (IQR). Chi-
square test was used to quantify correlations between dichotomous variables. 
Mann-Whitney U test and t-test were used to compare medians and means, 
respectively. P-value equal or less than 0.05 was regarded as statistically 
significant. 
 
Clearance for the study was given by the Institutional (KCMC) and National 
(Tanzania) Ethical Review Boards and informed written consent was obtained 
from each patient or a close relative. 
 
RESULTS 
General characteristics of the study population 
A total of 120 patients were enrolled. The mean age of the study population was 
39 years (SD +/- 10), 54% was male. Median CD4 T cell count was 65 cells/µl 
(IQR 20 – 147). As shown in Table 1, most patients presented with cough, 
chest pain and difficulty in breathing. Of the 120 patients, 19 (15.8%) presented 
with signs and symptoms directly related to respiratory disease only, while the 
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remaining 101 (84.2%) had co-morbidities as well, such as  oral candidiasis, 
different dermatological lesions, lymphadenopathy,  wasting or diarrhea, Table 
1.  Of the 120 patients, 100 (83.3%) used empirical antimicrobial treatment 
prior to or at the time of enrolment in the study and 44 (36.7%) were on 
multiple antimicrobial agents. The most commonly used antimicrobial agents 
were trimethoprin-sulfamethoxazole (TMP-SMX), penicillins and fluconazole, 
used by 59 (49.2%), 52 (43.3%) and 38 (31.7%) patients, respectively. Some 
other antimicrobial agents used were: anti-mycobacterial agents 15 (12.5%) 
patients, and metronidazole, cephalosporins or chloramphenicol in 3-5 patients 
each. 
 
Aetiology of pulmonary infection 
In 71 (59.2%) of the 120 patients causative agents were identified. In the 
remaining 49 (40.8%) patients no organisms were found. In the 71 patients, 89 
causative pathogens were isolated, in 14 two agents and in two three agents. In 
35 (29.2%) patients common bacteria were isolated (Streptococcus pneumoniae 
in 14,  S. pyogenes in one, Staphylococcus aureus in 7, coliform bacteria in 5, 
klebsiella species in 5 and Pseudomonas aeruginosa in 3) , in 28 (23.3%) M. 
tuberculosis, in 12 (10%) HHV8, in 9 (7.5%) P. jiroveci (identified 
microscopically) and in 5 (4.2%) fungi, (Table 2). The fungi identified were 
Cryptococcus neoformans in 3 patients and Aspergillus fumigatus in two. The 
cryptococcal cases were identified by a positive cryptococcal antigen test in 
serum (which was negative in the remaining 117 patients) and in one of the 
three also cryptococci were seen microscopically in the BAL fluid. In a few 
patients yeasts (candida, other) were seen in low concentrations, but these were 
regarded as contaminants from the oropharynx.  
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Real time PCR for P. jiroveci was positive in 17 patients, including the 9 cases in 
which P. jiroveci was seen microscopically. Of the 8 cases positive by real time 
PCR only, in 4 no other organisms were isolated and 2 of the eight were on 
treatment with TMP-SMX for clinical suspicion of PCP. The mean (SD) CT value 
for P. jiroveci detected by both real time PCR and microscopic examination of 
stained BAL fluid was 27 (+/- 4) and the mean CT value for P. jiroveci detected 
by real time PCR only was 35 (+/- 4), t – test = -20.4, p = 0.003.  Only the 9 
(7.5%) cases diagnosed microscopically as well were regarded as indicating PCP, 
thus explaining the pulmonary disease of these patients. 
Among the 28 patients in whom M. tuberculosis was isolated, in 21 this was the 
only pathogen, while 7 cases had co-infection with common bacteria or (in one 
case) HHV8. In 7 cases P. jiroveci was the only pathogen isolated, while two 
patients had both P. jiroveci and coliform bacteria in BAL. Of the 35 patients in 
whom common bacterial pathogens were isolated, 18 had a single bacterial 
pathogen, the remaining had multiple types of infections. No cases of M. 
tuberculosis and P. jiroveci co-infection were found.   
 
Correlation of aetiological agents with radiological and clinical parameters 
Ten patients (8.3%) had normal chest radiographs. In six of these 10 patients 
microorganisms were isolated in BAL fluid; 1 M. tuberculosis, 4 common 
bacteria, and 1 Aspergillus fumigatus infection. The bacteria isolated included 
Staphylococcus aureus, Streptococcus pneumoniae, klebsiella and coliform 
bacteria, either single or in combination. In the remaining four patients with 
normal chest radiograph no organisms were isolated.  
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In 23 of the 28 TB patients chest radiograph showed nodular lesions, Table 3. 
Association between microbiological diagnosis of TB with the radiographic 
presence of nodules was statistically significant, χ2 = 7.3, p = 0.008. The 
diagnosis of TB was further statistically significantly associated with presence of 
the nodular subgroup of micronodules: 21 patients with TB had micronodules on 
the chest radiographs, χ2 = 9.9, p = 0.002. No significant association was found 
between TB and other types of radiographic features or between radiographic 
features and other identified pathogens.  
Of 28 TB patients, 23 had low haemoglobin, χ2 = 9.0, p = 0.005. PCP was 
associated with dyspnoea; all 9 patients with PCP had dyspnoea, χ2 = 8.1, p = 
0.004.     
Seventeen patients (14.2%) had clinical Kaposi’s sarcoma (KS) lesions Table 1; 
10 on the skin, 5 on the palate, and 2 in the airway. Three patients had both 
detectable KS lesion and HHV8 DNA in the BAL fluid, two patients with lesions in 
the airway and the other one on the skin. No statistically significant association 
was found between presence of HHV8 in the BAL fluid and presence of 
detectable KS lesion.  
 
Correlation between causative agents of the chest infection and level of 
immunity  
The overall median CD4 T cell count for all patients in whom causative 
pathogens were found was 47 cells/ml (IQR; 14 – 91) while in patients in whom 
no organisms were found was 100 cell/ml (IQR; 36 – 188), (Mann-Whitney U 
test, p = 0.01).  Patients with M. tuberculosis had median CD4 T cell count of 54 
cells/ µl (IQR, 29 – 128), patients with HHV8 47 (IQR, 9 – 185), patients with 
common bacterial pathogens 44 (IQR, 10 -136), with P. jiroveci 26 (IQR, 7 – 91) 
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and patients with fungi 14 cells/ µl (IQR, 1 – 69). No statistically significant 
difference in CD4 T cell count was found between these groups.  
 
Outcome  
Twenty out of the 120 patients (16.7%) died during the one month follow up 
period. Nine of the 28 patients (32.1%) with TB died, in six of the nine patients 
M. tuberculosis was the only pathogen isolated, while of the other three, two 
also had co-infection with HHV8 and one with Staphylococcus aureus. Five of the 
12 patients (41.7%) with HHV8 died; in two of the five patients HHV8 was the 
only pathogen isolated, while of the remaining three, two had co-infection with 
TB and one with Streptococcus pneumoniae. One of the three patients with 
Cryptococcus neoformans died; in this patient also Staphylococcus aureus and 
klebsiella bacteria were found. One patient died in whom Staphylococcus aureus 
was identified as the only pathogen. Six (12.2%) of the 49 patients with 
undetermined aetiology of chest infection died. None of the 9 patients with PCP 
died. M. tuberculosis and HHV8 were statistically significantly associated with 
mortality, χ2 = 5.7, p = 0.02 and χ2 = 6.0, p = 0.03, respectively. 
 
DISCUSSION 
In the studied population of severely immunosuppressed HIV-infected patients 
with pulmonary infection, the spectrum of pathogens identified was wide, 
ranging from common bacteria, M. tuberculosis, P. jiroveci, HHV8 and fungi. 
Common bacterial infection was the leading cause of pulmonary infection, 
however by far the most deadly single causative bacterial pathogen for chest 
infection was M. tuberculosis. One-third of the TB patients in this study died 
within one-month of follow up. The TB burden in countries highly affected by HIV 
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has increased tremendously and has generally resulted into high mortality (2;8-
11). PTB/HIV co-infected patients exhibit a higher risk of death than other co-
infections in HIV infected patients even when they are matched for CD4 T cell 
count, which is largely due to adverse interaction of the two infections (12;13).  
We found that presence of micronodules on chest radiograph, as well as 
anaemia, were statistically significantly associated with TB. Generally, features 
differentiating TB from other common pulmonary infections in HIV infected 
individuals are few (4;14;15). Given the sputum scarcity in HIV infection and low 
yield of acid fast bacilli (AFB) smear (16), presence of micronodular lesions in 
chest radiographs in the absence of other aetiological agents of respiratory 
infection in these patients should be highly suggestive of TB.  
 
HHV8 was among the most common pathogens found in BAL in this study and 
presence of HHV8 was significantly associated with mortality. HHV8 DNA in BAL 
is mainly associated with Kaposi's sarcoma (KS) of the lungs with high sensitivity 
and specificity than cutaneous KS (17). Lung parenchyma is the primary site of 
pulmonary KS (18) and lesions are therefore easily missed  by bronchoscopy. 
Pulmonary KS, unlike cutaneous KS, contributes decisively to morbidity and 
mortality especially in resource-poor setting where specific treatment is lacking 
(19).  To our knowledge, we are the first to report the presence of HHV8 in BAL 
fluid from HIV seropositive patients from Africa. HHV8 is highly prevalent in sub-
Saharan Africa and some parts of southern Europe but less common elsewhere 
(20).  It can therefore be expected that Kaposi’s sarcoma also contributes 
significantly to pulmonary pathology in sub-Saharan Africa. Our findings are in 
line with this. Besides that, HHV8 has also been associated with primary effusion 
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lymphoma and multicentric Castleman’s disease (21;22), which have very poor 
prognosis and are associated with HIV infection (23;24).    
 
Prevalence of P. jiroveci in this study was higher than previously reported from 
Tanzania (25;26). However, this prevalence may still be an underestimation 
since patients with hypoxaemia despite administration of oxygen could not 
undergo bronchoscopy and thus were excluded from the study. Also, nearly 50% 
of patients had used TMP-SMX prior to enrolment into the study. Lower 
prevalence of PCP in Africa has been largely attributed to diagnostic problems, 
the current trend however shows an overall increase in PCP in developing 
countries (27;28) which could be due to increased awareness and improvement 
in the diagnosis of P. jiroveci. Additional use of real time PCR in this study 
showed a much higher prevalence of PCP than using standard staining 
techniques alone. This is due to the higher sensitivity of real time PCR compared 
to staining techniques (29). However, the median CT value of the cases detected 
by real time PCR alone was significantly higher than that of cases detected by 
staining techniques as well as real time PCR. There was also no overlapping of 
the standard deviations of the CT values. This finding suggests that the validity 
of this rapid molecular technique to distinguish between clinical PCP disease and 
colonization lies on the application of an appropriate CT cut off value (29).  
High prevalence of PCP in this study was not associated with mortality since 
none of the patients with PCP died during the one-month follow up. This may be 
due to our clinical practice of applying early presumptive treatment with TMP-
SMX when PCP is suspected. This implies that in this way the high mortality 
associated with PCP is preventable especially in patients presenting with 
dyspnoea, a symptom which was found to be significantly associated with 
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detection of P. jiroveci in BAL fluid. Instituting presumptive treatment has been 
found to lower mortality in patients with PCP (30).  
 
Common bacteria were also highly prevalent in this study, despite the fact that 
the majority of patients used empirical antibiotic treatment prior to enrolment 
into the study. A similar trend has been observed in other studies in Africa with 
streptococcal pneumonia being the commonest (3;15;26;31-33). Usually 
common bacteria occur in patients with relatively preserved CD4 T cell count, 
but a recent study in north Africa also found that common bacteria were more 
likely to occur at lower CD4 T cell count, (3) and thus common bacteria should 
also be suspected even in advanced HIV/AIDS.  
Few fungal infections (three Cryptococus neoformans, two Aspergillus fumigatus) 
were identified in this study. The incubation period of twenty-one days used for 
fungus culture, however, may have hindered identification of Histoplasma 
capsulatum. In the two patients in whom only cryptococcal antigen test was 
positive, cryptococcal pulmonary infection was entertained as the cause of 
morbidity since no other manifestations of cryptococcal infection (such as 
meningitis) were found.  
 
Other serious co-morbidities not pertaining to pulmonary infection were also 
quite prevalent in this study. These conditions which usually confound morbidity 
are quite common in HIV infected patients from this region (15;26).  
 
In more than 40% of patients no causative organisms were identified. Part of 
this may be attributed to the fact that over 80% used empirical antimicrobial 
treatment prior to the laboratory investigations, but we may have missed 
Chapter Three: Aetiology and presentation of pulmonary infections in AIDS 
 56
pathogens undetectable by our diagnostic methods. This group of patients had a 
somewhat higher median CD4 T cell count and a significantly lower mortality 
rate than the patients in whom causative agents were isolated. In other studies 
the percentage of patients with undetermined aetiology in HIV infection varies, 
but may be almost half of the study population (15;33).  
 
In conclusion, in this group of severely immunosuppressed patients with 
pulmonary infection, we found a wide spectrum of aetiological agents. The main 
identified pathogens were M. tuberculosis, Streptococcus pneumoniae / S. 
pyogenes, HHV8, P. jiroveci and Staphylococcus aureus.  Mortality was high, 
particularly in TB patients and in patients with HHV8. Micronodular chest 
radiographic lesions and anaemia were associated with TB. PCP was significantly 
associated with dyspnoea.  
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 Table 1. Clinical and laboratory features of the study population (n=120) 
_____________________________________________                        
Symptoms 
Cough, n (%)      118 (98.3) 
Chest pain, n (%)     99 (82.5) 
Dyspnoea, n (%)     65 (54.2)  
Wasting, n (%)     37 (30.8) 
Diarrhea, n (%)     15 (12.5) 
Use of antibiotics prior to admission, n (%) 100 (83.3) 
Signs 
Oral candidiasis, n (%)    50 (41.7) 
Fever, n (%)     41 (34.2)  
Skin lesions* n (%)    38 (31.7) 
Lymphadenopathy, n (%)    19 (15.8) 
Kaposi’s sarcoma lesion, n (%)   17 (14.2) 
Herpes zoster lesion, n (%)   16 (13.3) 
Herpes simplex, n (%)    3 (2.5) 
Respiratory rate, mean (SD)   27 (9) 
Laboratory tests 
Oxygen saturation in %, mean (SD)   92 (8)  
CD4 T cell count (cells/μl), median (IQR) 65.0 (20 – 147) 
Haemoglobin (g/l), median (IQR)  90.0 (77 – 115) 
WBC count (x 109 /l), median (IQR)  5.5 (3.7 – 8.4) 
Neutrophil count (x 109 /l), median (IQR) 2.5 (1.6 – 3.0) 
Lymphocyte count (x 109 /l), median (IQR) 1.6 (1.1 – 3.0) 
ESR (mm/hr), median (IQR)   70 (117 – 136) 
_______________________________________________ 
• Other than Kaposi’s sarcoma and herpes zoster lesions 
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Table 2. Causative agents in 120 HIV-infected patients with pulmonary infection  
 AGENTS (*)    FREQUENCY      %___  
 M. tuberculosis    28  23.3 
S. pneumoniae / S. pyogenes (**) 15  12.5 
Human herpes virus 8   12  10.0 
Pneumocystis jiroveci   9  7.5  
 Staphylococcus aureus   7  5.8 
Coliform bacteria    5  4.2 
 Klebsiella species    5  4.2 
 Cryptococcus neoformans   3  2.5   
 Pseudomonas aeroginosa   3  2.5  
 Aspergillus fumigatus   2  1.7   
 No organism isolated    49  40.8
 ____________________________________________________ 
(*) More than one causative agents were found in 16 patients: 14 patients 
with two causative agents, and two patients with three. 
(**) Streptococcus pneumoniae 14; Streptoccus pyogenes 1.
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Table 3. Radiographic features of different causative pathogens (n, %)  
 PATHOGEN MILIARY  NODULES INFILTRATES CAVITIES 
HILAR 
NODES 
PLEURAL 
EFFUSION NORMAL  
MTB (n = 28) 1 (3.6) 23(82.1) 13(46.4) 7 (25) 
6 
(21.4) 6 (21.4) 1 (3.6) 
Bacteria (n = 35) 2 (5.7) 
15 
(44.1.) 14 (40.0) 3 (8.8) 2 (5.9) 4 (11.7) 4 (11.7) 
HHV8 (n = 12) 1 (8.3) 5 (41.7) 7 (58.3) 1 (8.3) 
2 
(16.8) 5 (41.7) 0 (0) 
P. jiroveci  
(n = 9) 0 (0) 5 (55.6) 5 (55.6) 0 (0) 0 (0) 1 (11.1) 0 (0) 
Fungi (n = 5) 1 (20) 2 (40) 3 (60) 0 (0) 1 (20) 1 (20) 1 (20) 
No M.O*. 
(n = 49) 2 (5.7) 30 (61.2) 30 (61.2) 13 (26.5) 
5 
(10.2) 10 (20.4) 4 (2.0) 
* No MO: no microorganism isolated  
MTB: Mycobacterium tuberculosis 
HHV8: Human herpes virus 8 
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ABSTRACT 
Background  
During the first month of treatment of pulmonary tuberculosis (TB), mortality 
among TB/HIV co-infected patients is high and the cause is unclear. Human 
herpes-viruses (HHV) are common in immunosuppression. The interaction 
between TB and HHV is unclear.  
Methods  
We determined by PCR the prevalence of Epstein-Barr virus (EBV), 
Cytomegalovirus (CMV), Herpes simplex viruses 1 and 2 (HSV-1 and HSV-2) and 
Human Herpes Virus 8 (HHV8) in bronchoalveolar lavage (BAL) fluid of 50 HIV 
infected Tanzanian patients with evidence of chest infection: 25 with TB and 25 
with other chest infections. We correlated the one-month mortality in both 
groups to the HHV prevalence.   
 Results  
In 41 (82%) patients, HHV were identified; 21 in the TB and 20 in the non-TB 
group. Prevalence of EBV (78%) and CMV (24%) were the highest. Ten patients 
(20%) died within one-month, 8 (32%) TB and 2 (8%) non-TB patients 
(p=0.11). HHV was not an independent predictor of fatal outcome.    
Conclusion 
In this study we found a very high prevalence of human herpes viruses in the 
BAL fluid of symptomatic and severely immunosuppressed HIV-infected 
Tanzanian patients. Prevalence of HHV was not associated with presence of TB, 
and not associated with mortality in TB patients in one-month follow up.   
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INTRODUCTION  
Pulmonary tuberculosis (TB) is commonly associated with Human 
Immunodeficiency (HIV) infection, especially in the severely HIV-affected 
countries of eastern and southern Africa, like Tanzania where TB has increased 
rapidly in the past decades.(1;2) Despite low levels of resistance of M. 
tuberculosis (MTB) to anti-tuberculosis drugs,(3) about 30% of TB / HIV dually 
affected patients die during the course of treatment,(2-4) and more than half of 
the deaths occur within the first month of treatment. (2;4) The reasons for the 
high mortality are not well understood in the majority of the cases.  Infection 
with the human herpes viruses (HHV) is ubiquitous. In HIV/AIDS, infection with 
Cytomegalovirus (CMV) or Herpes simplex virus (HSV) can result in pneumonia, 
and infection with Human herpes virus 8 (HHV8) in Kaposi sarcoma of the 
lung.(5) HHV are frequently present in the bronchoalveolar lavage (BAL) fluid 
from severely immunocompromised HIV-infected patients with pulmonary 
symptoms, but not present in BAL fluid of healthy, immunocompetent 
individuals.(6)  
 
In daily practice, especially in resource-limited settings which are highly 
burdened by both HIV and tuberculosis, viral infections are not routinely 
investigated in patients with respiratory symptoms. We therefore do not know 
the prevalence of HHV in TB/HIV co-infection, the association between HHV and 
TB in HIV and the role of these viruses in the outcome of patients with TB/HIV 
co-infection. Clinical studies have suggested that beta-herpes virus infection 
may increase the risk for other infections, the severity of infection, or the tempo 
of disease progression. For example, increased incidences of bacterial and fungal 
infections have been reported in association with CMV.(7) The cause of the 
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adverse effects of HHV may be due to the immunomodulatory effects of human 
beta-herpesviruses that have been reported in vitro and in vivo, as well as the 
interaction of these viruses with HIV-1.(7)   
In this study among HIV infected patients with evidence of chest infection in 
Tanzania, we used PCR to determine the prevalence of the most common HHV: 
Epstein-Barr virus (EBV), CMV, HHV8 and HSV-1 and HSV-2 in BAL fluid. We 
determined the prevalence of HHV in patients with TB and those with non-
tuberculous pulmonary infection (non-TB). Furthermore, we related the one-
month mortality in both groups to the prevalence of HHV-DNA in BAL fluid. 
 
MATERIALS AND METHODS   
The study was performed at Kilimanjaro Christian Medical Centre (KCMC), Moshi, 
the reference hospital for the northern zone of Tanzania, between November 
2003 and September 2004. We enrolled 50 HIV-infected patients with 
pulmonary infection, 25 with proven TB and 25 with non-TB pulmonary 
infections. The TB group was MTB positive by both Lowenstein-Jensen (LJ) 
culture and real time (rt) PCR and the non-TB group was MTB negative by both 
LJ culture and rtPCR of the BAL fluid. Culture was done by in-house made LJ, 
and rtPCR was done as described by Savelkoul and colleagues.(8) TB patients 
were randomly selected from a larger study on causes of chest infection in HIV 
infected patients with clinical evidence of chest infection and an abnormal chest 
radiograph. The matched control for each TB patient was identified as the first 
patient with non-TB lung disease appearing in the dataset who was of the same 
age (+/- 5 years) and comparable CD4 T cell count (+/- 25 cells/mm3).   
To obtain BAL, patients underwent bronchoscopy with BAL using flexible 
fiberoptic bronchoscope (Olympus p45 Tokyo, Japan).  Briefly , after routine 
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preparation of the patient, the bronchoscope was wedged in one of the heavily 
involved segmental bronchi as seen on the chest radiograph, or in the middle 
lobe in case of diffuse lung involvement. Then aliquots of 50 ml of sterile saline 
at body temperature were instilled up to a maximum of 150 ml, and sucked back 
into a sterile container.  The BAL fluid obtained was used for detection of 
causative microorganisms. Culture for M. tuberculosis by Lowenstein-Jensen (LJ) 
solid medium was done using the BAL sediment obtained after decontamination 
with 4% NaOH and centrifugation at 1500 g for 10 minutes.  Real time PCR of 
BAL fluid was performed using IS6110 insertion element as a multicopy target 
for molecular detection of M. tuberculosis complex.(8) A cut-off cycle threshold 
(ct) value of 40 cycles was used. Detection of other organisms (e.g. bacteria, 
fungi) was done by staining and culture using standard procedures.  
 
Blood samples were taken for haemoglobin (HB), total white blood cell count 
(WBC), HIV test and CD4 count. Anti-HIV antibodies were detected using 
Capillus ™ HIV-1/HIV-2 rapid test (Trinity Biotech, Bray, Ireland) and 
Vironostika ® HIV uniform II ag/ab microwell enzyme immunoassay 
(bioMerieux, Marcy 1’Etoile, France). CD4 counting was done by flow-cytometry 
(Becton Dickinson Facs Count machine with BD FacscountTM reagent).  
A portion of the BAL fluid was used for investigation of CMV, EBV, HSV-1/2, and 
HHV8; DNA extraction of the BAL samples (200 µl) was performed with the 
MagNA Pure LC Isolation station with the Total Nucleic Acid Isolation Kit (Roche 
Molecular Diagnostics, Germany) according to the manufacturer’s instructions. 
DNA was eluted in 50 µl, and 10 µl was used for PCR. CMV DNA was detected by 
rt-PCR using the primers and probes previously described by Kalpoe and 
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collaborators,(9) on a LightCycler platform (Roche Molecular Diagnostics, 
Germany). 
EBV and HSV-1/2 DNA were detected by rt-PCR using respectively the 
LightCycler EBV quantification kit and LightCycler HSV 1/2 detection kit as 
described by the manufacturer (Roche Molecular Diagnostics, Germany). 
LightCycler PCRs were set up in a final volume of 20 µl with the Fast start DNA 
Master Hybridization Probes Kit (Roche Molecular Diagnostics, Germany). After 
one step at 95°C for 10 min the samples were cycled 45 times (denaturation at 
95°C for 5 s, annealing at 55°C for 10 s, and extension at 72°C for 10 s all steps 
with a ramp rate of 20°C/s). Fluorescence curves were analyzed with the 
LightCycler software, version 3.5. Semi quantitative analysis was given for EBV 
and CMV only, since there is no standard line available for HSV. HHV-8 DNA was 
detected by conventional PCR as described by Chang and collaborators.(10) 
Data on the outcome of the patients were collected during the period of 
hospitalization and for outpatients during 4 weeks of follow up. All patients were 
given appropriate treatment based on the diagnosis reached by the attending 
team. All laboratory samples for the study were obtained prior to the start of 
anti-TB treatment. The study in no way interfered with the management of 
patients. Results obtained from this study during the course of patient’s 
management were used in the management as needed.   This study was part of 
the Chest Infection Study, which was conducted at the KCMC hospital. Ethical 
clearance was obtained from KCMC and from the Tanzanian national body 
governing research (NIMR). Informed written consent was obtained from every 
patient before any procedure was performed.  
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Data analysis 
Using SPSS version 13 statistical package, normally distributed values were 
presented as mean with standard deviation (+/-SD). In other cases data were 
expressed as median with inter-quartile range (IQR). The McNemar’s exact test 
and Wilcoxon Rank-sum test for related samples were used to test differences in 
the matched case-control data in case of dichotomous and continuous variables, 
respectively. For variables that were not used in the matching procedures, 
associations were tested for statistical significance using the Chi-square for 
dichotomous variables and Spearman’s correlation coefficient for continuous 
variables, respectively. A p-value equal or less than 0.05 was regarded as 
statistically significant. 
 
RESULTS   
Characteristics of the study population 
Fifty patients were enrolled in the study; forty-three (86%) in-patients and 7 
(14%) out-patients. For in-patients the median duration of hospitalization was 
10 days (IQR 7-14 days). The mean age for the study population was 38 (+/- 8) 
years. Females comprised 54% of the study population. Seventeen (34%) of the 
50 patients had fever, 29 (58%) had dyspnoea and mean oxygen saturation was 
91% (+/- 9). As shown in Table 1, these characteristics, as well as CD4 T cell 
count, HB and WBC count, were similar in the two groups of patients (i.e. TB and 
the non-TB). Forty-seven patients (93%) had used various types of antibiotics, 
but not antimycobacterial agents before admission to this hospital. In the non-
TB group, causative organisms were identified in 14 (56%) of the 25 patients: in 
9, bacteria were cultured (2 S. pneumoniae, 1 S. pyogenes, 2 Staph. aureus, 2 
Ps. aeruginosa and 2 coliform bacteria), in 2 Pneumocystis jeroveci and in 3 
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patients fungi were identified (1 Cryptococcus neoformans, 2 Aspergillus 
fumigatus), while in the remaining 11 patients (44%) no causative organism was 
identified.       
 
Herpes viruses identified  
In 41 (82%) of 50 patients, one or more human herpes virus DNA were 
identified in the BAL fluid, 21 in the TB group and 20 in the non-TB group 
(McNemar test, p = 1.0). EBV was identified in 39 (78%) patients, CMV in 12 
(24%), HHV8 in 7 (14%), HSV-1 in 7 (14%), and HSV-2 in 1 (2%). Nineteen 
(46.3%) of the 41 patients had more than one type of HHV in the BAL fluid. Of 
these 19 patients, 8 were in the TB and 11 in non-TB group (McNemar test, p = 
0.55). Sixteen (84.2%) of the 19 patients with multiple HHV were female (χ2 = 
4.45, p = 0.035).  
EBV had the highest prevalence in both groups: 20 (80%) of 25 patients with TB 
and 19 (76%) of 25 patients with non-TB chest problems had positive PCR in 
BAL for EBV (McNemar test, p = 1.0). CMV was identified in 3 (12%) of the TB 
patients and in 9 (36%) of the patients with non-TB infections (McNemar test, p 
= 0.11). HHV8 DNA was detected in 2 (8%)  patients with TB and 5 (20%) 
patients with non-TB infections (McNemar test, p = 0.45), HSV-1 in 4 (16%) 
patients with TB and 3 (12%) patients with non-TB infections (McNemar test, p 
= 1.0), and HSV-2 was seen in one non-TB patient (Figure 1).  
 
 Viral load estimation for EBV and CMV  
Median EBV load in the TB group was 60 copies/ml (IQR 40 – 500) and not 
different from that for the non-TB group, 80 copies/ml (IQR 10 – 500) (Wilcoxon 
Rank-sum, p=0.66). The median viral load for CMV in the TB group was 5000 
Chapter Four: Human herpes viruses in BAL fluid of PTB/HIV co-infected patients 
 73
copies/ml (IQR 100 – 10000) and that for non-TB group was 1000 copies/ml 
(IQR 300 – 7500) (Wilcoxon Rank-sum, p=0.86).  
Correlation of herpes viruses identified with laboratory and clinical parameters 
Ten (52.6%) of the 19 patients with multiple HHV had low WBC i.e. less than 
3.5*109/l, while in the patients with single type of HHV only 3 (13.6%) of 22 
patients had low WBC (χ2 = 4.3, p = 0.017).  
Mean oxygen saturation of the 12 patients with CMV was 90% (+/- 8%). Nine 
patients (75%) had dyspnoea and 7 (58.3%) had fever. Seven patients (58.3%) 
had both fever and dyspnoea.  
In the non-TB group, eight of the nine (88.9%) with CMV DNA in the BAL fluid 
did not grow any other organism in culture of the BAL fluid.  
Of the 7 cases with HSV-1 DNA, 6 had CD4 T cell count of less than 50 cells/ml, 
while that of the remaining case was 82 cell/ml. HSV – 1 was statistically 
significantly associated with CD4 T cell count less than 50 cells/ml, (χ2 = 4.15, p 
= 0.042). Three of the 6 patients with CD4 T cell count less than 50/ml, had 
CD4 T cell less than 5 cells/ml.  The patient with HSV-2 had CD4 T cell count of 
36 cells/ml. No association was found between CD4 T cell count and presence of 
other HHV, whether single or multiple HHV in the same patient.  
Seven patients had HHV8 in the BAL fluid and 8 patients had clinically detectable 
Kaposi’s sarcoma (KS) on routine clinical examination, but only two patients had 
both HHV8 in the BAL fluid and clinically detected KS lesions; one KS lesion was 
seen on the soft palate and the other in the trachea. There was no statistically 
significant association between presence of KS lesions and HHV8 in BAL fluid.  
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Clinical outcome in relation to presence of herpes viruses  
Ten out of the 50 patients (20%) died during the one-month follow-up period. Of 
these, 8 (32%) were TB cases and 2 (8%) did not have TB (McNemar test, p = 
0.11). Of the 8 who died in the TB group, 4 were AFB smear positive and started 
on anti-TB treatment immediately, 2 were put on empirical anti-TB treatment on 
fourth and tenth day after admission, respectively. The other two were put on 
empirical common antibiotic treatment by the attending team pending culture 
results. Seven of the 8 patients who died in the TB group had at least one type 
of HHV DNA in the BAL fluid and the other one did not have HHV. Of the two who 
died in the non-TB group, one had and the other did not have HHV DNA in BAL 
fluid.  
The presence of viral infections was not associated with fatal outcome (χ2 = 
0.34, p = 0.85) and CD4 T cell count at enrolment was not a predictor of fatal 
outcome in this selcted group of patients (Wilcoxon rank-sum, p=0.42). 
 
DISCUSSION 
In this study we found a very high prevalence of HHV in BAL fluid of HIV-infected 
Tanzanian patients presenting with pulmonary infections. The prevalence was 
almost two-fold higher than in a similar study conducted in Danish HIV-infected 
patients,(6) although the two studies were similar in terms of sample size of the 
study, age and CD4 T cell count of the patients. In the study conducted in 
Denmark, the overall prevalence of HHV in HIV-1- infected patients presenting 
with pneumonia was 44%.(6) In our study, the rate of multiple types of HHV of 
46.3 % in one patient was also very high compared to the Danish study.(6) This 
showed a distinct difference in HHV burden between these two HIV study 
populations from two different socio-economical and environmental settings, 
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despite similar levels of HIV-immunosuppression. It has been speculated that 
recurrent malarial or other parasitic infections, may contribute to the high 
prevalence of HHV-DNA in respiratory samples in Africa.(11) Frequent parasitic 
infections are very common in sub-Saharan Africa, including in our study area.  
Malaria and other parasites affect the immune system and may impair HHV-
specific T cell immunity and, thus, influence HHV- DNA levels.(12)  
 
In our study the prevalence of HHV DNA in BAL fluid was equally high in both 
patients with TB and those with non-TB chest problems. Active M. tuberculosis 
infection in HIV-1 infection enhances replication and increases HIV-1 viral 
load,(13) resulting into fast progression of HIV-1 infection.  We did not find 
significantly higher viral loads for EBV and CMV in TB patients compared with 
non-TB patients. This indicated that presence of HHV in BAL fluid was not 
influenced by M. tuberculosis infection and vise versa.  
 
Of the four human herpesviruses, EBV was identified in 39 (78%) of 50 patients. 
This high prevalence was much higher than what was found in Denmark 
(5.5%).(6) A high prevalence of EBV infection in a developing country compared 
to a developed country was also observed in a study by Grando LJ and 
colleagues,(14) who identified oral EBV in 56% of Brazilian children and 27% of 
American children. Relatively few studies are available concerning EBV and 
pulmonary disease in AIDS,(6) however one could speculate that high frequency 
of EBV in HIV-infected patients observed in our study will increase the risk of 
developing EBV-related pathologies such as Kaposi’s sarcoma,(15) 
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lymphoproliferative disorders, lymphoma, (5) and interstitial lung disease with 
fibrosis,(16) and worsen the long term outcome of these patients. 
 
The clinical importance of pulmonary CMV in HIV infected patients is 
controversial. CMV is rarely a primary cause of pneumonia in these patients.(17) 
The diagnosis of CMV pneumonitis according to Tamm and colleagues is based 
on symptoms of fever, dyspnoea, hypoxia, and diffuse infiltrates on chest 
radiograph in combination with microscopic detection of CMV in the BAL 
fluid.(18) According to the Canadian Society of Transplantation, in transplant 
patients, the presence of features of pulmonary disease and evidence of CMV 
DNA in BAL fluid in the absence of other documented cause is defined as 
probable CMV pneumonia.(19)  In our study all patients had signs and 
symptoms suggestive of respiratory infection and in most patients with CMV DNA 
in BAL no other organisms were found. CMV viral load however, was not high 
and the presence of CMV as infection or disease did not have an independent 
influence on the one-month outcome of the patients even without specific anti-
CMV treatment. However the detection of CMV in BAL even without evidence of a 
disease in this study is indicative of high risk of later development of CMV 
disease, (20)  or other complications associated with CMV e.g. other 
opportunistic infections, (7) and therefore long-term follow-up is needed for such 
patients. 
Of 7 patients with HHV8 in BAL fluid, only 2 had clinically visible Kaposi sarcoma 
(KS) lesions on routine clinical examination. Detection of HHV8 in BAL is 
associated with pulmonary KS,(21) however its association with skin KS is 
unreliable.(22) In our patients KS lesions in the lungs may have been missed by 
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bronchoscopy. This is well possible in case of minor lesions located distally in the 
endobronchial tree or in the lung parenchyma. Lung parenchyma is the primary 
site for pulmonary KS,(21) although it may occur in the visceral pleura, 
mediastinal lymph nodes and tracheobronchial tree.(23) In our patients, 
presence of HHV8 in BAL fluid without clinical evidence of lung KS may indicate 
subclinical KS or high risk for later development of KS.(24;25) Pulmonary KS, 
unlike skin KS, contributes decisively to morbidity and mortality, (24) and this 
remains so to-date in our set up due to lack of specific treatment for KS. These 
patients with HHV8 in BAL fluid also have a higher risk for later development of 
other conditions related to HHV8 such as primary effusion lymphoma (PEL),(26) 
and Multicentric Castlemans’ disease (MCD).(27) KS, PEL and MCD have been 
found to be associated with HIV infection.(5)  
 
Herpes simplex pneumonia is extremely rare even in AIDS patients. Afessa 
found only one case in 1,225 consecutive hospital admissions. (28) In our study 
the HSV prevalence of 14% was very high compared to other studies (29;30), 
although we do realize that presence of HSV DNA does not necessarily mean 
HSV pneumonitis. Usually herpes pneumonia is due to HSV-1.(29) Studies have 
shown that critically ill patients with HSV-1 in BAL fluid have 40% chance of 
dying,(31) mainly because of severe underlying disease and co-morbidity, which 
may predispose to endogenous reactivation of HSV-1. For this reason, isolation 
of HSV-1 from lung secretions was thought to be a marker of severe illness,(31) 
and poor prognosis. In our study however, despite of high prevalence and 
association with low CD4 T cell count (which is a marker of advanced HIV/AIDS), 
HSV-1 was not an independent determinant of fatal outcome in one-month 
follow-up.  
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Pneumonia due to HSV-2 is even rarer.(32) A report has shown that HSV-2 
pneumonia can lead to complications like pulmonary hypertension and heart 
failure, conditions which resolve with anti-herpetic drugs.(29) In our study the 
patient who had HSV-2 infection improved without specific antiviral treatment 
 
Finally, it is difficult to rule out completely that the presence of HHV-DNA in BAL 
fluid was caused by contamination from the upper respiratory tract. High levels 
of EBV-DNA have been reported in Uganda indicating that the risk of 
contamination is realistic.(11) In case of contamination, however, we would 
have expected to detect relatively much more frequent HSV-1 DNA in the lavage 
fluid since shedding of this virus, even in non-immunocompromised subjects, is 
very common.(33)   
 
Conclusion  
In this study we found a very high prevalence of human herpes viruses in the 
BAL fluid of symptomatic and severely immunosuppressed HIV-infected 
Tanzanian patients. The prevalence of any HHV was equally high in TB and non- 
TB patients. Thus, we were unable to show in this relatively small study that M. 
tuberculosis enhanced reactivation and replication of HHV and we also were not 
able establish any influence of HHV infection to TB. In both the TB and the non-
TB group, the prevalence of EBV was the highest of all HHV. Mortality in TB 
patients at one-month follow up was very high, however presence of HHV in BAL 
fluid was not an independent predictor of one-month mortality. A larger study, 
also using immuno-histochemical staining for HHV of BAL material is warranted 
to elucidate the clinical significance of HHV in HIV infected patients.  
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Table 1. Characteristics of the two groups of HIV-infected patients.   
Parameter TB Non-TB 
Number of patients, N 25 25 
Hospital stay in days, median (IQR) 10 (7-15) 9 (7-14) 
Age, mean (SD) 38 (8) 37 (8) 
M : F ratio 1 : 1.1 1 : 1.3 
Oxygen saturation in %, mean (SD)  94 (6) 89 (10) 
Dyspnoea, n (%) 13 (52) 16 (64) 
Fever, n (%) 8 (32) 9 (36) 
CD4 T cell count/mm3, median (IQR) 47 (30 – 81) 50 (17 – 97) 
HB g/l, median (IQR) 82 (65.5 – 96.0) 89(67.5 – 111.0) 
WBC *10 9/l, median (IQR) 5.4 (3.1 – 9.3) 4.9 (3.3 – 6.6) 
IQR: interquartile range; HB: haemoglobin; WBC: white blood cell count      
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Figure 1. Number of patients with herpes viruses in BAL fluid in 25 HIV infected 
patients with TB and 25 HIV infected patients with non-TB pulmonary infections   
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ABSTRACT 
Background  
 
Tuberculosis (TB) in Africa is increasing due to the HIV epidemic and in 
HIV/AIDS patients it presents atypically. Pulmonary tuberculosis (PTB) in Africa 
is mainly diagnosed clinically, by chest radiograph or by sputum smear for acid 
fast bacilli (AFB).  
Methods  
We evaluated in 120 HIV infected patients with chest infection the diagnostic 
accuracy of AFB smear of sputum and bronchoalveolar lavage fluid (BAL), 
sputum M. tuberculosis (MTB) culture, real-time PCR and MycoDot® serological 
test, using MTB culture of BAL as gold standard. We correlated PCR cycle 
threshold values (CT) to the culture results. Retrospectively, we evaluated the 
development of active TB in patients with positive PCR but negative culture.  
Results  
Culture of BAL fluid identified 28 patients with PTB. Fifty-six patients could not 
produce adequate sputum. Sputum AFB smear and the serological test had 
sensitivities of 66.7% and 0%, respectively. PCR with CT 40 was positive in 73 
patients, 27 of which were also TB culture positive (96.4% sensitivity and 52.3% 
specificity of PCR). PCR with CT 32 had sensitivity of 85.7% and specificity of 
90.9% to diagnose PTB in BAL. No patients with positive PCR but negative 
culture developed active TB during 18 months follow-up.  
Conclusion 
In these HIV infected patients, AFB smear and serology had very low 
sensitivities. PCR of BAL with CT value 32 had improved specificity to diagnose 
active PTB. A prospective follow up study is warranted in TB/HIV endemic 
settings, applying real time PCR to both sputum and BAL.  
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INTRODUCTION 
About one-third of the world population is infected with Mycobacterium 
tuberculosis (MTB). By 2000 there were 8.3 million new cases and up to 2.2 
million deaths per year due to tuberculosis (TB) (1). Human immunodeficiency 
virus (HIV) infection is a potent risk factor for TB. HIV increases the risk of 
reactivating latent MTB (2), of rapid TB progression after infection or reinfection 
with MTB (3) and of raised transmission rate in the community (4). The TB 
burden in countries with a generalized HIV epidemic has therefore increased 
rapidly over the past decade, especially in the severely affected countries of 
eastern and southern Africa (5). In these countries up to 31% of new TB cases 
are attributed to HIV infection (1). In Tanzania, new TB cases increased five fold 
from 11,753 in 1983 to 61,603 in 2001 largely due to HIV/AIDS (6).   TB has 
therefore become the most common disease associated with AIDS and the 
leading cause of morbidity and mortality (7;8).    Diagnosis of pulmonary 
tuberculosis (PTB) in these countries depends largely on the clinical picture, 
radiographic findings and sputum Acid Fast Bacilli (AFB) smears (9). Largely this 
is due to the lack of other diagnostic facilities. 
Unlike the straightforward diagnosis and typical presentation of PTB in HIV-1 
seronegative individuals (10;11), the diagnosis of PTB in HIV/AIDS is more 
difficult. PTB in HIV/AIDS frequently has atypical clinical and radiographic 
presentation (11-14).  Also, different causes of pulmonary infection in HIV/AIDS 
are often indistinguishable on the basis of clinical and radiological features (15). 
This increases the chances of inaccurate clinical diagnosis. Indeed, it has been 
found that more than 60% of AIDS patients on empirical therapy will need a 
change in their antibiotic treatment when the aetiology of the chest infection is 
eventually established (16). Therefore, for appropriate and effective treatment 
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an aetiological diagnosis is necessary, especially in PTB because of the high 
mortality associated with PTB in HIV/AIDS.    
 
The aim of the study in this TB and HIV endemic setting was to assess the 
performance of different diagnostic laboratory methods: AFB smear, culture, real 
time PCR (PCR) using sputum and/or bronchoalveolar lavage fluid (BAL) and the 
MycoDot® serological test in TB/HIV co-infected patients. All patients had 
symptoms and signs of chest infection. Other aims were, to determine the 
duration of BAL culture growth, to determine the proportion of smear-negative 
tuberculosis, to correlate the bacillar load to duration of culture growth, to 
correlate the BAL TB results with cycle threshold (CT) value in positive PCR 
cases, and to determine the long-term clinical significance of positive PCR when 
culture was negative for TB. To our knowledge this is the first study using real 
time PCR for TB in Sub-Saharan Africa.    
 
MATERIALS AND METHODS 
At Kilimanjaro Christian Medical Centre (KCMC) in Northern Tanzania, we 
enrolled 120 HIV infected patients of 18 years and above, who presented with 
features of chest infection: cough (dry or productive), fever, chest pain, or chest 
radiographic abnormalities. These patients were referred for bronchoscopy by 
the attending physician as part of patient’s management. More than four-fifths 
of these patients had previous empirical antibiotic treatment for suspected 
pneumonia before bronchoscopy. Pregnant women and patients with oxygen 
saturation less than 90% under 6 l/min of oxygen were excluded from the study. 
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Two sputum samples (morning-spot) were collected prior to bronchoscopy. 
Peripheral blood samples for haemoglobin (HB), total and differential white blood 
cell count (WBC), HIV test, CD4 T cell count and MycoDot® serological test were 
taken. Using a flexible fibreoptic bronchoscope (Olympus p45 Tokyo, Japan) 
bronchoscopy was performed by standard procedure. Briefly, the bronchoscope 
was wedged into one of the heavily involved segmental bronchi as seen on the 
chest radiograph. Alternatively, in the case of diffuse lung involvement, the 
bronchoscope was wedged in one of the segmental bronchi of the middle lobe. 
Then aliquots of 50 ml or less of sterile saline at body temperature, up to a 
maximum of 150 ml in total, were instilled and sucked back into a sterile 
container. A portion of the BAL fluid was used for the diagnostic tests.  
  
Sputum and BAL samples were pretreated by decontamination with 4% (w/v) 
NaOH and centrifugation at 1500 g for 10 minutes. The sediment was used for 
the different diagnostic tests.  Direct smears were examined for AFB after Ziehl 
Neelsen (ZN) staining. MTB culture was performed using in-house made 
Lowenstein-Jensen (LJ) solid medium, with a maximum incubation period of 8 
weeks. Reading and reporting of the results were done weekly. When colonies 
were seen in the LJ medium, ZN staining was done to confirm the presence of 
mycobacteria. For sputum smear to be positive at least one of the two samples 
had to be positive for AFB.  
 
Aliquots of BAL fluid were kept at –20 0 C until PCR for MTB and spoligotyping 
were done. DNA extraction of the BAL samples (200 µl) was performed with the 
MagNA Pure LC Isolation station with the Total Nucleic Acid Isolation Kit (Roche 
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Molecular Diagnostics, Germany) according to the manufacturer’s instructions. 
DNA was eluted in 50 µl, and 10 µl was used for PCR.  
 
MTB DNA amplification was performed by PCR of BAL fluid using insertion 
element IS6110 as a multicopy target for molecular detection of MTB complex 
(17).  Briefly, a set of Mycobacterium tuberculosis-specific primers, F (GGG TAG 
CAG ACC TCA CCT ATG TG) and R (CCT TTG TCA CCG ACG CCT A), was used to 
amplify 88 bp of the IS6110-gene. Detection took place with a Mycobacterium 
tuberculosis-specific MGB-probe, FAM-labelled (TCG CCT ACG TGG CCT TT). DNA 
amplification/detection was done in 30 μl reaction volume with the ABI PRISM 
7000. Template DNA, 333 nM of each primer and 150 nM probe. The PCR-
program consisted of 2 min 50 °C, 10 min 95 °C and 45 times 15 sec at 95 °C 
and 1 min at 60 °C. The same primers amplify the IS6110 gene of the internal 
control, MSM1008. This DNA is added to see if samples contain inhibitors, which 
affect the efficiency of the PCR. Detection of the amplified internal control took 
place by a VIC-labelled TAMRA probe (CAG CTG CTA CAT GCC GGC GC). A cut-
off cycle-threshold (CT) value of 40 cycles was used.  
 
For those who were MTB positive by BAL culture, spoligotyping was performed 
as described (18). Amplification of the spacers was performed using DNA extract 
and primers (DRa and DRb) corresponding to the direct repeat (DR) region of 
the genome of M. tuberculosis. Of the DNA extract 10 μl were mixed with 40 μl 
PCR mix containing 5 μl 10x PCR buffer, 3 μl magnesium chloride (25 mM), 4 μl 
dNTP mix (2.5 mM dNTP each), 50 pmol DRa primer, 50 pmol DRb primer, 0.2 μl 
Taq polymerase and 0.25 μl Tris 1 M (pH 9.0), 0.5 μl UDG (1 U/μl). Amplification 
and hybridization were performed according to the manufacturer’s manual 
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(Isogen Bioscience BV, Maarssen, The Netherlands). The hybridized membrane 
was exposed to X-ray film for detection of the hybridization signal. The X-ray 
film (HyperfilmTM ECL, Amersham Bioscience UK Ltd.) was read manually to 
obtain a complete pattern of the spacers between the DR regions harboured by a 
particular strain. Preventive measures were taken against contamination with 
either previously amplified DNA or amplicons from previous reactions; the 
procedures were described by Kwok et al and Longo et al, respectively, (19;20). 
Computer-assisted analysis of spoligotyping patterns was carried out with 
Bionumerics 4.0 (Applied Maths, St-Martin-Latem, Belgium). 
 
Blood was tested for anti-HIV antibodies by Capillus™ HIV-1/HIV-2 rapid test 
(Trinity Biotech, Bray, Ireland) and Vironostika® HIV uniform II ag/ab microwell 
enzyme immunoassay (bioMerieux, Marcy 1’Etoile, France). CD4 T cell counting 
was done by flow-cytometry technique (Becton Dickinson Facs Count machine 
with BD FacscountTM reagent). Serum was examined using IgG-based MycoDot® 
assay to detect antimycobacterial antibodies against Lipoarabinomannan (LAM) 
antigen (MycoDot ® Mossman associates, USA) using the manufacturer’s 
instruction manual.   
 
We evaluated 18 months after completion of patients’ enrolment the 
development of active TB in the subjects who were positive for MTB by PCR but 
negative by culture. This retrospective evaluation excluded the subjects who 
were given empirical TB treatment. For the remainder we looked for 
microbiological diagnosis of TB during this period. The case records were 
obtained from the Infectious Disease Clinic (IDC) of our institution where these 
HIV-infected patients attended. The IDC is the referral HIV centre for the 
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northern zone of Tanzania, where HIV infected patients attended regularly at an 
interval of one to three months and whenever necessary. They are monitored for 
HIV progression. They are examined, investigated and treated for co-infections, 
and started antiretroviral treatment (ARV) when indicated. The clinic is run by 
medical specialists and trained staff. It is supported by a range of departments 
including microbiology, pathology and radiology. Every visit is documented and 
patients’ records are kept in the department of medical records.   
   
Data analysis was done by SPSS version 10-software for Windows. Normally 
distributed values were presented as mean with standard deviation (SD). In 
other cases data were expressed as median with interquartile range (IQR). Chi-
square tests were used to quantify correlation between dichotomous variables 
and Spearman’s correlation coefficient was used to quantify correlations between 
continuous variables. P-value equal or less than 0.05 was regarded as 
statistically significant. 
Clearance for the study was given by the Institutional (KCMC hospital) and 
National Ethical Review Boards and informed written consent obtained from each 
patient or a close relative. 
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RESULTS 
General characteristics of the study population. 
We enrolled 120 patients; with a mean age of 39 years (SD +/-9). The male to 
female ratio was 1: 1.2 and median CD4 count 65 (IQR = 20 – 147) cells/ml.   
 
Laboratory methods for PTB diagnosis, and their sensitivity and specificity 
Table 1 shows the results of different diagnostic tests. Sensitivity and specificity 
were calculated using BAL MTB culture as the gold standard. Twenty-eight 
patients (23.3%) were MTB culture positive and 18 cases (15%) smear positive 
for AFB from the BAL specimens. Four of the 120 samples (3.3%) had 
contamination. Of the 28 BAL culture positive samples, 16 were AFB positive and 
12 AFB negative. Of the two remaining smear positive samples, one sample had 
contamination and the other was AFB positive but BAL culture negative. The 
sensitivity and specificity of BAL AFB smear were 57.1% and 98.9%, 
respectively. Sixty-four patients (53.3%) out of 120 produced adequate sputum. 
The remaining 56 (46.7%) either had a dry cough (43 patients, 35.8%) or had 
poor quality and/or inadequate amount of sputum (13 patients, 10.8%). Of the 
64 patients with adequate sputum, 12 were TB culture positive (18.8%), 8 
smear positive for AFB (12.5%) and 48 were TB culture negative in both sputum 
and BAL fluid. Two sputum samples were contaminated. The sensitivity and 
specificity of the 64 patients who could produce sputum were 100% and 100%, 
respectively for culture, and 66.7% and 100%, respectively for AFB smear. 
In BAL fluid, using 40 as the CT cut-off value of PCR, 73 samples were found to 
be positive for MTB; 27 of them were also BAL culture positive, 42 were culture 
negative and 4 samples were contaminated in culture. One culture positive 
sample was PCR negative for MTB and 46 samples were negative by both culture 
Chapter Five: PTB diagnosis in HIV infection and the contribution of real time PCR 
 96
and PCR. The sensitivity and specificity of PCR were 96.4% and 52.3%, 
respectively. 
By using 32 as the CT cut-off value of PCR, 34 samples were found to be positive 
for MTB; 24 of them were also culture positive, eight were culture negative and 
2 PCR positive were contaminated (the other 2 contaminated samples were PCR 
negative). One culture positive sample was PCR negative for MTB and 80 
samples were negative by both culture and PCR. The sensitivity and specificity of 
PCR (CT value = 32) were 85.7% and 90.9%, respectively (Table 1). 
Two patients (1.7%) were TB positive as determined by the MycoDot® test, 
another 4 patients had dubious results. None of the BAL culture positive patients 
was positive by the serological test. The sensitivity and specificity of the 
serological test were 0% and 97.6%, respectively. 
 
Correlation of BAL TB culture and AFB smear results with PCR cycle threshold 
(CT) value (n = 73 positive PCR) 
As seen in Figure 1, the median CT value in PCR for the 27 BAL TB culture 
positive cases was 24 (IQR 22 - 32) and that of the 42 BAL TB culture negative 
cases was 35 (IQR 34 – 37). The difference was statistically highly significant 
(Spearman’s correlation coefficient, p < 0.0001). The median CT value for the 17 
AFB smear positive cases was 24 (IQR 22 – 27) and that for the 56 negative 
cases 35 (IQR 32 - 37), Spearman’s correlation coefficient, p < 0.0001. Both 
culture and smear positive results were statistically significantly associated with 
high MTB DNA load and negative culture results associated with low MTB DNA 
load as determined by CT values in PCR.  
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Spoligotypes of cultured MTB strains 
In 25 of the 28 BAL samples with positive MTB culture, we were able to perform 
spoligotyping of the strains. In all 25 the spoligotypes indicated that the isolates 
belong to M. tuberculosis complex. Sixteen of the 25 showed different patterns. 
Two patterns were found in 2 strains, one pattern in 3 strains and one in 5 
strains.  
  
Duration of culture growth and correlation with number of colonies in BAL culture 
positive samples.   
Of the 28 BAL samples with positive TB culture, 6 samples (21.4%) allowed MTB 
to be cultured from them within four weeks, the rest 22 (78.6%) required a 
month or more for growth. Seventeen (60.7%) of the 28 samples grew only few 
colonies (i.e. a maximum of TB +1) and 11 (39.3%) samples grew more 
colonies (i.e. +2 and +3).   
 
Correlation between MTB PCR / culture results and level of immunity 
The median CD4 T cell count of the 27 patients positive for MTB by both PCR and 
culture was 47 (IQR 29 – 80) cells/µl, the median CD4 T cell count for the 42 
patients with positive PCR but negative MTB culture results was 76 (IQR 18 – 
186) cells/µl and the median CD4 T cell count for 46 patients with negative 
results by both PCR and culture was 72 (IQR 15 – 124) cells/µl. There were no 
statistically significant differences among these CD4 levels.    
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Causative agents identified and retrospective review of outcome after18 months 
in patients with positive TB PCR and negative BAL TB culture.  
Of the 46 patients who were PCR positive but culture negative, 14 patients 
(30%) were put on empirical anti-TB treatment (before PCR results were known) 
of which three died.  Clinical follow-up data were retrieved of the 32 patients 
who did not receive empirical TB treatment: 4 of these patients died later on 
subsequent admissions while the causes of death were not established. The case 
records of the remaining 28 patients were retrieved from the Infectious Disease 
Clinic where these patients were still attending during a period of 18 months or 
more after the PCR for tuberculosis was found to be positive. In 14 of them the 
following causative organisms were found either in BAL or in sputum: common 
bacteria in 10 (six Streptococcus pneumoniae, two Staphylococcus aureus and 
two coliform bacteria); Pneumocystis jiroveci in two; cryptococcus in one and 
Human Herpes Virus 8 in one. In the remaining 14 patients no causative 
organisms were identified. Fifteen of the 28 patients (53.6%) were on highly 
active antiretroviral therapy (HAART) at that time. Despite not receiving anti-TB 
treatment, none of the 28 patients was diagnosed to have active tuberculosis 
during this period. 
 
DISCUSSION 
We found that the microbiological diagnosis of PTB in HIV infected patients by 
the existing traditional methods was inefficient. Sputum AFB smear had limited 
ability to diagnose PTB. This is a serious problem given the resource limitation, 
lack of other diagnostic options and the endemic nature of both TB and HIV in 
Tanzania.  The low sensitivity of sputum AFB smear for PTB we observed is 
similar to other studies (21-23). In our study however, the low sensitivity of AFB 
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smear for PTB was coupled with the inability to produce adequate sputum in 
nearly 50% of patients. Sputum-scarcity in HIV infected individuals (especially 
with low CD4 counts) hampers the diagnosis of PTB by conventional AFB smear 
(24). For AFB smear to become positive it requires 5000 – 10000 AFB per ml 
(25). Therefore sputum-scarcity and the paucibacillary nature of TB in HIV 
infection (26), can result into misdiagnosis or into classifying patients as smear-
negative PTB. In this study nearly three-quarter of the BAL culture confirmed TB 
were either sputum smear negative or did not produce sputum. Smear negative 
PTB in HIV/AIDS patients more often than smear positive presents with atypical 
picture; both clinically and radiographically (from normal chest radiography to 
slight or atypical changes) (27;28), which makes the diagnosis of PTB in this 
group even more difficult. Apart from their role in the transmission of MTB (29), 
in smear-negative patients the diagnosis of PTB is delayed, which resulted in  
increase in mortality (30-32).  
Although culture was more sensitive than AFB smear, culture growth was slow; 
most samples did not show visible colonies of MTB before one month, thus 
delaying the diagnosis.  
The MycoDot® serological TB test which is cheap, rapid and technically not very 
demanding was extremely insensitive in this study of HIV/AIDS patients, while it 
has been shown to be fairly sensitive and highly specific in HIV seronegative 
patients (33). In our study the specificity of MycoDot was also very high. Unlike 
the sensitivity, the specificity of MycoDot has been shown not to be influenced 
by HIV infection (33;34).  Sensitivities as low as 3% has been reported 
previously (34).  The extremely low sensitivity noted in this study may be 
attributed to the low median CD4 T cell count, since the sensitivity of MycoDot 
test is directly proportional to CD4 T cell profile (33).  
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Real time PCR which is faster, but technically more demanding and expensive 
was found to be highly sensitive in this study. High sensitivity of PCR has also 
been reported by a study using conventional PCR on sputum samples from 
Kenya, another TB and HIV endemic area (35). The higher sensitivity 
demonstrated in our study than that found in Kenya may also be attributed to 
the use of BAL fluid instead of sputum. It has been found that the use of BAL 
improves sensitivity compared to use of sputum (36). DNA contamination is a 
possible cause of false positive results in PCR methods. However compared to 
conventional PCR, real time PCR lowers the chance of contamination during 
sample processing substantially and reduces both false positive and false 
negative results. Also, we performed all molecular tests in three separate rooms: 
a clean room for preparing mixtures, one room for DNA isolation and one room 
for DNA amplification, thus reducing the chance for DNA contamination 
considerably. Also the use of uracil as a mix component is a substantial 
improvement in the prevention of DNA contamination. Adding uracil to the 
mixture will break down all DNA strands containing UTP (produced by 
amplification in the laboratory), before starting the PCR program.  
Low specificity due to the decontamination technique used for culturing is also 
unlikely, since the contamination rate was within normal ranges. The statistically 
significant correlation we observed (Figure 1) between MTB culture positive 
results with low CT values (i.e. high DNA load) and culture negative with high CT 
value in this study also argues against the influence of a harsh decontamination 
technique. Harsh decontamination technique more likely would have resulted in 
culture negative but positive PCR with low CT value. Low specificity therefore 
may be partly explained by recent history of TB treatment and the exquisite 
sensitivity of the PCR technique (17;37).  
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Lowering the CT values of PCR demonstrated a better correlation with MTB 
culture results. Of 28 MTB positive cultures, 24 had a CT value equal or less than 
32 while of 88 MTB negative cultures, 80 had a CT value above 32, resulting in a 
sensitivity of PCR of 85.7% and specificity of 90.9% (Table 1) These findings 
imply that a CT value of 32 and below was indicative of active TB and that a CT 
value above 32 indicated a mere presence of TB DNA, but not active disease. 
Therefore PCR in BAL with 32 as a cut off CT value may be useful as a rapid 
method for diagnosis of active tuberculosis. 
Latent MTB infection is common in TB endemic regions where the first 
mycobacterial infection is acquired during childhood and is kept under control by 
the immune system resulting into only about 10% of them developing the 
disease in their lifetime (38). Even when the infection is successfully controlled 
by the immune system, some bacilli will remain in the tissues in a latent state 
(39). In a study of PCR applied to superficially normal lung tissue obtained at 
necropsy from patients who had died from causes other than TB in Ethiopia and 
Mexico, up to 38% of samples tested were positive for MTB, whereas none of the 
samples from Norwegian individuals were PCR positive (40). In this study, 
alveolar macrophages were found to be the most common cells with positive 
mycobacterial DNA labelling. Based on these findings and because the alveolar 
macrophages are easily accessible at bronchoscopy by BAL, we postulate that, in 
view of the high endemicity of tuberculosis in Tanzania, the high percentage of 
samples with positive mycobacterial DNA in the absence of active PTB, actually 
may represent latent TB in these patients.  
In conclusion, we found that around half of HIV infected patients with symptoms 
and signs of PTB do not produce (adequate) sputum, which makes 
microbiological diagnosis difficult. But even in those who manage to produce 
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sputum, microbiological diagnosis of PTB using the WHO recommended method 
for resource-limited settings is inefficient. As a consequence many PTB cases are 
missed and therefore not treated appropriately. The serological test had very 
limited value in TB diagnosis in HIV infected patients due to very low sensitivity. 
Culture was limited by prolonged duration of mycobacterial growth. Real time 
PCR of BAL was limited by low specificity despite high sensitivity, although 
specificity increased to over 90% when a cut off point of 32 for the CT value in 
PCR was adopted. A prospective follow up study of PCR is warranted in a TB/HIV 
endemic resource-poor setting, applying real time PCR to both sputum and BAL.  
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Table 1. Comparison of different Mycobacterium tuberculosis (MTB) diagnostic 
tests, and sensitivity and specificity of each, using BAL MTB culture as the 
gold standard 
      BAL MTB CULTURE RESULTS   Sensitivity Specificity
      Positive Negative Contamination TOTAL (%) (%) 
BAL AFB smear  Positive 16 1 1 18 57.1 98.9 
  Negative 12 87 3 102   
  TOTAL 28 88 4 120     
Sputum culture Positive 12 0 0 12 100 100 
  Negative 0 48 2 50   
  Contamination 0 1 1 2   
    TOTAL 12 49 3 64     
Sputum AFB smear Positive 8 0 0 8 66.7 100 
  Negative 4 49 3 56   
    TOTAL 12 49 3 64     
BAL PCR (CT 40)  Positive 27 42 4 73 96.4 52.3 
  Negative 1 46 0 47   
    TOTAL 28 88 4 120   
BAL PCR (CT 32) Positive 24 8 2 34 85.7 90.9 
  Negative 4 80 2 86   
  TOTAL 28 88 4 120   
Serological test Positive 0 2 0 2 0 97.6 
  Negative 27 83 4 114   
  Dubious 1 3 0 4   
    TOTAL 28 8 4 120     
 Sensitivity and specificity of PCR in BAL are given for two CT cut off values:  40 
and 32. Using the latter, specificity of PCR improved significantly.  
 AFB: acid fast bacilli; BAL: bronchoalveolar lavage; PCR: real time PCR 
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Figure 1. Differences in median CT values (IQR) of real time PCR between 
positive and negative results of culture and AFB smear of BAL fluid.
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ABSTRACT  
Background 
Tuberculosis (TB) is a major health problem and its increase is largely due to 
HIV infection. TB and HIV are endemic in sub-Saharan Africa. Determination of 
the prevalent M. tuberculosis strains and their drug susceptibility is important for 
TB control. 
Methods  
TB positive culture respiratory samples from 130 patients were genotyped. The 
spoligotypes were correlated with anti-tuberculous drug susceptibility in HIV-
infected and non-HIV patients from Tanzania.  
Results 
One-third of patients were TB/HIV co-infected. Forty-seven spoligotypes were 
identified. Fourteen isolates (10.8%) had new and unique spoligotypes. The 
major spoligotypes contained nine clusters: CAS1-Kili 30.0%, LAM11- ZWE 
14.6%, ND 9.2%, EAI 6.2%, Beijing 5.4%, T-undefined 4.6%, CAS1-Delhi 3.8%, 
T1 3.8% and LAM9 3.8%. Twelve (10.8%) of the 111 phenotypically tested 
strains were resistant to anti-TB drugs. Eight (7.2%) were monoresistant 
strains: 7 to isoniazid (INH) and one to streptomycin. Three strains (2.7%) were 
MDR and one (0.9%) was resistant to INH and streptomycin. Mutation in the 
katG gene codon 315 and the rpoB hotspot region showed a low and high 
sensitivity, respectively, as predictors of phenotypic drug resistance.  
Conclusions 
CAS1-Kili and LAM11-ZWE were the most common families. Strains of the 
Beijing family and CAS1-Kili were not or least often associated with resistance, 
respectively. HIV status was not associated with spoligotypes, resistance or 
previous TB treatment.  
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INTRODUCTION 
Tuberculosis (TB) persists as a major cause of morbidity and mortality, affecting 
almost a third of the world’s population(1). Inadequate detection and cure rates 
have been identified as reasons for a mounting global tuberculosis burden (2). 
Human immunodeficiency virus (HIV) is by far the major cause of the current 
increase in tuberculosis infection. The presence of HIV increases the risk of 
reactivation of a latent Mycobacterium tuberculosis (MTB) infection (3) and rapid 
thus progression of the infection (4); HIV also increases MTB transmission rates 
at the community level, therefore threatening the health and survival of HIV- 
seronegative individuals as well (5). Sub-Saharan Africa is endemic for both TB 
and HIV infection (6), and pulmonary tuberculosis (PTB) in the HIV-affected 
countries of eastern and southern Africa, such as Tanzania, has increased rapidly 
in the past decades (7).  
 
Molecular genotyping is an important tool for the understanding of TB 
epidemiology. It can predict transmission rate and identify dominant strains, 
strains with an enhanced capacity to spread, strains associated with outbreak 
(8), severe disease (9) and drug resistance. Spacer oligonucleotide typing 
(spoligotyping) is one of the molecular genotyping techniques; it is fast, robust, 
reliable, easy to perform, and cost-effective (10). On the basis of the variability 
of the direct-repeat (DR) locus (10;11), spoligotyping can detect different M. 
tuberculosis strains, such as the  Beijing genotype which is associated with 
enhanced febrile response in patients during treatment, and multiple drug 
resistance (MDR) (9;12;13). 
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For TB control, monitoring the emergence of drug resistant strains is essential. 
While detection of drug resistance by phenotype is hindered by the prolonged 
time to identify resistant strains, genotypic prediction of drug resistance is 
faster. Data are accumulating on the correlation between gene mutations and 
phenotypic resistance. Such data however are sparse, particularly from sub-
Saharan Africa where the disease burden is highest. The primary mechanism for 
acquiring resistance in M. tuberculosis is the accumulation of point mutations in 
gene coding for drug targets or drug-converting enzymes (14). Mutations in the 
catalase peroxidase gene (katG) (15;16) and in a gene encoding the enoyl acyl 
carrier protein reductase (inhA) (17) have been found to account for 60 to 70% 
and 10 to 15% of INH-resistant MTB isolates, respectively (18). Mutations 
resulting in an amino acid change within the 81-bp core region of the RNA 
polymerase β-subunit (rpoB) gene are found in 96% of rifampicin-resistant M. 
tuberculosis strains (19). 
  
The objectives of this study were to determine the genetic biodiversity of MTB by 
spoligotyping and to correlate spoligotypes and anti-tuberculous drug 
susceptibility in HIV-infected and non-HIV patients in northern Tanzania, one of 
the TB and HIV endemic countries of eastern Africa.  
 
MATERIALS AND METHODS 
In the Kilimanjaro region of northern Tanzania, between April and September 
2005, we collected sputum or bronchoalveolar lavage (BAL) fluid by direct 
expectoration or bronchoscopy, respectively, from 220 patients suspected of 
having PTB. The patients presented with coughing, evening fevers and abnormal 
chest x-rays. The patients were seen at Kibong’oto National Tuberculosis 
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Referral Hospital (KNTH) and Kilimanjaro Christian Medical centre (KCMC), a 
tertiary care hospital. The specimens were obtained prior to initiation of TB 
treatment. For each patient, any history of TB treatment in the past was noted. 
Specimens were digested and decontaminated with NaLC and 2%NaOH by the 
standard procedure (20). Sediments were used for diagnosis of TB: direct 
smears for acid-fast bacilli (AFB) by the Ziehl-Neelsen (ZN) method (20) and 
cultures in Lowenstein-Jensen (LJ) solid medium in three slants with or without 
0.75% glycerol or with 0.6% sodium pyruvate. One hundred and thirty TB-
positive culture samples (confirmed by smear) were subjected to spoligotyping 
and genotypic testing for drug resistance to isoniazid (INH) and 22 for 
rifampicin; 111 samples underwent phenotypic DST because the reculture of 
nineteen strains was not possible. Phenotypic drug resistance testing was 
performed for INH, rifampicin, ethambutol, and streptomycin and genotypic 
testing was carried out for a mutation in the katG 315 codon to INH and for a 
mutation in the rpoB hotspot region to rifampicin. Genotypic resistance to 
rifampicin was tested with samples which were INH-resistant, contained 
phenotypic rifampicin-resistant strains, or had selected spoligotypes; phenotypic 
rifampicin -sensitive strains were used as controls. 
 
DNA extraction  
A loopful of Mycobacterial colonies from cultures was suspended in 1 ml of 
physiological saline solution and heated at 80 0C for 10 minutes to kill the bacilli. 
The cell debris was removed by centrifugation at 13,000 x g for two minutes. 
The supernatant obtained was stored at -20 0C until used for DNA amplification 
(21). 
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Spoligotyping 
Amplification of the spacers was performed using DNA extract and primers (DRa 
and DRb) corresponding to the direct repeat (DR) region of the genome of M. 
tuberculosis according to the procedure described by v.d. Zanden et al (22). 
Briefly, 10 μl of the DNA extract were mixed with 40 μl PCR mix containing 5 μl 
10x PCR buffer, 3 μl magnesium chloride (25 mM), 4 μl dNTP mix (2.5 mM dNTP 
each), 50 pmol DRa primer, 50 pmol DRb primer, 0.2 μl Taq polymerase and 
0.25 μl Tris 1 M (pH 9.0), 0.5 μl UDG (1 U/μl). Amplification and hybridization 
were performed according to the manufacturer’s manual (Isogen Bioscience BV, 
Maarssen, The Netherlands). The hybridized membrane was exposed to X-ray 
film for detection of the hybridization signal. The X-ray film (HyperfilmTM ECL, 
Amersham Bioscience UK Ltd.) was read manually to obtain a complete pattern 
of the spacers between the DR regions harbored by a particular strain. 
Preventive measures were taken against contamination with either previously 
amplified DNA or amplicons from previous reactions; the procedure was 
described by Kwok et al. and Longo et al; respectively (23;24). Computer-
assisted analysis of spoligotyping patterns was carried out with Bionumerics 4.0 
(Applied Maths, St-Martin-Latem, Belgium).  
The patterns obtained received a spoligo-international type (SIT) according to 
the cluster assignment after the sequences were processed with the 
International Spoligotype Database of the Institut Pasteur de Guadeloupe, 
(http://www.pasteur-guadeloupe.fr/tb/spolDB4) (25). New spoligotypes 
identified in the study were added to the SpolDB4. 
 
 
 
Chapter Six: MTB genotypic diversity and drug susceptibility pattern 
 117
Phenotypic drug resistance testing 
The proportional method for drug susceptibility testing (DST) of M. tuberculosis, 
as described in the manual, was used (26); Briefly, for each drug a 1: 10 
dilution of standardized inoculum was inoculated onto the drug free control and 
drug-containing media. The extent of growth in the absence or presence of drug 
was compared and expressed as a percentage. If growth at the critical 
concentration of a drug was >1%, the isolate was considered to be clinically 
resistant. 7H10 agar with 0.2 and 1 mg/l isoniazid (INH), 1 and 5 mg/l 
rifampicin, 5 and 10 mg/l ethambutol and 5 and 10 mg/l streptomycin were 
used. 7H10 agar tubes with 1 ml of culture in 9 ml sterile aquadest without 
antibiotics served as growth control. Reading was only performed if at least 50 
CFU of M. tuberculosis growth appeared. Ten strains from the Dutch 
International Reference Laboratory for Mycobacteriology were used as controls: 
three M. tuberculosis strains sensitive to INH, rifampicin, ethambutol and 
streptomycin, and seven strains variably resistant to the four used first line anti-
TB drugs. 
 
Genotypic INH and rifampicin resistance testing 
Amplification of katG gene containing codon 315 was performed for detection of 
INH resistance, using a set of primers; Foward (GGG CTT GGG CTG GAA GAG) 
and reverse (ACA ACA GTT TCC TCG AGA TCC TGT) (27). This resulted in a 122 
bp long product. Detection of the katG-315 wildtype took place by a FAM-labeled 
probe (5’ CGCGATCACCAGCGGCATCG 3’) and detection of the most common 
katG-315 mutation from AGC to ACC by a VIC-labeled probe (5’CGC GAT CAC 
CAC CGG CAT CG 3’) by real time PCR. DNA amplification/detection was 
performed in 30 μl reaction volume with the ABI Prism® 7000 Sequence 
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Detection System (Applied Biosystems): 15 ul TaqMan® Universal PCR Master 
Mix (AppliedBiosystems) template DNA, 400 nM of each primer and 200 nM of 
each probe. The real time PCR-program consisted of 2 min at 500C, 10 min at 95 
0C, 45 cycles of 15 seconds at 95 0C, 1 min at 600C.  
For the detection of rifampicin resistance, sequencing was carried out with the 
3100-Avant sequencer (Applied Biosystems). Amplification of a 437 bp fragment, 
containing the rpoB-hotspot region, took place with a PTC 200 thermocycler 
(Biozym) by forward primer rpoB-F1 (5’TGGTCCGCTTGCACGAGGGTCAGA3’) and 
reverse primer rpoB-R1 (5’ CGATCACACCGCAGACG3’), as described by v.d. 
Zanden et al. (19). The reaction mixtures in a final volume of 55 µl contained 10 
µl Q-buffer from Qiagen, 5.5 µl Taq buffer (10 mM Tris, 1.5 mM MgCl2, 50 mM 
KCl), 50 pmol of primers rpoB-rev1 and rpoB-for2, 0.23 mM dNTPs, 1U 
SuperTaq and 50 ng DNA and 0.22 µg TaqStart. The cycling parameters includes 
an initial denaturation at 96°C for one min followed by one min at 93°C, primer 
annealing at 63°C – 60°C for one min (2 cycles at each 1°C decrement) and one 
min for primer extension at 68°C. This was followed by 20 subsequent cycles of 
amplification;  93°C for one min, 60°C for one min 68°C for one min, followed 
by an additional cycle of 5 min at 68°C to complete the elongation of the PCR 
intermediate products. 
PCR products were checked for integrity on ethidium bromide agarose gels and 
purified with the Qiaquick PCR purification kit (Qiagen GmbH, Hilden, Germany). 
For DNA sequencing reactions, the fluorescence-labeled dideoxynucleotide 
technology with the protocol of the manufacturer was used (Applied Biosystems, 
Foster City, USA). Unincorporated dye terminators were removed with MilliPore 
Multiscreen Assay System (Millipore, Molsheim, France) according to 
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manufacturer’s protocol, the reaction products were separated and detected with 
an ABI Prism 3700 automatic DNA sequencer (PE biosystems). Both strands of 
the polymorphic region of the rpoB gene were sequenced.  
The results of sequencing of test strains were compared with the rpoB-hotspot 
wildtype using Bionumerics software (Applied Maths, St-Martin-Latem, Belgium) 
to detect any mutation. 
Blood was collected from all patients for detection of anti-HIV antibodies using 
the Capillus ™ HIV-1/HIV-2 rapid test (Trinity Biotech, Bray, Ireland) according 
to the manufacturers instructions,with positive and negative controls for each 
test run. Samples positive in the rapid test were confirmed by ELISA using 
Vironostika ® HIV uniform II ag/ab microwell enzyme immunoassay 
(bioMerieux, Marcy 1’Etoile, France). CD4 counts were determined using flow-
cytometry technique (Becton Dickinson Facs Count machine with BD FacscountTM 
reagent). 
Data analysis was done by SPSS version 10-software for Windows. Normally 
distributed values were presented as mean plus standard deviation (SD). In 
other cases data were expressed as mean plus standard error mean (SEM). Chi-
square was used to express correlations between dichotomous variables and 
Spearman’s correlation coefficient, to quantify correlations between continuous 
variables. P-value equal to or less than 0.05 was regarded as statistically 
significant. 
Ethical clearance was obtained from the Research Ethics Committee of KCMC 
hospital and a signed informed written consent was obtained from patients prior 
to enrolment of the patients in the study. 
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RESULTS 
Characteristics of the study population 
In total 130 positive-culture samples from 220 patients were included in the 
study. The majority of the patients in this study were from the Chagga (41.1%) 
and Masai tribes (11.6%). Other tribes were represented by less than 5% each. 
Fifty-four (41.9%) were peasants, 28 (21.7%) business people, 18 (14%) 
miners and 10 (7.8%) herders, the remaining had other occupations. The mean 
age (SEM) was 37 years (1). Eighty-three (63.8%) were male patients. Fourteen 
patients (10.8%) had a history of previous treatment for tuberculosis. Forty-
seven (36.2%) patients were HIV seropositive. Mean CD4 cell count (SEM) for 
the HIV seropositive patients was 200 (35) cells/ml and for the HIV seronegative 
group the mean CD4 count (SEM) was 555 (38) cells/ml. 
 
Spoligotypes  
A total of 47 spoligotypes was identified among the 130 M. tuberculosis isolates. 
Fourteen isolates (10.8%) had new and unique spoligotypes (SIT 0) while 116 
isolates (89.2%) belonged to 33 previously known spoligotypes. A total of 106 
isolates (81.5%) from nine different phylogenetic clusters formed the major 
isolates (i.e. with five or more isolates for each spoligotype). These were CAS1-
Kili with 39 (30%) isolates (strains 60-98), LAM11- ZWE 19 (14.6%) (strains 0-
19), ND 12 (9.2%)(strains 119-130), EAI 8 (6.2%)(strains 47-54), Beijing 7 
(5.4%)(strains 109-115) and T-undefined 6 (4.6%)(strains 41-46) as well as 
CAS1-Delhi (strains 99-103), T1 (strains 31-35) and LAM9 (strains 20-24) with 5 
isolates (3.8%) each (Figure).  
Three new shared spoligotypes (a common pattern shared by two or more 
isolates) were established from our findings by comparing them with the 
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spoligotypes which were available in the SpolDB4: one EAI (SIT 2482, strain 49) 
with that found in Zambia, one T-undefined (SIT 2482, or SIT 2484, strain 42) 
with that found in the USA and one CAS1 variant – undefined (SIT 2485, strain 
107) with that found in Sweden.  
 
Drug susceptibility testing (DST) 
Out of 111 TB isolates which were subjected to DST, 12 (10.8%) were resistant 
to at least one anti-TB drug. Eight (7.2%) of the 111 were monoresistant 
strains: 7 resistant to INH and one to streptomycin. Four (3.5%) strains were 
resistant to multiple drugs: one (0.9%) was resistant to INH and streptomycin 
and the other three (2.7%) strains were MDR strains: two (1.8%) strains were 
resistant to all four anti-TB drugs and one (0.9%) strain was resistant to INH, 
rifampicin and ethambutol. Resistance of the 111 isolates for each drug was as 
follows: INH 11 (9.9%) strains, streptomycin 4 (3.6%), rifampicin 3 (2.7%), and 
ethambutol 3 (2.7%).  
Four of the 130 (3.1%) MTB isolates were found to have a mutation in a katG 
gene codon 315. Four of the 22 tested isolates were found to have a mutation in 
the hotspot region of the rpoB gene. Of the 11 strains phenotypically resistant to 
INH, four strains were also genotypically resistant to INH. The resistant strains 
were phenotypical retested at the Dutch Mycabacteriology Reference Laboratory 
showing the same results. The sensitivity of the mutant katG gene to predict 
phenotypical resistance to INH was 30.8% and the specificity was 100%. 
All three strains phenotypically resistant to rifampicin were also genotypically 
resistant to rifampicin. Both sensitivity and specificity of a mutation in the rpoB 
gene to predict phenotypical resistance to rifampicin was 100%. 
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As shown in the Table, two of the 49 isolates (4.1%) belonging to four variants 
of the CAS1 family (CAS1-Kili, CAS2, CAS1-undefined, CAS1-Delhi) showed 
resistance to at least one drug and four could not be tested. Six of the 30 
isolates (20%) of the LAM family (LAM3 or S, LAM9, LAM11-ZWE) showed 
resistance to one or more anti-TB drugs. Three of the 16 isolates (18.8%) of the 
T family (T3-UGA, T1, T-undefined) showed resistance. One of the 13 isolates 
(7.7%) of the EAI family (EAI, EAI-variant, EAI-undefined), one of the 12 
isolates (8.3%) of the ND family, and one of the three isolates (33.3%) from the 
MANU family (MANU1, MANU2) showed resistance to at least one anti-TB drug. 
None of the seven M. tuberculosis Beijing isolates was resistant to anti-TB drugs. 
Out of the 12 resistant isolates two (14.3%) were new and unique isolates 
(strain 116 and 126): the three MDR isolates were CAS1- Kili (strain 89), EAI 
(strain 48) and LAM 11 – ZWE (strain 13) (Figure) 
 
Previous TB treatment, HIV status and drug resistance. 
Out of 14 patients who had a history of previous treatment for PTB, one (7.1%) 
had a MDR-MTB strain and the other 13 (92.9%) had strains sensitive to all four 
first line anti-TB drugs. Five of the 47 HIV-infected individuals (10.6%) showed 
resistance to at least one drug. Three of the 47 HIV – infected individuals 
(6.4%) had a history of previous treatment for TB and none of them had strain 
resistant to anti-TB drug. 
   
DISCUSSION 
There was a wide diversity of spoligotypes in this study group; the 130 MTB 
isolates produced 47 different spoligotypes. The clades observed in this study 
were more than three-quarters of the total of 62 clades/lineages currently 
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documented in the fourth international spoligotyping database, SpolDB4 (25). 
This diversity may be attributed to increased human movement in this area due 
tourism, mining, asylum seeking (refugees) and transborder/international 
business. Historically, many people from Europe and Asia also lived here during 
pre- and post-independence times.  The structure of the TB population is 
determined by geography, demography, and human migration. Studies have 
shown that the host’s geographical origin is predictive of the clinical M. 
tuberculosis isolates and there is an apparent stable association of TB bacilli 
populations with their human hosts in various environments (28). New types 
(i.e. orphan spoligotypes) accounted for one-tenth of all spoligotypes in this 
study. The low percentage of new types may also be a result of increased human 
movements. Countries with a history of isolation have been shown to have a 
large number of new spoligotypes (8). In this study two of the three new shared 
spoligotypes were formed between two geographically widely separated isolates 
(strain 42 and 107). This again is more likely to be due to the increased human 
movement than homoplasy (i.e. acquisition of two similar structures without a 
common ancestor). If it is assumed that tuberculosis may have affected the 
early hominids in East Africa, evolved clonally and then spread to the rest of the 
world coincidentally with human migration out of Africa (10;11;28), then it is 
interesting to find that almost all strains go back to the origin of Homo sapiens 
sapiens. The site of this study is within the area of Olduvai Gorge in northern 
Tanzania, which is regarded as the “cradle of mankind”. In this context, strains 
no. 116-118 with MANU-derived spoligotypes are of particular interest (Figure). 
 
Among the different phylogenetic clusters found in this study, there were only 
nine major clusters with five or more isolates, but they comprised 81.5% of all 
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isolates. This indicates the high transmission rate within the population. This 
high transmission rate may also be influenced by the marked prevalence of HIV 
infection which increases the risk of tuberculosis for all people in a community, 
both those with HIV infection and the HIV seronegative community members 
(5). Two clusters were by far the most prevalent: CAS1-Kili and LAM11-ZWE 
family, with a prevalence exceeding ten percent. The predominance of these two 
families by more than ten percent has been demonstrated by another study 
based on IS6110-restriction fragment length polymorphism (RFLP). The study 
showed that the Kilimanjaro and Meru families were the most prevalent in this 
area (29), the names of the families being derived from the two adjacent 
mountains found in this area. While the Kilimanjaro family refers to CAS1-Kili, 
the Meru family is identical to LAM11-ZWE (25). Another recent study, 
performed in Dar-es-Salaam, suggested the existence of new CAS1-Kili genotype 
variants (designated as CAS1-Dar) (30). However, the absence of spacer 2 and 
15 in the spoligotype-signatures reported by these authors was not found, even 
once, in our study. A single clinical isolate, strain 104 (ST247) looks similar to 
the CAS-Dar variants. This may be explained either by a specific loss of spacers 
2 and 15 in the CAS1-Dar variants or by false negative hybridization spots. 
Spacer 2 and 15 may indeed sometimes provide barely interpretable results. If 
confirmed, the absence of spacers 2 and 15 may provide interesting clues about 
the microevolution of CAS1-Kili in Tanzania.  
More than 5% of cases were Beijing isolates which were the fifth most frequent 
spoligotype. The presence of seven Beijing isolates had already been reported in 
Dar-es-Salaam (30). The mean age of the patients with the Beijing family was 
the lowest compared to those with other isolates (Table). It has already been 
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reported that Beijing is associated with young age (31) which implies recent and 
ongoing transmission. 
 
A striking finding was that not one single case of M. bovis or M. africanum was 
found in this study. This study cohort consisted mainly of peasants and herders, 
including the Masai people who are essentially semi-nomads or herders and their 
staple food includes milk and meat. In Uganda which is a neighbouring country, 
other genotypes of the M. tuberculosis complex, previously designated as “M. 
africanum 2” are the major cause of human tuberculosis (32). This finding may 
be a result of improved livestock and animal husbandry in Tanzania or due to 
anthropologically rooted differences between Uganda and Tanzania. 
 
All resistant isolates except one were resistant to INH, either alone or in 
combination with other drugs. The level of INH resistance was high; a similar 
trend has been observed in many African countries; in some countries up to 
one-third of the isolates is resistant to INH (33-36). This rate is alarming, 
especially since INH is the first-line drug, which is used throughout the course of 
TB treatment. This also means a high probability of the development of MDR in 
the future, since it has been observed that MDR often develops from initial INH-
monoresistant strains (35). Several reports show a low prevalence of MDR-MTB 
in Africa compared to Asia and Eastern Europe (37). But the trend seems to be 
steadily increasing since previous reports from Tanzania showed that INH 
monoresistance was about 5% and MDR was about 1% (38) while our study 
reveals a more than two-fold increase in both INH resistance and MDR. The 
upward trend in resistance has also been noted in neighboring countries 
(37;39). 
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Despite its high prevalence, the CAS 1 family showed the least association with 
anti-TB drug resistance (Table); family LAM and T were more frequently 
associated with anti-TB drug resistance. 
Another interesting aspect was the fact that all MTB Beijing isolates in this study 
were susceptible to all anti-TB drugs unlike reports from other studies (35;40). A 
previous study in Indonesia also showed no significant association between 
Beijing strains and drug resistance (9).   
 
One-third of the study population was infected by both HIV and TB; this is the 
common trend in sub Saharan Africa (41). The association of HIV infection, 
however, with previous treatment for TB was not statistically significant and that 
with anti-TB drug resistance was absent in this study. The smaller number of 
HIV- infected patients with a history of previous treatment for TB may be 
attributed to high mortality associated with the first MTB infection in TB/HIV co-
infected patients (42;43). There was no association between HIV status and 
spoligo patterns except for Beijing whereby only one person was HIV 
seropositive.  
The mean CD4 count for patients with Beijing was the lowest, although all 
patients except one were HIV seronegative. This low CD4 count despite being 
HIV seronegative may be due to the pronounced virulence of the Beijing strain. 
It has been demonstrated that the Beijing family is more virulent than other M. 
tuberculosis strains. The virulence is attributed to the ability of the strain to 
produce phenolic glycolipid which is able to interfere with host immunity (44)  
 
In conclusion, in this study we found a wide diversity of spoligotypes with 
predominance of two genotype families. The Beijing family was also among the 
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prevalent phylogenetic cluster. The most prevalent cluster CAS1-Kili and the 
most virulent Beijing were not or barely associated with anti-TB drug resistance. 
A substantial proportion of resistant isolates was found, INH monoresistance 
being the highest and thus signaling the danger of increasing MDR in the future. 
MDR was higher than that described in previous reports from Tanzania.  
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Table. Distribution of seven of the phylogenetic families by age, smear results, 
HIV status, CD4 count (n=130) and phenotypic resistance for anti-TB 
drugs (n = 111) 
 
Family Isolates Age Smear positive HIV positive CD4cell/ml Resistant 
 N=130 N=130 N=130 N=130 N=130 N=111 
  % n/N mean SEM % n/N % n/N mean SEM % n/N 
CAS * 37.7 49/130 38 2 81.6 40/49 34.7 17/49 471 64 4.4 2/45 
LAM ** 23.2 30/130 39 3 83.3 25/30 26.7 8/30 437 55 18.5 5/27 
T *** 12.3 16/130 35 2 81.3 13/16 50.0 8/16 436 92 14.3 2/14 
EAI # 10.0 13/130 39 3 69.2 9/13 46.2 6/13 432 64 8.3 1/12 
ND 9.2 12/130 37 4 58.3 7/12 41.7 5/12 413 99 16.7 1/6 
Beijing  5.4 7/130 29 2 85.7 6/7 14.3 1/7 380 69 0.0 0/6 
MANU 
## 
2.3 3/130 32 4 100 3/3 66.7 2/3 195 141 100 1/1 
 
* CAS:  CAS1-Kili; CAS1-Delhi; CAS1-undefined ;CAS2 
** LAM : LAM11-ZWE ; LAM9 ; LAM3 or S ; LAM-undefined 
*** T: T-undefined; T1; T3-UGA; T3 
# EAI : EAI ; EAI-variant ; EAI-undefined 
## MANU: MANU1; MANU2. 
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Figure: Description of Mycobacterium tuberculosis strains and clusters (SIT)   
found in Tanzania
  
 
 
 
 
 
 
 
Chapter 7 
 
Serum and BAL macrophage migration inhibitory factor 
levels in HIV infected Tanzanians with pulmonary 
tuberculosis or other lung diseases 
  
Gibson S Kibiki 
Andre JAM van der Ven 
Anneke Geurts-Moespot 
John Shao 
Thierry Calandra 
Fred CGJ Sweep 
Wil MV Dolmans 
 
 
Dept of Internal Medicine, Endoscopy Unit,  and  Medical microbiology,  KCMC, Tumaini University, P.O Box 
3010, Moshi, Tanzania; Dept of Internal Medicine, Division of General Medicine, University Medical Centre 
St Radboud, Nijmegen,  Dept of Chemical Endocrinology, University Medical Centre St Radboud, Nijmegen, 
The Netherlands; Infectious Diseases Service, Dept of Internal Medicine, centre Hospitalier Universitaire 
Vaudois, Lausanne, Switzerland.  
 
 
 Clinical Immunology, 2007; 123(1): 60 – 65 
Chapter Seven: Serum and BAL MIF in HIV infected patients with PTB 
 138
ABSTRACT 
Background  
Macrophage migration inhibitory factor (MIF) activates macrophages, promotes 
delayed-type hypersensitivity reaction, and regulates Th1/Th2 balance in 
inflammatory response.  Serum MIF concentration is high in patients with 
pulmonary tuberculosis (PTB). Higher MIF levels are associated with high 
mortality. No study has addressed MIF levels and its role in PTB/HIV-co 
infection.   
Methods 
We determined serum and BAL MIF levels in Tanzanian HIV-infected patients 
with and without PTB, and correlated the levels with one-month outcome.  We 
compared with serum MIF levels of HIV seronegative patients with PTB and of 
healthy controls.  
Results  
All HIV-infected patients irrespective of PTB infection had significantly higher 
serum MIF levels than HIV- seronegative patients with PTB, and higher than 
healthy controls. In HIV seropositive patients low serum MIF levels were 
associated with high one-month mortality.  
Conclusion 
HIV infection was associated with elevated serum MIF levels regardless of PTB 
infection. Low serum MIF levels were associated with high mortality.    
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INTRODUCTION 
Macrophage migration inhibitory factor (MIF) activates macrophage functions 
(e.g. cell adhesion, phagocytosis, and killing of tumour cells and intracellular 
parasites) (1;2) and localizes macrophages at the inflammatory loci (3). MIF 
also may have a role of Th1/Th2 balance regulation in inflammatory response 
and it promotes delayed type-hypersensitivity reaction (4-6). MIF mRNA and 
protein are constitutively expressed by many organs e.g. brain, pituitary gland, 
kidneys, liver, spleen, pancreas, skin, and lungs (7-9). In the immune system, 
MIF has been detected in monocytes, macrophages, dendritic cells, eosinophils, 
mast cells, basophils, T and B-lymphocytes, and neutrophils (1;9). From these 
sites, MIF is released after stimulation by microbial products (e.g. bacterial 
toxins) and after exposure to mycobacteria and proinflammatory cytokines 
(9;10). In the lungs, MIF is expressed by alveolar macrophages and epithelial 
cells of the bronchi. Alveolar macrophages play an important role in defense 
against tubercle bacilli (11).  
 
High MIF concentrations in blood have been found in patients with pulmonary 
tuberculosis (PTB), bacterial sepsis or shock (8-10). In M. tuberculosis infection, 
virulence of the strain, high concentration of the tubercle bacilli and duration of 
exposure are associated with strong induction of macrophage MIF production 
(12). High levels of serum MIF have been found to be associated with severity of 
tuberculosis, ARDS, sepsis and septic shock (8;10;13;14). Also large quantities 
of circulating MIF in the body have been associated with increased mortality in 
diseases caused by both gram-negative and gram-positive bacteria (13).  
In animal studies anti-MIF antibody therapy has been shown to prevent toxic 
shock or death caused by sepsis or bacterial toxins (8;9;14;14-16). This makes 
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administration of anti-MIF antibodies and MIF antagonists a possible therapeutic 
option in clinical conditions (3). Therefore, determination of MIF concentration 
may become important not only as a prognostic index but also as a predictive 
marker for immunotherapy.   
About one-third of the world population is infected with M. tuberculosis. By 2000 
there were 8.3 million new cases and up to 2.2 million deaths per year due to 
tuberculosis (17). Human immunodeficiency virus (HIV) infection is a risk factor 
for tuberculosis. HIV increases the risk of reactivating latent Mycobacterium 
tuberculosis (MTB) (18) and increases the risk of rapid progression of 
tuberculosis after infection or reinfection with MTB (19). The burden of 
tuberculosis in countries with a generalized HIV epidemic has therefore 
increased rapidly over the past decade, especially in the severely affected 
countries of eastern and southern Africa (20). TB has become the most common 
disease associated with AIDS and the leading cause of morbidity and mortality 
(21;22).  In these countries up to 31% of the new TB cases are attributed to HIV 
infection (17).  At the same time the diagnosis of PTB and its differentiation from 
other non-tuberculous pulmonary infections in HIV-infected individuals remains 
difficult due to poor sputum yield, atypical clinical and radiological presentation.    
To our knowledge the clinical significance of MIF levels in serum and in broncho-
alveolar lavage (BAL) fluid of PTB/HIV- dual infected patients has not been 
studied so far. No comparison of MIF levels has been done between HIV 
seropositive and seronegative individuals in relation to PTB. In this study we 
determined the concentrations of MIF in serum and BAL fluid of HIV-infected 
Tanzanian patients with lung disease, some with PTB, and others with lung 
disease due to other causes. We also determined serum MIF levels in Tanzanian 
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HIV-seronegative patients with PTB, and in healthy Tanzanian HIV-seronegative 
volunteers. 
 
MATERIALS AND METHODS 
Patients  
Between November 2003 and September 2004 we enrolled at Kilimanjaro 
Christian Medical Centre, a reference hospital for the northern zone of Tanzania, 
HIV-infected Tanzanian patients with PTB (Group 1: HIV infected/PTB) and 
without PTB (Group 2: HIV infected/non-tuberculous lung diseases). These two 
groups were obtained from a larger study (of 120 patients) on chest infections in 
HIV-infected patients, whereby all patients who qualified for groups 1 and 2 
according to the above criteria were enrolled. In addition we enrolled 50 HIV-
seronegative individuals as controls: 25 patients with culture-proven PTB (Group 
3) and 25 healthy volunteers (Group 4).      
Investigations performed in HIV infected patients (groups 1 and 2) 
Blood samples were taken for blood cell count, CD4 T cell count and MIF level 
determination. Bronchoscopy with BAL was performed by standard procedure 
using flexible fiberoptic bronchoscope (Olympus p45 Tokyo, Japan). Briefly, the 
bronchoscope was wedged in one of involved segmental bronchi as seen on the 
chest radiograph. In case of diffuse lung involvement, the scope was wedged in 
one of the segmental bronchi of the right middle lobe. Then aliquots of 50 ml or 
less of sterile saline at body temperature was instilled up to a maximum of 150 
ml, and sucked back into a sterile container. The BAL fluid was examined for 
causative microorganisms. Samples for MIF and diagnostic tests were taken 
prior to the start of anti-tuberculous treatment; however, over 90% of patients 
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had been on empirical antibiotics for suspected pneumonia before referral.  MTB 
culture was done using Lowenstein-Jensen solid medium after decontamination 
of BAL fluid with 4% NaOH, centrifugation and taking the sediment.  Also, M. 
tuberculosis DNA amplification was performed by real time (rt) PCR of BAL fluid 
using insertion element IS6110 as a multicopy target for molecular detection of 
M. tuberculosis complex (23). A cut-off cycle-threshold (ct) value of 40 cycles 
was used. Detection of other organisms (pyogenic bacteria, fungi including 
Pneumocystis jiroveci) was done by staining and culture using standard 
procedures. In addition the BAL fluid was examined for Human Herpes Virus 8 
(HHV8) by PCR. For the HIV-infected patients PTB was diagnosed if both MTB 
culture and PCR were positive, and non-tuberculous lung disease was diagnosed 
if both culture and PCR were negative. BAL sediment was stained with 
haematoxylin & eosin (H&E) for cell analysis to classify inflammation as acute, 
chronic or subacute based on whether the predominating cells were neutrophils, 
lymphocytes or both, respectively. Patients were followed up for 4 weeks, when 
admitted until discharge from hospital, then during clinic visits, or as outpatients 
for 4 weeks. PTB patients were treated according to Tanzanian guidelines and 
during the time of the study no antiretroviral treatment was available for HIV 
infected subjects. 
HIV testing was done using Capillus ™ HIV-1/HIV-2 rapid anti-HIV assay (Trinity 
Biotech, Bray, Ireland) and Vironostika ® HIV uniform II ag/ab microwell 
enzyme anti-HIV immunoassay (bioMerieux, Marcy 1’Etoile, France). CD4 T cell 
counting was done by flow-cytometry technique (Becton Dickinson FACS Count 
machine with BD FacscountTM reagent). 
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MIF ELISA 
The concentration of MIF in BAL (only for the HIV-infected patients) and in 
serum (for both patients and control groups) was measured by an enzyme-
linked immunosorbent assay (ELISA), using the 4-span approach, as described 
in detail by Grebenschikov et al (24;25). Antibodies were raised in chicken and 
rabbits using recombinant human MIF as an immunogen. The sandwich structure 
used included 4 different antibodies, a coating antibody (duck anti-chicken), a 
capture antibody (chicken anti–human MIF), a trapping antibody (rabbit anti–
human MIF), and finally a detection antibody (horseradish peroxidase–labeled 
goat anti-rabbit). For the standard, human MIF (expressed by Escherichia coli) 
was provided by R&D Systems Europe (Abingdon, UK). The analytic sensitivity 
for human MIF is 39 pg/ml. Precision profiling showed a coefficient of variation 
(CV) of 20% at 45 pg/ml (i.e., functional level) that decreased to 7% at higher 
concentrations. For estimation of the accuracy of this ELISA method, a 
lyophilized reference preparation (marked 140799) was used. The mean 
concentration of human MIF in this preparation was 20.7 ng/ml, and the within-
run CV and between-run CV amounted to 6% (n = 8) and 12% (n = 11), 
respectively (over a period of 13 months). 
 
Radiograph 
Systematic interpretation of posterior-anterior view chest radiographs was done 
by a consultant radiologist and reviewed by a chest physician. In case of 
disagreement a third opinion was sought from another radiologist. 
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Ethical considerations 
Institutional and national ethical clearance was obtained for the study. From all 
study persons informed written consent was obtained. PTB patients were treated 
according to Tanzanian guidelines. 
 
Statistics 
Using SPSS version 10 statistical package for Windows, normally distributed 
values were presented as mean with standard deviation (SD). In other cases 
data were expressed as median with interquartile range (IQR). Spearman’s 
correlation coefficient was used to quantify correlations between continuous 
variables. Differences between groups were tested with non-parametric Wilcoxon 
Rank sum test. Linear regression models were used to adjust for potential 
confounders. P-value equal or less than 0.05 was regarded as statistically 
significant. 
 
RESULTS 
Characteristics of the four study groups  
A total of 73 HIV- infected patients with lung diseases were enrolled. In 27 HIV- 
infected patients, BAL fluid was positive by both culture and PCR for M. 
tuberculosis (Group 1). Age and sex of these patients who were classified as 
active PTB is given in table 1. In this group median CD4 T cell count was 47.0 
(IQR 29.0 – 80.0) cells/μl.   
In 46 HIV patients both TB culture and PCR for M. tuberculosis in BAL fluid were 
negative i.e. they had non-tuberculous lung disease (Group 2). In the BAL fluid 
of these patients, we identified the cause of the lung problem in 22 patients 
(47.8%): 9 bacterial pneumonia (2 S. pneumoniae, 1. S. pyogenes, 2 S. aureus, 
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2 P. aeruginosa, and 2 coliform bacteria); 5 Pneumocystis jiroveci, and 3 fungal 
infections (1 Cryptococcus neoformans, 2 Aspergillus fumigatus); 5 HHV8 
(indicating possible Kaposi sarcoma of the lung (26)); in the remaining 24 
patients (52.2%) no causative organism was identified. Age and sex ratio of 
these patients is shown in table 1. In this group median CD4 T cell count was 
71.5 (IQR 15.0 – 123.8) cells/μl.  
Age and sex of the 25 HIV-seronegative PTB cases (i.e. Group 3) and of the 25 
HIV-seronegative healthy volunteers (i.e. Group 4) are also presented in table 1.   
  
 MIF concentration in HIV- infected PTB patients and in HIV-infected patients 
with non-tuberculous lung disease 
Concentration of MIF in the 73 HIV infected individuals ranged from 14.2 to 636 
ng/ml in serum (median of 134.2) and from 0.2 to 247.7 ng/ml in BAL (6.9 
ng/ml). There was no statistically significant correlation between concentration 
of MIF in serum and BAL (r2 = 0.11, p = 0.35).  
Median value for serum MIF in the 27 HIV-infected PTB patients was 130.5 
ng/ml (IQR 75.5-171.5).  Median value for serum MIF in the 46 HIV-infected 
patients with non-tuberculous lung disease was 136.4 ng/ml (IQR 72.4-213.2). 
The difference was not statistically significant. Median values for MIF in BAL fluid 
were much lower than in serum; both in the HIV-infected PTB patients (7.4 
ng/ml) and in the HIV-infected patients with non-tuberculous lung disease (5.9 
ng/ml) and the difference between the two groups was statistically not 
significant.  
Neither MIF level in serum nor in BAL could discriminate PTB from other lung 
diseases in HIV-infected patients, even after adjusting for potential confounding 
factors such as CD4 T cell count, white blood count and age (data not shown) 
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Correlation of MIF levels with clinical findings in HIV- infected patients. 
Serum MIF levels did not correlate with CD4 T cell count (r2 = 0.18, p = 0.14), 
white blood cell count (r2 = 0.34, p = 0.06), neutrophil count (r2 = 0.06, p = 
0.62) or lymphocyte count (r2 = 0.19, p = 0.11). Similarly BAL MIF levels did 
not correlate with CD4 T cell count (r2 = 0.02, p = 0.9), white cell count (r2 = 
0.17, p = 0.14), neutrophil count (r2 = 0.12, p = 0.33) or lymphocyte count (r2 
= 0.04, p = 0.24). Analysis of H&E stained slides of BAL sediment, showed that 
concentration of MIF in serum was not associated with acute inflammation when 
compared with chronic inflammation (r2 = 0.02, p = 0.9).   
In PTB patients, BAL MIF levels were significantly higher in those with nodules 
on chest radiograph (median 8.82 ng/ml, IQR 2.53 – 19.39), than in patients 
without nodules (median 2.32, IQR 0.84 – 13.35, Wilcoxon-Rank sum test, p = 
0.003). No statistically significant difference was found between median serum 
MIF levels in PTB patients with nodules on chest radiograph (134.8, IQR 69.5 – 
184.8) and in PTB patients without nodules (132.5 ng/ml, IQR 86.6 – 136.0, 
Wilcoxon-Rank sum test, p = 0.61). No significant differences were found for 
infiltrates or cavities.  
 
Correlation of MIF levels with clinical outcome 
In the 73 HIV seropositive patients (27 with PTB and 46 with non-tuberculous 
lung disease), 12 patients (16.4%) died due to their lung disease during the one 
month follow-up period (seven patients with PTB and five patients with non-
tuberculous lung disease). The median serum MIF concentration of those who 
died was 78.8 ng/ml (IQR 26.5 – 139.7) and of those who survived was 138.6 
ng/ml (IQR 90.2 – 207.0, Wilcoxon-Rank sum test, p = 0.011). Median BAL MIF 
concentration of those who died was 9.4 ng/ml (IQR 1.8 – 28.6) and in those 
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who survived was 5.3 ng/ml (IQR 1.7 – 16.9, Wilcoxon-Rank sum test, p = 
0.77). No significant association was found between BAL MIF, CD4 T cell count 
or WBC (total or differential count) and outcome.  
 
MIF levels in HIV- infected patients, HIV-seronegative patients with PTB and in 
healthy controls 
The median serum MIF concentration in the 73 HIV-infected patients with lung 
disease (group 1 and 2) was significantly higher (134.2 ng/ml, IQR 75.1 – 
190.8) than the serum MIF concentration in the 50 HIV-seronegative individuals 
(consisting of 25 patients with PTB and 25 healthy volunteers), which was 42.8 
ng/ml (33.3 – 70.5, Wilcoxon-Rank sum test, p < 0.0001).  
As shown in figure 1, HIV- seropositive patients with PTB had significantly higher 
median serum MIF levels (130.5 ng/ml, IQR 75.5 – 171.5) than HIV-
seronegative patients with PTB (47.6 ng/ml, IQR 34.1 – 152.2, Wilcoxon-Rank 
sum test, p = 0.004), and higher median serum MIF levels than found in the 
healthy control group (39.3 ng/ml, IQR 27.0 – 59.3, p < 0.0001).  
Interestingly, HIV- seropositive patients with non-tuberculous lung disease had 
also higher serum MIF concentrations (136.4 ng/ml; IQR 72.4 – 213.2) than 
HIV-seronegative patients with PTB, (p = 0.016) and healthy volunteers (p < 
0.0001; p value not shown in figure 1).  
Within the 50 HIV-seronegative individuals, the difference between median 
serum MIF concentrations (47.6 ng/ml, IQR 34.1 – 152.5) of the PTB group and 
the healthy volunteers (39.3 ng/ml, IQR 27.0 – 59.0) was also statistically 
significant (Wilcoxon-Rank sum test, p = 0.03; p value not shown in figure 1).  
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DISCUSSION 
We found high serum MIF levels in HIV-infected patients. The levels were equally 
high in both, patients with PTB and with non-tuberculous lung disease. The 
serum MIF levels were about 20-fold higher than BAL MIF levels. No statistically 
significant correlation in MIF levels was found between serum and BAL in these 
HIV infected patients. In addition, no statistically significant difference was found 
in BAL MIF levels between the HIV infected patients with PTB and those without 
PTB.  
Lack of statistical significant differences of serum and BAL MIF levels between 
patients with pulmonary tuberculosis and those with non-tubercular pulmonary 
disease shows that HIV infection has a major influence on the levels of MIF and 
masks the influence of co-infections.  Consequently, measuring MIF levels does 
not help to distinguish patients with PTB, which is a major disease in HIV, from 
those patients with non-tuberculous pulmonary diseases.  
 
We found no statistically significant differences in serum MIF levels among 
different chest radiographic patterns. A study in non-HIV patients with PTB 
similarly showed no significant differences of serum MIF levels among 
radiological stage groups (10). However in our study we found that presence of 
nodular lesions in the chest radiographs of patients with PTB correlated with high 
levels of MIF in BAL fluid. This suggests possible correlation between MIF levels 
in the lungs and radiographic stages in PTB/HIV co-infected patients.   
 
Lower levels of circulating MIF in HIV infection were associated with increased 
mortality at one-month follow-up. This finding differs from findings in other 
studies in animals and human beings (8;10;13). In these studies higher levels of 
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circulating MIF were clearly indicative of severe disease and fatal outcome. This 
finding in our study therefore raises doubts on the role of anti-MIF therapy in 
lung diseases in HIV-infected individuals.  
 
In TB/HIV dual infection, HIV infection has been found to facilitate fast 
progression of TB (19) and TB to enhance replication and progression of HIV 
infection (27;28). The interaction of the dual infection can result into altered 
cytokine regulation (11). We postulate that the results in this study may be 
influenced by such alteration.   
  
In this study, serum MIF levels were significantly higher in patients with PTB/HIV 
co-infection than in patients with PTB without HIV infection; pointing to the 
influence of HIV infection on high MIF levels.  And also the serum MIF levels of 
PTB/HIV co-infected patients in this study were nearly 10-fold higher than MIF 
levels which were found by Yamada et al in PTB patients without HIV infection 
(10). 
 
Furthermore, we also observed that our PTB patients without HIV infection had 
higher MIF levels than that of a similar group of patients (i.e. PTB without HIV-
infection) in the Japanese study (10). The median value in our study was more 
than two-fold higher than the mean serum MIF concentration in the Japanese 
study.  
 
Similarly, the Tanzanian healthy HIV seronegative control group had nine-fold 
higher levels of MIF than that of the healthy HIV seronegative control group in 
the study by Yamada et al (10), which had a mean of 4.38 + 1.34 ng/ml. And 
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also the serum MIF levels in the Tanzanian volunteers were three-fold higher 
than the levels measured in healthy Dutch volunteers (median/IQR = 13.2 /10.0 
– 16.5).  
 
Apart from the differences in immunoassays (e.g. antibody characteristics and 
calibration standards), the differences between different study populations may 
be due to factors such as environmental or genetic in the human host. Factors 
such as MIF polymorphism, subclinical, non-symptomatic condition or chronic 
infection (e.g. latent tuberculosis, which is present in the majority of healthy 
adult Tanzanians) may have influenced the comparatively higher MIF levels of 
the HIV seronegative Tanzanians. The differences we have found between 
control groups emphasize on the importance of selecting an appropriate control 
group, which genetically and environmentally is closely linked to the study 
population.  
 
Although the levels of serum MIF in the healthy Tanzanian volunteers in this 
study, was comparatively higher than healthy control groups in other studies, 
the levels were still statistically significantly lower than MIF levels of the 25 HIV 
seronegative Tanzanians with PTB.   
   
In summary, in this study among Tanzanian subjects, HIV infection appeared to 
be associated with elevated serum MIF levels. The MIF levels could not 
discriminate PTB, a major disease in HIV infection from other lung diseases. The 
effect of PTB on MIF levels in HIV co-infection was masked by HIV infection. Low 
levels of MIF were associated with increased one-month mortality. This finding 
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indicates that further safety studies are warranted before immunotherapy using 
anti-MIF antibodies can be applied as part of treatment.  
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Table 1. Characteristics of the study populations 
Group 1: HIV - infected patients with PTB (n = 27) 
Age, mean (SD) 39.2 (8.9) 
M: F ratio 1: 1.1 
 
CD4 count, median (IQR) 47.0 (29.0 - 80.0) 
Group 2: HIV-infected patients with non-tuberculous lung 
disease (n = 46) 
Age, mean (SD) 39.3 (10.6) 
M: F ratio 1: 1.2 
 
CD4 count, median (IQR) 71.5 (15.0 - 123.8) 
Group 3: HIV-seronegative patients with PTB (n = 25) 
Age, mean (SD) 33.2 (13.8) 
M: F  2.6: 1 
 
Group 4: HIV-seronegative healthy volunteers (n = 25) 
Age, mean (SD) 38.7 (10.9) 
M: F ratio 1: 1.1 
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Figure 1. Median serum MIF and IQR in the four groups: HIV-seropositive with 
and without PTB and HIV-seronegative with and without PTB. The difference 
between serum MIF in the HIV-infected patients with PTB or without PTB was not 
statistically significant. Serum MIF in HIV- infected patients with PTB was higher 
than in HIV-seronegative with PTB (p = 0.004) as well as without PTB (p < 
0.0001).   
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ABSTRACT 
Background  
During advanced AIDS tuberculosis often presents atypically with smear-
negative and non-cavitary disease, yet immune features associated with this 
change are poorly characterized.   
Methods 
We examined the local immune response in a cohort of Tanzanian AIDS-
associated tuberculosis patients that underwent bronchoalveolar lavage.   
Tuberculosis infection was confirmed in BAL fluid by culture, probe, and PCR. 
Results  
Among tuberculosis patients CD4 count correlated positively with the extent of 
cavitary disease as well as BAL Tb load (qPCR CT).  Tb patients had significantly 
higher GM-CSF than non-Tb patients, and those with non-cavitary Tb had 
significantly higher BAL IP-10 and IL-7 than those with cavities.  BAL neutrophils 
were as prevalent as monocytes/macrophages or epithelial cells, and 
immunohistochemistry revealed that neutrophils, monocytes/macrophages, and 
epithelial cells were major sources of the IP-10 and IL-7.   
Conclusion 
These data suggest a dysregulated cytokine profile may contribute to the Tb of 
advanced AIDS. 
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INTRODUCTION 
Mycobacterium tuberculosis (Tb) is the world’s most deadly bacterial pathogen 
[1].  Tb rates and mortality are higher in HIV infected persons[2] and Tb 
accelerates HIV replication and heterogeneity [3, 4].  The tendency for 
tuberculosis to present atypically during AIDS, without the hallmark of upper 
lobe cavitary lung disease, is well-established [5-8].  A proposed explanation for 
the lack of lung cavitation with advanced AIDS is the loss of a CD4-mediated 
IFN-γ or DTH response to drive the granuloma and cavitation process [9, 10].  
Unfortunately, supporting data that evaluate the cytokine profile from AIDS-
associated Tb patients are few, particularly from the bronchoalveolar 
compartment, and particularly from sub-Saharan Africa where disease burden is 
highest.  We therefore sought to examine the immune characteristics of AIDS 
patients with well-documented Tb infection across a range of CD4 counts and 
radiographic presentations.  
 
MATERIALS AND METHODS 
Patient population and bronchoscopy  
Informed consent was obtained from all participants and the University of 
Virginia Human Investigation Committee and the Kilimanjaro Christian Medical 
Centre Ethics Committee reviewed and approved the project.  Bronchoscopy with 
bronchoalveolar lavage was performed by standard procedure using a flexible 
fiberoptic bronchoscope (Olympus p45, Tokyo, Japan) wedged into involved 
segmental bronchi.  In the case of diffuse lung involvement, the scope was 
wedged into one of the segmental bronchi of the right middle lobe. 
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Detection of Tuberculosis   
Each BAL fluid was assayed by AFB smear (at KCMC), culture (2 ml on solid and 
liquid media at UVA), PCR (at UVA, see below), and by Ziehl-Neelsen stain of 
BAL cell block (at UVA, see below).  Tuberculosis infection was defined by 
positive culture with confirmation of M. tb complex by DNA probe (n = 13).  The 
Tb-negative group (n = 21) was defined as AFB smear, culture, and PCR 
negativity.  Eight patients were excluded from further analysis because their Tb 
status was uncertain (5 were smear positive but culture negative and PCR 
negative; 3 were smear negative and culture negative but PCR positive).  Four 
patients were excluded because their BAL grew non-tuberculous mycobacteria 
and we could not rule out overgrowth of Tb.  Among the non-tuberculosis cases, 
10 had the bronchoscopic appearance Kaposi’s sarcoma.  Other diagnostic tests 
were performed per the attending physician’s orders but were not revealing. 
 
Tb PCR   
Real time PCR for the IS6110 gene was performed on BAL fluid using the assay 
and primers of Pounder et al [11]. Briefly, 2 ml of the BAL fluid was centrifuged 
at 16,000 × g for 5 min and 200 μl of PrepMan Ultra sample preparation reagent 
(Applied Biosystems, Foster City, CA) was added to the pellet.  The mixture was 
vortexed, boiled for 15 min, and centrifuged at 16,000 × g for 5 min to remove 
cellular debris.  PCR of 5 μl of extracted DNA was performed in a total volume of 
25 μl containing 12.5 μl of iQ SYBR Green Supermix 2× (Bio-Rad, Hercules CA), 
iTaq DNA polymerase (50 U/ml), 6 mM MgCl2, 20 nM SYBR Green I, 0.5 μM of 
each primer, 100 ng M. tb DNA for positive control, and water for negative 
control. Cycling conditions entailed 1 cycle at 95°C for 15 min followed by 40 
cycles at 95°C for 10 s, 58°C for 20 s, and 76°C for 20 s. 
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Radiographic analysis   
All patients had chest radiographs read in blinded fashion by a radiologist 
(C.F.K.).  CXR scores were determined as previously described [12].  The extent 
of cavitation was estimated by measuring the diameter of each cavity (mm) on 
CXR, assuming cavities were roughly spherical (4/3 π r3), and summing the 
volumes of all cavities. 
 
CD4T cell count   
CD4 T cell count was measured using the Coulter Manual CD4 Count kit 
(Beckman Coulter, Hialeah, FL). 
 
Cytokine measurements.  
Five ml of BAL fluid was added to DTT (0.05% final concentration) to dissolve 
mucus and filtered with 0.22 μm filters (MILLEX GP, Millipore, Cork, Ireland).  
Fluid was then concentrated in Amicon Ultra -15 filters (10,000 MWCO; Millipore) 
and assayed for 22 cytokines/chemokines using the human 22-plex cytokine kit 
(Upstate, Charlottesville, VA) on a Luminex-100 instrument according to the 
manufacturer's instructions.  For TGF-β1 quantitation, samples were acid-
activated to pH 1.5 with 1N HCl for 60 minutes prior to assay.  To adjust for BAL 
dilution, all cytokine data was normalized to the total protein content in the fluid 
as determined by BCA assay (Pierce, Rockford, IL). 
 
Histology and immunohistochemistry (IHC)   
Ten ml of BAL fluid was stored in RNALater (Ambion, Austin, TX) at –70°C and 
cell blocks were made by pelleting the material, fixing in 10% formalin, and 
embedding in paraffin.  Tissue sections were stained with hematoxylin and eosin, 
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Ziehl-Neelsen, and IHC was performed for IP-10 and IL-7.  All pathology was 
scored blindly by a pathologist (L.M.).  For each sample a cellularity score was 
determined for epithelial cells, monocytes/macrophages, lymphocytes, and 
neutrophils as follows: 0 = none, 1 = few, 2 = scattered, 3 = many. Ziehl-
Neelsen stained cell blocks were viewed at 1000× and scored for AFB positivity 
as follows: 0 = none, 1 = rare, 2 = few, 3 = scattered throughout.  For IHC, 3 
micron-thick paraffin sections were obtained using a Leica Microtome, mounted 
on superfrost/PLUS glass slides and deparaffinized to deionized water.  Samples 
were incubated overnight at 4°C using IP-10 and IL-7 antibodies (R & D 
systems, Minneapolis, MN) with dilutions ranging from 5 μg/ml to 125μg/ml.  
Samples were rinsed in PBS and incubated with a biotinylated secondary 
antibody for 30 minutes at room temperature.  Samples were then incubated 
with the ABC kit (Vector, Burlingame, CA) for 30 min at room temperature, 
rinsed in PBS, and stained with DAB Substrate (Vector) before counterstaining.  
An IHC score was determined for each cell population (epithelial cells, 
monocytes/macrophages, lymphocytes, and neutrophils) according to the 
following scale: 0 = weak, majority of cells not staining; 1 = intermediate; 2 = 
strong, majority of cells staining. 
 
Statistics   
Means and medians were compared using t test and Mann-Whitney test, 
respectively.  Correlations were measured using the Pearson linear correlation.  
All P values are two-tailed.  Data shown are mean ± SD unless otherwise 
indicated. 
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RESULTS 
Utility of BAL PCR for detection of Tuberculosis infection 
The endoscopy unit at the Kilimanjaro Christian Medical Centre is one of few 
centers in the region equipped for bronchoscopy and serves as a referral center 
for patients with chest disease of unknown etiology.  We enrolled and consented 
46 such patients known to be HIV-positive and performed Tb diagnostics and 
cytokine analysis on BAL. Tuberculosis infection was identified in 13/46 (28%) 
by culture with confirmation of M. tb complex by DNA probe.  Against this gold-
standard, BAL PCR exhibited better sensitivity and specificity than BAL AFB 
smear (100%/91% vs. 54%/85%).  Furthermore real time PCR CT (cycle 
threshold) exhibited the expected quantitative correlation with time to positive 
culture (CT vs. days to positivity; r = 0.68, P = 0.01) and AFB score (CT vs. AFB 
score; r = 0.67, P = 0.02). 
 
CD4 count correlates with cavitary disease and endobronchial Tb burden  
There were no significant differences between the Tb-positive and Tb-negative 
populations in terms of age, gender, CXR score (4.8 ± 1.4 vs. 7.4 ± 0.9, P = NS), 
or CD4 count (194 ± 41 vs. 146 ± 31, P = NS).  Among tuberculosis patients, 
average CD4 count was higher in patients with cavities as detected by CXR (Fig. 
1A).  Additionally, CD4 count correlated positively with cavitary volume and BAL 
Tb burden (qPCR CT; Fig 1B, C). 
 
BAL cytokine/chemokine response in AIDS-associated tuberculosis   
Scant data is available on the BAL response during AIDS-associated Tb.  Most 
reports derive from HIV-negative Tb in developed countries and findings have 
been extremely variable [13-15].  First, we examined the cell blocks prepared 
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from the BAL fluid.  As expected, lymphocytes were scant (cellularity score 0.6 ± 
0.5), but we were surprised to find a substantial amount of neutrophils, many of 
which contained intracellular M. tuberculosis bacilli (Fig. 2; cellularity scores 2.1 
± 0.9 for neutrophils, 2.3 ± 0.7 for monocytes/macrophages, and 2.0 ± 0.6 for 
epithelial cells, respectively, P = NS).  We next performed a broad 
characterization of 23 chemokines and cytokines in BAL fluid using the Luminex 
assay, with all cytokine data normalized for dilution against the total protein 
content in the fluid.  The analysis showed that the Tb-positive group exhibited 
higher BAL GM-CSF levels than Tb-negative individuals (the definition of 
tuberculosis-negativity required AFB smear, culture, and PCR negativity; P = 
0.007), while all other cytokines/chemokines were not statistically changed 
(Table 1).  Upon comparing the immune profile within the Tb group, individuals 
with non-cavitary Tb had significantly higher BAL IL-7 and IP-10 than those with 
cavitary disease (P = 0.02).  Other cytokines/chemokines were not significantly 
associated with radiographic findings or CD4 count.  Finally, 
immunohistochemistry of BAL cell blocks revealed that IP-10 was produced by 
epithelial cells, monocytes/macrophages, and neutrophils but not lymphocytes 
(IHC positivity score 1.5 ± 0.5, 1.6 ± 0.5, 1.2 ± 0.8, 0.1 ± 0.4, respectively; n = 
12, P = NS between epithelial cells, monocytes/macrophages, and neutrophils).  
Meanwhile IL-7 was produced predominantly by epithelial cells and 
monocytes/macrophages (IHC score 1.5 ± 0.7, 1.3 ± 0.6, versus 0.7 ± 0.6 and 
0.0 ± 0.0 for neutrophils and lymphocytes; n = 11, P < 0.05 comparing epithelial 
cells and monocytes/macrophages versus neutrophils or lymphocytes).  For both 
IP-10 and IL-7, the absence of lymphocyte staining may certainly reflect their 
paucity given HIV infection. 
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DISCUSSION 
The importance of this work lies in the characterization of the immune profile at 
the site of infection from a substantial number of HIV-infected, probe-confirmed 
Tb patients from sub-Saharan Africa.  Many studies from developing world sites 
perform only smear or culture but not probe or PCR for confirmation of M. tb 
complex.  This would have led to a significant rate of erroneous assignment to 
both the Tb-positive and Tb-negative groups in our population.  As a noteworthy 
aside, we feel that PCR directly on BAL, while technically demanding in a 
resource limited setting, has tremendous advantages in terms of accuracy over 
smear and rapidity over culture/probe. 
 
The comparison of cytokine responses between the Tb and non-Tb groups 
revealed a statistical increase in BAL GM-CSF in the setting of Tb, a finding that 
has not been previously reported.  One might predict this chemokine may exert 
a partially protective response given its role in Tb containment and granuloma 
development in mice [16].  Whether additional exogenous GM-CSF would be 
therapeutic in active Tb is unknown: in one small study clinical improvement was 
modest [17].  Potentially driven by the increase in GM-CSF, we were struck by 
the BAL neutrophilic response we saw in these Tb patients, particularly given the 
abundant bacilli within the neutrophils.  The role of neutrophils in Tb is 
unresolved: intracellular killing has been demonstrated in vitro by some but not 
others [18, 19].  In mouse models, neutrophils do not affect survival but do 
contribute to granuloma formation [20, 21].  Taken together, we speculate that 
the increased GM-CSF and neutrophil response is an attempt by the host to 
control Tb, particularly in the setting of AIDS. 
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The association we found between CD4 count and cavitary disease and 
endobronchial Tb burden was not surprising.  Several studies have documented 
this trend [5-8, 10], supporting the hypothesis that CD4 cells contribute to the 
pathogenesis of cavitary disease and endobronchial spread.  The mechanism by 
which this cavitation process occurs is clearly of paramount importance to the 
AIDS/Tb epidemic due to its implication on Tb transmission.  We therefore 
sought to examine the cytokine/chemokine profile between the cavitary and 
non-cavitary groups.  Based on limited human or mouse data we predicted a 
correlation between loss of cavitation and a loss of TNF-α or IFN-γ [22-24], 
however diminution of these cytokines in the non-cavitary group was modest 
and not statistically significant.  More readily apparent was the association 
between the loss of cavitation and IL-7 and IP-10.  To our knowledge IL-7 has 
not been reported in the BAL of Tb patients.  One could postulate that the IL-7 is 
merely a marker for the advanced AIDS of the non-cavitary group given its 
association with CD4 decline [25], however IL-7 may be relevant to HIV 
pathogenesis via its upregulation of RANTES (and thereby promotion X4 virus) 
[26].  The localization of IL-7 production by immunohistochemistry to bronchial 
epithelial cells and macrophages was not surprising and has been reported by 
others [27, 28]. 
 
IP-10 is an IFN-γ inducible chemokine critical for effector T cell development and 
trafficking in mice [29].  Its elevation during tuberculosis has been reported [20, 
30], however a neutrophilic source has not been described.  Some authors 
postulate a protective role for this chemokine [31] yet our findings of extremely 
high levels in the advanced AIDS/non-cavitary group would argue against an 
unequivocally protective function for IP-10.  Indeed given the positive effect of 
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IFN-γ on IP-10 transcription (as well as that of IL-1α and TNFα in some systems 
[32]), the high IP-10/low IFN-γ/low IL-1α/low TNFα pattern of the non-cavitary 
group was unexpected and suggest loss of IP-10 regulation or induction by other 
known mediators such as TLR ligands [33, 34]. 
 
Human data are important to direct research in experimental and animal 
models, particularly given the complexity of AIDS-associated Tb which cannot be 
easily replicated.  Based on our findings we question the role of GM-CSF and 
neutrophils during AIDS-associated Tb.  Additionally, the function of IL-7 on Tb-
specific HIV progression and of IP-10 in T cell trafficking in tuberculosis would 
seem fertile topics for research. 
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Figure 1.  Association between CD4 count, cavitary disease, and Tb PCR in BAL.  
CD4 count of HIV+/Tb+ patients was compared (A) between those with and 
without cavitary findings on CXR, (B) versus total cavitary volume, and (C) 
versus BAL PCR cycle threshold (CT). Figure A shows mean + SE; *, P < 0.05 by 
t-test or Mann-Whitney test. Correlations used the Pearson linear correlation. 
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Figure 2.  IP-10 and IL-7 in AIDS-associated tuberculosis.  Formalin-fixed, 
paraffin-embedded cell blocks were prepared from BAL fluid and 
immunohistochemistry performed with anti-IP-10 and anti-IL-7 primary 
antibody.  Positive staining macrophages (arrows) and neutrophils (arrowheads) 
are shown.  No background staining was observed without IP-10 (lower left) or 
IL-7 antibody (not shown).  Ziehl-Neelsen (ZN) stain shows M. tuberculosis 
bacilli both inside neutrophils (arrowhead) and extracellularly (arrow).  All 
photomicrographs come from one of the seven patients with non-cavitary 
tuberculosis. 
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TABLE 1.  Comparison of BAL cytokine/chemokines between HIV-infected 
patients with cavitary Tb, non-cavitary Tb, and without tuberculosis 
Cytokine/ 
chemokine 
Tb cavitary 
(n = 6) 
Tb non-
cavitary  
(n = 7) 
P 
(cavitary vs. 
non-cavitary) 
Non-Tb 
(n = 21) 
P 
(Tb vs.  
non-Tb) 
IL-1α 205.3 ± 112.9 ± 43.4 NS a 143.3 ± 33.1 NS 
IL-1β 91.8 ± 116.1 ± 52.7 NS 93.0 ± 24.6 NS 
IL-2 6.3 ± 1.5 4.6 ± 1.4 NS 5.7 ± 0.9 NS 
IL-3 1.1 ± 1.1 NDb NS 1.9 ± 1.2 NS 
IL-4 3.7 ± 1.2 2.9 ± 1.2 NS 2.6 ± 0.6 NS 
IL-5 10.3 ± 2.3 10.7 ± 1.7 NS 8.8 ± 1.0 NS 
IL-6 73.0 ± 306.9 ± 94.3 NS 136.7 ± 43.0 NS 
IL-7 28.0 ± 5.9 57.5 ± 7.3 0.02 32.0 ± 3.7 NS 
IL-8 456.5 ± 1272.2 ± NS 730.4 ± NS 
IL-10 NDb 5.5 ± 4.5 NS 1.1 ± 0.6 NS 
IL-12p40 47.3 ± 61.2 ± 14.3 NS 47.3 ± 14.1 NS 
IL-12p70 8.0 ± 1.8 12.9 ± 2.8 NS 10.3 ± 1.3 NS 
IL-13 8.1 ± 1.6 10.2 ± 1.8 NS 8.7 ± 1.1 NS 
IL-15 4.8 ± 2.2 7.9 ± 3.8 NS 7.5 ± 1.4 NS 
IFN-γ 354.7 ± 59.9 ± 16.2 NS 63.8 ± 12.8 NS 
TGF-β1 2.2 ± 1.1c 2.8 ± 1.5 NS 1.7 ± 0.5 c NS 
TNF-α 25.6 ± 10.3 ± 5.9 NS 10.3 ± 3.5 NS 
EOTAXIN 54.6 ± 102.1 ± 27.0 NS 82.0 ± 11.9 NS 
GM-CSF 8.1 ± 1.6 12.9 ± 2.2 NS 5.1 ± 1.0 0.007 
IP-10 350.5 ± 1709.9 ± 0.02 306.2 ± 75.1 NS 
MCP-1 42.6 ± 117.6 ± 39.7 NS 47.3 ± 6.2 NS 
MIP-1α 56.8 ± 57.9 ± 17.5 NS 46.7 ± 5.0 NS 
RANTES 37.0 ± 4.7 64.2 ± 14.8 NS 318 ± 3.2 NS 
Data shown as mean ± SE pg cytokine/mg protein.   
a NS = not statistically significant. P values reflect t-test, however all significant P values were also 
met when comparing medians (Mann-Whitney test). 
b ND = not detected for any specimen. 
c TGF-β1 data available for only 6 cavitary Tb specimens and 19 non-Tb specimens.  
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ABSTRACT 
Background 
Toll-like receptor 4 (TLR4) plays an important role in the pattern-recognition 
of Mycobacterium tuberculosis, and polymorphisms in the TLR4 gene 
influence the function of the receptor. We therefore investigated in a cohort 
of HIV-infected Tanzanian patients whether the Asp299Gly TLR4 
polymorphism is associated with the development of active tuberculosis. We 
found a higher risk of developing active tuberculosis as well as a reduction in 
CD4 T cell counts in patients with Asp299Gly polymorphism. 
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INTRODUCTION 
Due to the growing number of HIV infections in sub-Saharan Africa, the 
number of co-infections of HIV and Mycobacterium tuberculosis is also 
increasing fast, with a significant contribution to morbidity and mortality 
(1;2). It is well known that the incidence of infection with M. tuberculosis is 
much higher than that of active tuberculosis (TB), even in the case of co-
infection with HIV. Toll-like receptors are a class of receptors which are 
important for the recognition of pathogens by the innate immune system and 
for bridging the innate and acquired immune response (3). Research 
revealed that TLR4 mediates cytokine production stimulated by M. 
tuberculosis, and that TLR4 knock out mice are more susceptible to infection 
with M. tuberculosis (4;5). Therefore we wanted to asses whether the TLR4 
polymorphism Asp299Gly, which is common in Africa, is involved in the 
development of active TB in HIV infected patients. 
 
MATERIALS AND METHODS 
At Kilimanjaro Christian Medical Center (KCMC) in Tanzania, we enrolled 120 
HIV infected patients presenting with symptoms of chest infection and/or 
chest radiographic abnormalities. These patients underwent bronchoscopy 
with collection of bronchoalveolar lavage (BAL) fluid for TB culture and real 
time PCR (qPCR) DNA amplification for M. tuberculosis (6). These results 
were used to form: Group 1; Active TB disease (culture and qPCR positive) 
and Group 2; no active TB (culture negative and qPCR negative or positive). 
Patients with a negative culture and positive qPCR were followed during 18 
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months whereby none developed active TB. Patients on anti-TB treatment 
were regarded as active TB cases if qPCR was positive despite negative 
culture. Sixteen patients were excluded because of incomplete data, thus a 
total of 104 patients remained for analysis. From all these patients the TLR4 
Asp299Gly polymorphisms was determined, as described before (7). 
 
RESULTS 
Twenty-four patients had active TB and 80 had no active TB. Gender and age 
did not differ between the two groups. The percentage of Asp299Gly 
polymorphism of patients with no active TB was 7.5%, (N = 6 /80) compared 
to a 2.8-fold higher prevalence within the active TB group (20.8%, N = 
5/24). This difference almost reached significance (χ2 P = 0.06), suggesting 
that HIV-infected patients carrying the Asp299Gly allele have an increased 
susceptibility to develop active TB. These findings are in line with the in-vivo 
reports that TLR4 is a receptor involved in the recognition of the soluble 
factor of M. tuberculosis and for whole mycobacterium ligands (8;9). 
Difference between our results and those of Newport et al, who was not able 
to find a role of TLR4 Asp299Gly polymorphism in non-HIV infected 
individuals, indicates that the role of TLR4 recognition and activation of the 
innate immune system is likely to be more pronounced in HIV infected 
individuals (10-12). Another cause of the differences between the studies 
may be the different genetic background (West-Africa / Gambia and East-
Africa / Tanzania), as the ethnicity is known to interact with TB susceptibility 
(12;13). 
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Because all patients were HIV-infected, we also looked at the difference 
between CD4 T cell counts. As expected, patients with active TB had a lower 
median CD4 T cell count compared with the no active TB group (Mann-
Whitney U-test, P = 0.01, Figure 1A). Interestingly, within the group of 
patients without the Asp299Gly polymorphism, median CD4 T cell counts 
were significantly lower in individuals with active TB, compared to individuals 
in the no active TB group (Mann-Whitney U-test, P = 0.01, Figure 1A). This 
difference was no longer present in patients with the Asp299Gly 
polymorphism who all except one had CD4 T cell counts below 100 cells/mm3 
(Mann-Whitney U-test, P = 0.79) (Figure 1A). Further investigation revealed 
that distribution of the Asp299Gly polymorphism in subgroups of patients 
according to the clinically-important categories of CD4 T cell counts (350, 
200, 100 cells/mm3, Figure 1B) showed increased prevalence of the 
Asp299Gly polymorphism in all subgroups of patients having CD4 T cell 
counts below 350, 200 and 100 cells/mm3. However, only in patients with 
CD4 T cell count below 100 cells/mm3 the prevalence of the Asp299Gly 
polymorphism (15.6%) was significantly higher than in patients with CD4 T 
cells of more than 100 (2.5%; χ2 P = 0.03). It should be noted that only one 
individual with the Asp299Gly polymorphism had CD4 T cell counts above 
100 (Figure 1B). On the one hand, this striking observation is likely due to 
the mechanisms through which Asp299Gly increases susceptibility to TB. On 
the other hand, this phenomenon is likely to be important for the pathology 
and clinical presentation of HIV infection because both therapeutic and 
antibiotic prophylaxis decisions are based on CD4 T cell counts. So the 
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surprising difference between CD4 T cell counts within TLR4 polymorphisms 
indicates that the HIV-infected status is important for the impact of TLR4 
Asp299Gly. CD4 T cell counts are the most important prognostic factor in 
HIV-infection for the development of opportunistic infections, including TB. 
  
DISCUSSION 
Different factors may explain the observed low number of CD4 T cells in HIV-
infected patients bearing the TLR4 Asp299Gly polymorphism. TLR4 is known 
to activate the interferon response, thus inhibiting HIV replication. Therefore, 
individuals bearing the TLR4 Asp299Gly polymorphism may have a more 
pronounced viral replication, with enhanced loss of CD4 T cells and increased 
susceptibility for TB. Another explanation can be that the absence of potent 
inflammation in TLR4 Asp299Gly HIV-infected individuals leads to less 
symptoms due to infection with M. tuberculosis, therefore patients will 
present to the hospital at a later stage of the disease. Additional studies with 
prospective follow-up of newly diagnosed HIV-infected patients bearing either 
wild-type or the Asp299Gly allele is needed to answer these questions. 
 
In conclusion, Asp299Gly polymorphism at the level of TLR4 is associated 
with an increased chance to develop active TB in HIV-infected patients, and 
this seems to involve an effect of this polymorphism on the CD4 T cell counts 
in these patients. 
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Figure 1: (A) Median CD4 T cell counts of the 104 patients studied grouped by their 
tuberculosis and TLR4 polymorphism status. (B) Distribution of the 299 allele of the 
patients when they were grouped by CD4 T cell counts equally to or above, and 
below 350, 200 and 100 cells/mm3, respectively. Numbers in the bars represent 
numbers of patients in each. 
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GENERAL DISCUSSION 
This thesis centres on clinical and immunological studies of tuberculosis (TB) 
in patients with HIV infection. It comprises a range of studies, firstly clinical 
studies on the impact of HIV infection on morbidity and mortality in a referral 
hospital. Next, diagnostic studies on the aetiology of chest problems in HIV 
infected patients, diagnostic problems in TB in HIV infection and on the role 
of human herpes viruses (HHV) as co-infection. Then follows a study on M. 
tuberculosis (MTB) genotypes and TB drug resistance. Finally, several 
pathophysiological studies are presented comprising immunological 
responses of the host to MTB in a HIV milieu and a role of TLR4 
polymorphism in the development of active TB. These studies were done in 
Tanzania, one of the sub-Saharan countries heavily affected by the two 
diseases (1-5). Data on TB and HIV infection from sub-Saharan Africa are 
sparse and insufficient.  
 
Our quest to research more on co-infection between TB and HIV was 
triggered by the findings of our initial study (chapter 2) which showed that 
pulmonary infections were the leading causes of hospitalization, morbidity 
and in-hospital mortality, and MTB was the leading single infectious cause of 
morbidity and mortality, a finding which is similar to other studies (2;6). The 
impact was made worse by a low clinical suspicion index for HIV infection. 
We found that only about a half of the actual HIV infected in-patients were 
tested based on clinical suspicion that HIV infection was the underlying 
disease. The two infections (TB and HIV) in this way amount to serious 
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negative socio-economical consequences for this economically already 
constrained country, as well as to a heavy burden on the health care system. 
The apparent role of pulmonary infections in morbidity and in-hospital 
mortality in HIV infected individuals observed, prompted a study into the 
causes of these infections (chapter 3), where we used bronchoalveolar 
lavage (BAL) fluid obtained with a small type bronchoscope (Olympus p45) to 
get BAL fluid from distal parts of the lung where the interaction between the 
offending pathogens and defending host factors takes place. We found that 
M. tuberculosis, common bacteria, HHV8 and Pneumocystis jiroveci were the 
leading causes of chest infection. Apart from opportunistic infections which 
capitalize on the lowered innate immunity, this study revealed that common 
bacterial pathogens of community acquired pneumonia were among the 
major causes of pulmonary infections even at a very low CD4 T cell counts. 
Identification of more bacteria may have been hampered by the fact that 
more that 80% of patients had used antibiotics prior to sampling for the 
bacteriological studies. PCP was more prevalent than previously reported 
from this region (3;7), this is likely to occur if appropriately searched for and 
when different diagnostic tests were used in combination. However the 
impact of MTB infection in patients infected with HIV was enormous and 
outweighed all other causes of lung infection: PTB/HIV co-infection was the 
leading cause of both morbidity and mortality. Its atypical radiological and 
clinical presentation coupled to poor sputum production and yield resulted 
into missed or delayed diagnosis and hence opening a window for increased 
transmission, delayed treatment and poor outcome. Our findings therefore 
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argue for more aggressive testing strategies for both TB and HIV to increase 
case detection rate, improve case management, and prevent further 
transmission. 
 
In Chapter 4, we found that HIV infection was associated with high 
prevalence of the most common human herpes viruses (Epstein-Barr virus 
(EBV), Cytomegalovirus (CMV), Human herpes virus 8 (HHV8), Herpes 
simplex virus 1 (HSV1) and Herpes simplex virus 2 (HSV2). Their abundance, 
irrespective of the other co-infecting pathogens, may imply possible long 
term negative impact on the outcome of TB/HIV co-infection, given their role 
in various pathologies e.g. EBV in lymphoproliferative disorders and 
lymphoma, and HHV8 in Kaposi’s sarcoma, Castleman’s disease and primary 
effusion lymphoma (8-13). However, we cannot be totally sure that the HHV 
DNA demonstrated by PCR in all cases also signified disease due to that 
virus. Therefore, a larger study also including immunohistochemical stainings 
of BAL material to identify tissue reactions due to the virus, and longer follow 
up is warranted to shed more light on their role in TB/HIV co-infection.  
 
As presented in Chapter 5, current diagnostic tests are inefficient in TB 
diagnosis:  the WHO recommended AFB smear of sputum for resource-
limited settings showed to be limited by very low sensitivity in TB/HIV co-
infected patients, even when BAL fluid was used instead of sputum. Other 
methods, which are either rarely available, expensive, or technically too 
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demanding showed to have varying sensitivity and specificity. The current CT 
cut off value of 40 in real time PCR for MTB resulted into low specificity of 
this molecular technique; this could be improved by changing the cut off 
value for the CT  to 32 in TB endemic region. Using the latter cut off value for 
the PCR applied to BAL material, latent TB may be differentiated from active 
TB. We recommend however this to be confirmed in a prospective follow-up 
study in which real time PCR is applied to both sputum and BAL material.   
 
The prevailing high rates of MTB transmission occurring in the region where 
our studies were done (northern Tanzania), was demonstrated (Chapter 6) 
by the high prevalence of only a couple of genotypes: Cas1-Kili accounted for 
more than one-third of the genotypes and LAM11–ZWE for more than one-
tenth. Predominance of the same genotypes in this region was also 
previously reported using a different molecular technique (14). More than a 
third of these patients were HIV co-infected. High MTB transmission rate is 
associated with HIV infection, on top of poor socio-economical status 
(15;16). Beijing MTB strain was among the major spoligotypes although it is 
a recent strain in this region. The fact that MTB Beijing was associated with 
young age and that it was a major spoligotype was an indication that it is a 
recent strain and its transmission is ongoing (17).   
The upward trend of anti-TB drug resistance we observed could worsen the 
outcome of TB which is already poor when it is associated with HIV infection. 
Resistance to INH reached a double digit, MDR and resistance to all first line 
drugs was higher than previously reported from this country (4). This 
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indicated an imminent danger of developing extensively drug resistant MTB 
(XDR), which is associated with both MDR and HIV infection (18). The delay 
in obtaining MTB drug susceptibility (DST) results and limited correlation 
between DST and the faster genotypic resistance testing, is a challenge for 
early identification of treatment non-responders in this part of the world. The 
delay in identification of non-responders and resistant strains will compound 
high rates of transmission and poor treatment outcome.   
 
In Chapter 7, we reported an immunological study in HIV infected TB 
patients showing that levels of macrophage migration inhibitory factor (MIF) 
were higher in HIV infected patients with TB than in non-HIV infected 
individuals with TB. Unlike in studies without HIV infection (19-21), in the 
HIV infected TB patients we studied, low MIF levels were associated with 
poor outcome. These results indicate that the on-going trials on the 
immunotherapeutic use of anti-MIF therapy to alter fatal outcome associated 
with bacterial infections in non-HIV infected patients (19;21-25) may not be 
helpful to the majority of TB patients from sub-Saharan Africa because they 
are co-infected with HIV. Our study was the first to study MIF levels in BAL 
and serum of TB/HIV co-infected individuals.  
 
We assayed a broad spectrum of cytokines/chemokines in BAL fluid of 
patients with TB, strictly defined by TB culture (in which MTB complex was 
confirmed by DNA probe) and real time PCR for the IS6110 gene, to avoid 
misdiagnosing TB. We found (Chapter 8) that cytokine profiles were 
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different depending on the radiographical presentation: non-cavitary TB was 
associated with higher BAL IP 10 and IL 7.  These findings apart from being 
new in the field of TB/HIV also showed that advanced AIDS has a different 
radiological presentation and an altered immunological response compared to 
HIV infection with preserved immunity.  We also found that chest 
radiographic features were related to the level of immunity (i.e. CD4 T cell 
levels): cavitary lesions on chest radiograph were associated with high CD4 T 
cell count and atypical features appeared at low CD4 T cell count.  
 
As reported in Chapter 9, apart from diagnostic problems, also other factors 
contribute to high morbidity and mortality due to TB in this part of the world. 
For the Asp299Gly TLR4 polymorphism, which is highly prevalent in sub-
Saharan Africa (26) we showed an association with development of active 
TB; patients with the polymorphism were more likely to develop the disease 
than those without the polymorphism. We also observed an association 
between the 299 polymorphism and low CD4 T cell counts, which could as 
well lead to poor outcome. This looks like a disadvantageous evolutionary 
shift since the HIV pandemic: from the protective role of Asp299Gly 
polymorphism against high mortality in malaria (26), to the increased 
susceptibility to tuberculosis and low CD4 T cell count in TB/HIV co-infection, 
as we observed in this study. However this hypothesis warrants further 
studies to explore the interaction of the three diseases (TB, malaria and HIV) 
since both are chronically present in sub-Saharan Africa.       
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AVENUES FOR FUTURE RESEARCH 
 
1. To define the role of anti-MIF antibody therapy in a broad range of 
CD4 T cell counts in TB/HIV co-infected patients. Also, to determine 
levels of MIF in BAL (with a method for quantification of the obtained 
BAL material) in additional study groups, particularly TB infected 
patients without HIV infection. 
2.  To determine the role of IL-7 in HIV progression in patients co-
infected with TB, in order to understand whether it is only a marker of 
advanced AIDS due to its association with low CD4 T cell count or 
contributes to HIV pathogenesis through upregulation of RANTES 
production.  
3. To determine the function of IP-10 in TB/HIV co-infection given the 
apparently dual phenotype of CD4 T cells in TB, both protective (given 
the increased rates of active TB with CD4 T cell decline) and 
deleterious (given the association of CD4 cells with cavitary TB and TB 
burden) observed in our study. 
4. To evaluate the long term clinical significance of positive real time PCR 
for MTB in HIV infected and immunosuppressed patients with negative 
MTB culture. Also, to study real time PCR in sputum and to optimize 
the CT cut off value of real time PCR in TB endemic settings to 
differentiate active TB from latent TB.  
5. To determine why Asp299Gly TLR4 polymorphism is highly prevalent 
in sub-Saharan Africa, despite high susceptibility and mortality 
associated with TB in its bearers, and to determine in view of the 
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interaction between TB, HIV and malaria, whether the prevalence of 
Asp299Gly polymorphism will go down in future in sub-Saharan Africa. 
6. To determine the long-term impact of infection with human herpes 
viruses in TB/HIV co-infection, given their high prevalence and their 
role in various pathological conditions. 
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SUMMARY 
 
This thesis describes clinical and immunological aspects of co-existence in the 
human host of Human immunodeficiency virus (HIV) and Mycobacterium 
tuberculosis (MTB).    
 
Chapter one gives an introduction to the developing HIV epidemic and in its 
wake the epidemic of tuberculosis (TB) in tropical Africa, elucidating the 
atypical presentation and diagnostic problems encountered in a resource poor 
setting. It also highlights research needs in clinical aspects of TB/HIV co-
infection and in its pathophysiology and immunology. Further, an outline is 
given of the research presented in the following chapters of this thesis.  
 
Chapter two on HIV-associated morbidity and mortality among inpatients at 
a tertiary care referral hospital in northern Tanzania reveals that over a ten-
year period there was an incremental trend in hospitalization and mortality 
attributable to HIV infection. Pulmonary infections were by far the leading 
causes of morbidity and mortality in both paediatric and adult in-patients. 
While the contribution of HIV infection to both hospitalization and poor 
outcome was enormous, 44 % of the patients who tested HIV seropositive in 
a point-prevalence survey were previously unaware of their infection and 
were unsuspected clinically as having HIV infection. A plea was made for an 
improved policy on HIV testing to increase case detection rates, improve 
case management and prevent spread of the infection. 
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In Chapter three we report a study on aetiology and presentation of AIDS – 
associated pulmonary infections. A wide spectrum of causative agents was 
identified. Tuberculosis was common as expected, but prevalence of Human 
herpes virus 8 (HHV8) and Pneumocystis jiroveci was relatively high for a 
country in sub-Saharan Africa. An aetiological diagnosis could not be made in 
more than 40% of patients. These organisms were largely undistinguishable 
by chest radiographic features, except micronodules, which were significantly 
more found in tuberculosis. Also we found that even at very low CD4 T cell 
levels common bacteria were common causes of pneumonia. M. tuberculosis 
and HHV8 were the main causes of death due to pneumonia in HIV infection.  
 
In Chapter four data are presented on the prevalence of Human herpes 
viruses (HHV) in bronchoalveolar lavage (BAL) fluid of two groups of severely 
immunosuppressed HIV infected patients with pulmonary infections, 25 with 
pulmonary tuberculosis (TB), and 25 with non-TB pulmonary infections. The 
groups were matched for age and CD4 T cell count (average 50 cells/µl). We 
showed that HHV in this part of the world are highly prevalent: Epstein-Barr 
virus (EBV) was found in 78%, Cytomegalovirus in 24%, HHV8 in 14% and 
HSV-1 in 14%. HHV were equally prevalent in both, patients with TB and 
with non-TB lung infections, and HHV prevalence was higher than found in 
western countries. The difference in mortality between the two groups after 
one-month follow up was statistically not significant. A study with longer 
follow up, in a group of patients with a wider range of CD4 T cell counts is 
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needed to elucidate the pathogenetic role of HHV in HIV infected patients 
with pulmonary infection. 
 
In Chapter five a study is presented on laboratory diagnosis of pulmonary 
tuberculosis in TB/HIV co-infection and the contribution of real time PCR in 
the setting of Tanzania. In nearly half of HIV/AIDS patients a microbiological 
diagnosis of TB could not be made by examination of sputum, as patients 
either produced no sputum or inadequate sputum. In resource-limited 
settings sputum is the principle source for the microbiological diagnosis of 
TB. Even when samples were taken from the BAL compartment, currently 
available diagnostic techniques are far from optimal in diagnosing TB in HIV 
co-infected patients. Compared to culture, which is still the gold standard, ZN 
smear and MycoDot® serological tests had low sensitivity and real time PCR 
had low specificity. The specificity could however be improved, without 
significantly affecting its sensitivity, by adopting a lower cycle threshold (CT) 
value. The long period to positivity (4 weeks or more) is a limiting factor of 
culture. We found that during one and a half year of follow up, none of the 
patients with positive real time PCR but negative culture of BAL fluid 
developed active TB. Before definite conclusions can be drawn, however, the 
clinical significance of positive real time PCR in sputum and BAL when culture 
is negative needs to be studied in a prospective follow up study with longer 
follow up.  
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In Chapter six results are presented of a study on genotypic diversity and 
drug susceptibility of M. tuberculosis in Tanzanian patients of whom one third 
was co-infected with HIV. Many different spoligotypes were found, including 
MTB Beijing, found until recently only in other countries than Tanzania. This 
implies increased human movement and cross-infections. The dominant 
spoligotypes were only few and also only few were unique strains, which also 
implies high transmission rate. We found no or little association between the 
dominant spoligotypes and anti-TB drug resistance, but identified an upward 
trend of MTB resistance to commonly used anti-TB drugs, which is a 
worrisome finding. The percentages of INH resistance and MDR have doubled 
compared to recent previous reports. This signals that anti-TB drug 
resistance is an increasing problem. We were also able to show that 
genotypic drug susceptibility testing though fast, cannot stand by it self to 
pick clinically resistant strains without phenotypic drug susceptibility testing.  
 
In Chapter seven we showed that HIV infection has a major influence on 
serum macrophage migration inhibitory factor (MIF) levels in HIV 
seropositive patients from Tanzania with pulmonary infections. Serum MIF 
levels in HIV infected patients with TB and in HIV infected patients with non-
TB pulmonary infections were equally high. Consequently, determination of 
MIF cannot distinguish TB from other common pulmonary infections in HIV 
infection. MIF levels in patients with HIV infection were several times higher 
than in individuals without HIV infection. We also found that the individuals 
from Tanzania we studied had higher levels of MIF than was found in other 
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studies from different geographical locations. Unlike previous studies showing 
an association of high MIF levels with severity of the disease and poor 
outcome in individuals without HIV infection, we found in our patients from 
Tanzania that in HIV infection mortality was associated with low MIF levels.  
 
In Chapter eight data are presented on interferon γ-inducible protein 10 
(IP10) and interleukin-7 (IL 7) in BAL fluid in AIDS-associated tuberculosis. 
Also the correlation is presented between immune status as expressed by 
CD4 T cell count and the chest radiographic appearance. Cavitary lesions and 
large cavities occur when the cellular immunity is fairly preserved. Atypical 
radiographic features become apparent with deterioration of the immunity. 
Chest radiographic features are also reflected by the local immune response; 
patients without cavitary lesions exhibited higher BAL interferon-γ IP 10 and 
IL 7. Whether IL 7 is a marker of advanced AIDS or contributes to HIV 
pathogenesis through its up-regulation of RANTES production remains 
unclear. The major sources of IP 10 and IL7 as shown by 
immunohistochemistry are BAL neutrophils, monocytes/macrophages, and 
epithelial cells. We were also able to show that BAL granulocyte macrophage 
colony-stimulating factor (GM-CSF) was distinctly higher in TB patients than 
in non-TB patients. This raises argument that if the high levels of GM-CSF are 
a host protective attempt given the role of GM-CSF in TB containment and 
granuloma development, then there may be possibilities of immunotherapy 
using exogenous GM-CSF.      
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In Chapter nine data on Toll- like receptor 4 (TLR4) polymorphism in Africa 
are presented. Toll-like receptors are important in the host defence against 
Mycobacterium tuberculosis. Also, it has been recently shown that individuals 
with Asp299Gly polymorphism have a higher malaria parasitaemia, but suffer 
less from cerebral malaria. In our study, we showed that HIV infected 
patients in Tanzania carrying the Asp299Gly polymorphism had a higher 
chance to develop active tuberculosis than HIV infected patients without the 
polymorphism. We also showed that this could be explained largely by a 
significant reduction in CD4 T cell level of the patients with the 
polymorphism. Since Asp299Gly is found in up to a fifth of the population in 
Africa, this may explain in part why the incidence of tuberculosis in this part 
of the world is so high. The association of the polymorphism Asp299Gly with 
low CD4 T cell count may be due to a direct effect of TLR4 receptors on CD4 
T cell kinetics.  
Thus, the advantage of having the polymorphism for malaria may turn into a 
disadvantage due to its effect in tuberculosis for patients co-infected with 
HIV. This is likely to lead to a lower prevalence of this polymorphism in 
Africa.  
 
In Chapter ten the findings reported in the chapters 2 – 9 are discussed and 
put in perspective of the evolving epidemic of patients with dual infections of 
HIV and MTB in tropical Africa. Also avenues for future research are explored. 
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MUHSATARI 
Tasnifu hii inaangalia tatizo la ugonjwa wa kifua kikuu unapowapata watu 
waliopungukiwa na kinga ya mwili kutokana na kuwa na virusi vya UKIMWI.  
 
Sura ya kwanza ni utangulizi unaoonyesha mfumuko wa ugonjwa wa 
UKIMWI na namna UKIMWI ulivyobadili sura nzima ya ugonjwa wa kifua 
kikuu katika nchi za Afrika kusini mwa jangwa la Sahara. Sura hii pia 
inaelezea juu ya utata uliopo katika kuutambua ugonjwa wa kifua kikuu kwa 
wagonjwa wenye virusi vya UKIMWI. Kisha katika sura hii tafiti zilizomo 
katika tasnifu hii zinaainishwa.    
 
Sura ya pili inaonyesha ukubwa wa tatizo la ugonjwa wa UKIMWI katika 
hospitali ya rufaa ya KCMC; ikionyesha ni kiasi gani cha wagonjwa hulazwa 
hospitalini hapa kwa sababu ya UKIMWI. Sura hii inaonyesha kuwa ugonjwa 
huu umekuwa ukiongezeka mwaka hadi mwaka kwa kipindi cha miaka kumi 
mfululizo. Sura hii inaonyesha kwamba magonjwa ya homa ya mapafu kwa 
ujumla ndiyo sababu kubwa ya kulazwa na hata kufa kwa wagonjwa wenye 
virusi vya UKIMWI. Pamoja na hayo pia sura hii inaonyesha kwamba bado 
kiasi cha 44% ya wagonjwa wenye UKIMWI huwa hawatambuliki kwa 
kuangalia dalili za ugonjwa huo tu. Hivyo yapaswa kutafuta njia mbadala za 
kuwezesha upimaji wa wagonjwa wengi zaidi ili kupunguza maambukizi na 
pia kuanza matibabu mbadala mapema. 
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Sura ya tatu ni taarifa ya utafiti kuhusu mlolongo wa vijidudu 
vinavyosababisha ugonjwa wa homa ya mapafu. Utafiti unaonyesha kuwa 
bakteria wa ugonjwa wa kifua kikuu, Human herpes virus 8 (HHV8), na 
Pneumocystis jiroveci ndivyo vijidudu visababishi  vya mara kwa mara vya 
ugonjwa huu wa homa ya mapafu. Pia utafiti huu unaonyesha kwamba 
takribani 40% ya wagonjwa hao wa ugonjwa wa homa ya mapafu haikuweza 
kutambulika vijidudu visababishi vya ugonjwa huo hata baada ya kufanya 
uchunguzi yakinifu. Utafiti huu unaonyesha kwamba picha za x-ray ya kifua 
haziwezi kuainisha kwa ukamilifu sababu ya ugonjwa wa homa ya mapafu, 
ingawa kuwepo kwa micronodules kwenye picha ya X-ray ya kifua kunaweza 
kuhusishwa na ugonjwa wa kifua kikuu. Bakteria wa aina zote kwa ujumla 
wanaendelea kuwa ndiyo sababu kubwa ya ugonjwa wa homa ya mapafu, na 
bakteria  wa ugonjwa wa kifua kikuu na virusi vya HHV8 ndiyo chanzo 
kikubwa cha vifo kwa wagonjwa wa UKIMWI.  
 
Sura ya nne inaonyesha kiasi gani cha wagonjwa wa UKIMWI pia wana aina 
nyingine za virusi kama aina ya Human herpes viruses. Kwa kupima maji 
maji yaliyochukuliwa kutoka kwenye mapafu kwa kutumia Bronkoskopia 
inaonyesha kuwa tatizo la virusi hivi ni kubwa kwa wagojwa wa UKIMWI 
katika eneo hili kuliko ilivyo sehemu nyingine duniani. Virusi vya Epstern 
Barr, Cytomegalo na Human herpes 8 ndivyo vinavyoongoza kwa wingi. Hata 
hivyo uwepo wa virusi hivi katika utafiti huu haukuweza kuhusishwa na 
kuwepo kwa bakteria wa ugonjwa wa kifua kikuu kwa wagonjwa hawa wenye 
upungufu mkubwa wa kinga ya mwili. Pia imeonekana kwamba vifo vya 
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wagonjwa hawa kwa kipindi cha mwezi mmoja wa kwanza havikuchangiwa 
na kuwepo kwa vijidudu vya Human herpes viruses kwa wagonjwa hawa wa 
UKIMWI. Hata hivyo ukweli kuhusu madhara ya kuwepo virusi hivi kwa 
wagonjwa wa UKIMWI na kifua kikuu yanaweza tu kuanishwa kwa uhakika 
zaidi baada ya utafiti wa muda mrefu zaidi. 
 
Sura ya tano inachambua njia zinazotumika katika kugundua ugonjwa wa 
kifua kikuu kwa wagonjwa wa UKIMWI. Inaeleza ugumu wa kugundua 
bakteria wa kifua kikuu ( hasa kwa wagonjwa wenye upungufu mkubwa wa 
kinga ya mwili). Ugumu huo unatokana na shida ya wagonjwa hawa kutoa 
makohozi, uwezo mdogo wa kipimo cha Ziehl Neelsen wa kutambua bakteria 
wa kifua kikuu, uwezo mdogo wa MycoDot(R) kuweza kutofautisha bakteria 
wa kifua kikuu kutoka kwa aina nyingine ya vijidudu kwa wagonjwa wa 
UKIMWI. Pia utafiti huu unaonyesha kiasi gani kipimo cha kisasa cha “real 
time PCR” kinaelemewa katika kutofautisha ugonjwa kutokana na bakteria 
wa kifua kikuu au kuwepo tu kwa bakteria hawa bila ugonjwa katika 
mazingara haya ya kukithiri kwa ugonjwa wa kifua kikuu. Hivyo utafiti huu 
unashauri kwamba itumike “cut-off ya 32” badala ya “cut-off ya 40” ili 
kuweza kutofautisha kati ya makundi haya mawili. Kwa sababu wale ambao 
hawakuonekana kuwa na bakteria hawa kwa njia ya kuotesha (ila kwa PCR 
tu) hawakuugua ugonjwa wa kikfua kikuu kwa muda wote wa mwaka mmoja 
na nusu wa kuangaliwa. 
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Sura ya sita ni utafiti unaoelezea kuhusu jamii ya bakteria wanaounda kundi 
la Mycobacterium tuberculosis complex. Utafiti huu unahusisha aina hizo za 
bakteria wa kifua kikuu na usugu wao kwa dawa za kutibia ugonjwa wa kifua 
kikuu. Katika utafiti huu tunaona kwamba kadri ya theruthi moja ya 
wagonjwa wa kifua kikuu pia wana virusi ya UKIMWI. Tunaona kuwa pamoja 
na kuwa na aina nyingi za vibakteria vya kifua kikuu, asilimia kubwa ya 
wagonjwa wana ugua ugonjwa wa kifua kikuu kutokana na aina mbili tu za 
vijidudu vya jamii ya Mycobacterium tuberculosis complex, yaani Cas 1 Kili 
na LAM11-Zwe. Vibakteria vya aina ya Beijing ingawa ni vigeni katika eneo 
hili  vinaonekana kuongezeka. Vibakteria hivi vimekuwa vikihusishwa na 
usugu kwa dawa za ugonjwa wa kifua kikuu. Kuwepo kwa aina nyingi za 
bakteria wa jamii ya Mycobacterium tuberculosis complex na aina chache tu 
kuwa ndiyo viambukizi vya mara kwa mara ni dalili ya kuwepo kwa 
maambukizi mengi na ya mara wa mara  katika jamii. Utafiti pia unaonyesha 
kwamba idadi ya wagonjwa wenye vijidudu sugu kwa dawa za kifua kikuu 
inaongezeka ukilinganisha na taarifa za awali. Idadi ya wagojwa wenye 
vijidudu sugu kwa dawa ya Isoniazid na vijidudu vyenye usugu kwa dawa za 
isoniazid na rifampicin (multidrug resistant strains - MDR) imeongezeka mara 
dufu ukilinganisha na taarifa za awali. Hii ni dalili ya kukua kwa tatizo hili na 
huenda ikasababisha usugu wa kupindukia (extremely drug resistant – XDR). 
Tatizo la kuweza kugundua vijidudu sugu kwa muda muafaka bado halijapata 
utatuzi kwa sababu ya kuchukua muda mrefu kuviotesha vijidud vya kifua 
kikuu, na pia bado uhusiano wake na ule wa njia ya genotyping bado hauna 
uhakika wa kutambua kwa usahihi vijidudu sugu. 
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Sura ya saba inaelezea juu ya tofauti kati ya wagonjwa wenye virusi vya 
UKIMWI ukilingalisha na wale wasiokuwa na virusi hivyo. Tofauti hizo 
zilitokana na kwamba virusi vya UKIMWI vinatawala kwa kiasi kikubwa 
mgongano kati ya kinga ya binadamu na vijidudu vya ugojwa. Utafiti huu 
umeonyesha kwamba kiwango cha Macrophage migration inhibitory factor 
(MIF) kinakuwa juu sana kwa wagonjwa wa UKIMWI ukilinganisha na wale 
wasio na ugonjwa huo. Pia tunaona kuwa tofauti ni kwamba wale waliokufa 
kutokana na ugonjwa wa kifua kikuu walikuwa na kiwango cha chini cha MIF 
ukilinganisha na waliopona. Hii ni tofauti Kubwa ukilinganisha na wagonjwa 
wenye kifua kikuu bila ya kuwa na UKIMWI; kwa wale wasio na UKIMWI 
wanaokufa huwa na kiwango cha juu sana cha MIF kuliko wale wanaopona. 
 
Sura ya nane inaonyesha kwamba kwa wagonjwa wa kifua kikuu kiwango 
cha kupungua kwa kinga ya mwili kinaambatana na mabadiliko katika picha 
za X-ray ya kifua. Wale wanaokuwa na matundu katika picha zao za x-ray 
kinga yao ya mwili huwa angalao ni nzuri kidogo kuliko wale ambao huwa 
hawana matundu katika x-ray. Pia inaonyesha kwamba wale ambao hawana 
matundu huwa na kiwango kikubwa cha IP10 na IL 7 kuliko wale wenye 
matundu. Hivyo hivyo wale wenye ugonjwa wa kifua kikuu huwa na kiwango 
kikubwa cha GM-CSF kuliko wale ambao hawana ugonjwa wa kifua kikuu. Hii 
yote inaonyesha kiasi gani ugonjwa huu wa UKIMWI umebadili sura nzima ya 
magonjwa mengine. 
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Sura ya tisa inaelezea mabadiliko katika Toll – like receptor 4 (TLR4) 
Asp299Gly ambayo yametokea kwa binadamu baada ya miaka mingi ya 
kupambana na ugonjwa wa malaria yakiwa na lengo la kumkinga binadamu 
na ugonjwa huo, lakini sasa yanaonekana kuchangia kuugua ugonjwa wa 
kifua kikuu na kupungua kwa kinga ya mwili kwa wagonjwa wenye viruis vya 
UKIMWI. Hivyo basi madiliko haya ambayo mwanzoni yalikuwa ya manufaa 
kwa binadamu sasa yanaonekana kuwa na madhara kwa sababu ya kuwepo 
kwa ugonjwa huu wa UKIMWI. 
 
Sura ya kumi inajadili tafiti zote toka sura ya pili hadi sura ya tisa na 
kuelezea madhara makubwa yatokanayo na kuwa na magonjwa ya UKIMWI 
na kifua kikuu kwa wakati mmoja hasa katika eneo hili la Afrika. Na mwisho 
wa sura hii ni mwongozo wa tafiti nyingine ambazo zinafaa kufanyika kwa 
siku za baadaye ili kujibu baadhi ya maswali yaliyojitokeza katika tafiti hizi.  
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SAMENVATTING 
In dit proefschrift worden klinische en immunologische aspecten beschreven 
van gelijktijdige infectie met Human immunodeficiency virus (HIV) en  
Mycobacterium tuberculosis (MTB) bij de mens. 
 
Hoofdstuk 1 geeft een introductie op de ontwikkeling van de HIV-epidemie 
en de erop volgende epidemie van tuberculose (TB) in tropisch Afrika, 
waarbij de atypische presentatie en de diagnostische problemen in 
ontwikkelingslanden worden toegelicht. Ook wordt uiteengezet op welke 
gebieden wetenschappelijk onderzoek nodig is t.a.v. klinische aspecten van 
TB/HIV co-infectie, alsook t.a.v. van de pathofysiologische en 
immunologische kanten van deze dubbelinfectie. Dit hoofdstuk geeft ook een 
overzicht van de verschillende studies die in de erop volgende hoofdstukken 
van het proefschrift worden gepresenteerd.  
 
Hoofdstuk 2 beschrijft de met HIV geassocieerde morbiditeit en mortaliteit 
bij patiënten opgenomen op een derdelijnsziekenhuis in noord Tanzania. 
Over een periode van 10 jaar werd een toename gezien in de 
ziekenhuisopnames en de sterfte ten gevolge van HIV-infectie. Longinfecties 
waren verreweg de belangrijkste oorzaak van morbiditeit en mortaliteit, 
zowel bij volwassenen als kinderen. De bijdrage van HIV-infectie aan zowel 
ziekenhuisopname als sterfte was indrukwekkend, en 44 % van de patiënten 
die HIV-seropositief waren in een prevalentieonderzoek, waren zich tevoren 
niet bewust van hun HIV-infectie en deze werd ook niet vermoed door de 
Summary, Muhtasari, Samenvatting 
 220 
 
behandelende artsen. Gepleit wordt voor een beter testbeleid zodat meer 
gevallen van HIV-infectie kunnen worden opgespoord, de patiënten beter 
worden behandeld en verdere verspreiding van HIV-infectie wordt 
tegengegaan. 
 
Hoofdstuk 3 beschrijft een onderzoek naar verwekkers en klinische 
presentatie van met AIDS geassocieerde longinfecties, waarbij een grote 
variëteit van ziekteverwekkers werd geïdentificeerd. Zoals verwacht kwam 
tuberculose veel voor, maar ook Humaan herpes virus 8 (HHV8) en 
Pneumocystis jiroveci, zeker voor een land in Afrika ten zuiden van de 
Sahara. Een oorzakelijke diagnose werd niet gesteld bij meer dan 40% van 
de patiënten. De gevonden ziekteverwekkers konden op basis van de 
röntgenfoto van de longen vrijwel niet van elkaar worden onderscheiden. Wel 
werden micronodulaire afwijkingen significant meer gezien bij tuberculose. 
Ook werd vastgesteld dat, zelfs bij zeer lage waarden van het aantal CD4 T–
cellen, gewone bacteriën vaak de verwekkers van longontsteking waren. 
Tuberculose en infectie met HHV8 waren de belangrijkste doodsoorzaken bij 
met HIV geïnfecteerde patiënten met een longontsteking.  
 
In hoofdstuk 4 worden gegevens gepresenteerd over de prevalentie 
van Humane herpes virussen (HHV) in bronchoalveolaire lavage (BAL) 
vloeistof bij twee groepen met HIV geïnfecteerde patiënten met 
ernstige immunosuppressie en tekenen van longinfectie: 25 met 
longtuberculose, en 25 met een niet-tuberculeuse longinfectie. De 
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groepen waren gematched voor leeftijd en aantal CD4 T-cellen 
(gemiddeld  50 cellen/µl). HHV infectie kwam zeer veel voor in dit deel 
van de wereld: Epstein-Barr virus (EBV) werd gevonden bij 78%, 
Cytomegalovirus bij 24%, HHV8 bij 14% en HSV-1 bij 14%. De 
prevalentie van HHV bij de patiënten met longtuberculose was gelijk 
aan die bij de patiënten met niet-tuberculeuse longinfecties en hoger 
dan die in westerse landen. Het verschil in sterfte tussen de twee 
groepen een maand na opname in de studie was statistisch niet 
significant. Om de rol die HHV spelen bij met HIV geïnfecteerde 
patiënten met longinfectie op te helderen, wordt gepleit voor een 
onderzoek waarbij patiënten met een grotere variatie in CD4 T-cellen 
gedurende langere tijd worden vervolgd. 
 
In hoofdstuk 5 wordt een onderzoek gepresenteerd naar de 
laboratoriumdiagnose van longtuberculose bij patiënten met HIV-
infectie, en de bijdrage van real time PCR (rtPCR) hierbij, in de 
vigerende omstandigheden van Tanzania. Bij bijna de helft van de 
patiënten kon de microbiologische diagnose van tuberculose (TB) niet 
worden gesteld door sputumonderzoek, omdat de patiënten geen of 
inadequaat sputum produceerden. In arme landen is sputum de 
belangrijkste bron voor de microbiologische diagnose van 
longtuberculose. Zelfs als bronchoalveolaire lavage (BAL) vloeistof 
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wordt gebruikt zijn de momenteel beschikbare diagnostische 
technieken verre van optimaal om longtuberculose vast te stellen bij 
TB patiënten met HIV-infectie. Vergeleken met kweek als de standaard 
methode, bleek onderzoek op zuurvaste staven (ZN) alsook de 
serologische MycoDot® test, slecht te voldoen door hun lage 
gevoeligheid, terwijl de rtPCR een lage specificiteit had. De specificiteit 
van de rtPCR werd beter, zonder significant verlies aan sensitiviteit, als 
een lagere cycle threshold (CT) waarde werd gebruikt. Voor de TB 
kweek is de lange tijd (4 weken of meer) die nodig is voordat deze 
positief wordt, een beperkende factor. In ons onderzoek vonden wij 
dat geen enkele van de patiënten met positieve rtPCR maar negatieve 
TB kweek van BAL vloeistof, en die gedurende anderhalf jaar werden 
vervolgd, actieve TB ontwikkelden. Om een definitieve conclusie te 
trekken over de klinische betekenis van een positieve uitslag van de 
rtPCR, moet eerst een prospectief vervolgonderzoek worden gedaan 
waarbij de rtPCR wordt geëvalueerd in sputum en BAL bij patiënten 
met een negatieve TB kweek en die langer worden vervolgd dan in het 
huidige onderzoek gebeurde.  
 
In hoofdstuk 6 worden de resultaten gepresenteerd van een 
onderzoek naar de genotypische  diversiteit en de 
geneesmiddelengevoeligheid van 130 M. tuberculosis (MTB) isolaten 
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van Tanzaniaanse patiënten, waarvan eenderde een co-infectie met 
HIV had. Zevenenveertig verschillende spoligotypen werden gevonden, 
inclusief MTB Beijing, een type dat tot voor kort alleen buiten Tanzania 
was gevonden. Dit duidt op toegenomen menselijke migratie en 
kruisinfecties. De meeste spoligotypen (106/130) behoorden tot 
slechts 9 phylogenetische groepen. Er werden ook enkele unieke 
stammen gevonden, hetgeen wijst op hoge transmissie. Wij vonden 
geen duidelijke associatie tussen de dominante spoligotypen en 
resistentie tegen eerstelijnstuberculostatica. Wel leek een 
zorgwekkende toename te bestaan in het voorkomen van resistentie 
tegen tuberculostatica. Het percentage van INH-resistentie en dat van 
resistentie tegen meerdere geneesmiddelen (MDR stammen) was 
verdubbeld in vergelijking met vroeger gepubliceerde gegevens. Dit 
wijst erop dat resistentie tegen tuberculostatica een toenemend 
probleem is. Ons onderzoek liet ook zien dat genotypisch onderzoek 
om resistentie tegen tuberculostatica op te sporen weliswaar weinig 
tijd kost, echter op zichzelf ongeschikt is om klinisch relevante 
resistentie van MTB stammen op te sporen. Hiervoor blijven de 
bestaande fenotypische resistentietesten belangrijk.  
 
In hoofdstuk 7 tonen wij aan dat HIV-infectie in belangrijke mate de 
serumwaarden van macrophage migration inhibitory factor (MIF) 
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beïnvloedt bij patiënten met HIV en verschijnselen van longinfectie in 
Tanzania. De waarden van MIF in het serum van patiënten met HIV-
infectie en tuberculose (TB) waren even hoog als de MIF-waarden bij 
patiënten met HIV-infectie die niet-tuberculeuze longinfecties hadden. 
Door bepaling van MIF kan zodoende geen onderscheid gemaakt 
worden tussen longtuberculose en longinfecties van andere aard bij 
met HIV geïnfecteerde patiënten. De waarden van MIF bij patiënten 
met HIV-infectie waren aanzienlijk hoger dan bij mensen zonder HIV-
infectie. Ook vonden wij dat bij de personen uit Tanzania die wij 
onderzochten de MIF-waarden hoger waren dan de waarden die door 
onderzoekers uit andere delen van de wereld werden gevonden. Wij 
vonden, in tegenstelling tot de bevindingen van anderen bij mensen 
zonder HIV-infectie, dat bij onze Tanzaniaanse patiënten met HIV-
infectie, sterfte was geassocieerd met lage MIF-waarden.  
 
In hoofdstuk 8 worden gegevens gepresenteerd over interferon γ-
inducible protein 10 (IP10) en interleukin-7 (IL 7) in BAL-vloeistof van 
patiënten met tuberculose (TB) en AIDS. Ook wordt de correlatie 
gepresenteerd tussen het niveau van de immuniteit, gemeten aan de 
waarde van het aantal CD4 T-cellen, en de bevindingen op de 
röntgenfoto van de thorax. Holtevorming als zodanig, alsook grote 
holten, werden gezien als de cellulaire immuniteit nog redelijk goed 
Summary, Muhtasari, Samenvatting 
 225 
 
was, terwijl atypische beelden op de thoraxfoto werden gezien als de 
immuniteit ernstig gestoord was. De röntgenologische presentatie 
vindt ook zijn reflectie in de lokale immuunrespons: patiënten zonder 
holtevorming hadden hogere interferon-γ, IP 10 en IL 7 waarden in de 
BAL-vloeistof. Of  IL 7 een marker is voor AIDS in een laat stadium 
van de ziekte, of bijdraagt aan de pathogenese van HIV via een hogere 
RANTES productie, is nog onduidelijk. Immunohistochemisch 
onderzoek van BAL-materiaal liet zien dat neutrophielen, monocyten / 
macrophagen en epitheelcellen de belangrijkste bron voor IP 10 en IL7 
zijn. Ook toonden wij aan dat granulocyte macrophage colony-
stimulating factor (GM-CSF) in BAL duidelijk hoger was bij TB 
patiënten dan bij patiënten zonder TB. Dit is een argument voor de 
stelling dat hoge GM-CSF waarden een beschermingsmechanisme van 
de gastheer vertegenwoordigen. Als inderdaad GM-CSF bij tuberculose 
een functie heeft om de ziekte binnen de perken te houden en de 
ontwikkeling van granulomata te bevorderen, opent dit mogelijkheden 
om exogeen GM-CSF te gebruiken voor immunotherapie bij 
tuberculose. 
 
In hoofdstuk 9 worden de uitkomsten gepresenteerd van een 
onderzoek naar Toll- like receptor 4 (TLR4) polymorfisme in Tanzania. 
Toll-like receptors spelen een belangrijke rol bij de afweer door de 
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gastheer tegen Mycobacterium tuberculosis. Recent onderzoek liet zien 
dat personen met een Asp299Gly polymorfisme een hogere malaria-
parasitemie hebben, echter minder cerebrale malaria. In ons 
onderzoek toonden wij aan dat met HIV geïnfecteerde patiënten in 
Tanzania die het Asp299Gly polymorfisme hadden, een grotere kans 
hebben op het krijgen van actieve tuberculose dan HIV-geïnfecteerde 
patiënten zonder dit polymorfisme. Wij lieten ook zien dat dit voor het 
grootste deel wordt veroorzaakt door een significant lager aantal CD4 
T-cellen bij de patiënten met het polymorfisme. Omdat het Asp299Gly 
polymorfisme  voorkomt bij ongeveer een vijfde van de bevolking van 
Afrika, kan hiermee verklaard worden waarom tuberculose zoveel 
voorkomt in dit deel van de wereld. De associatie van het Asp299Gly 
polymorfisme met een laag aantal CD4 T-cellen kan het gevolg zijn 
van een direct effect van de TLR4 receptoren op de kinetiek van de 
CD4 T-cellen.  
Aldus kan het oorspronkelijke voordeel van het polymorfisme ten 
aanzien van malaria overgaan in een nadeel door het negatieve effect 
bij patiënten met tuberculose die met HIV geïnfecteerd zijn. Hierdoor 
zal waarschijnlijk in de toekomst de prevalentie van dit polymorfisme 
in Afrika gaan dalen.  
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In hoofdstuk 10 worden de bevindingen zoals gerapporteerd in de 
hoofdstukken 2 – 9 besproken en geplaatst in het perspectief van de 
zich ontwikkelende epidemie van dubbelinfecties met HIV en M. 
tuberculosis bij patiënten in tropisch Afrika. Ook worden doelstellingen 
aangegeven voor toekomstig wetenschappelijk onderzoek op dit 
terrein. 
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